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Abstract 
 
Imatinib (Glivec®) has transformed the treatment and prognosis of chronic myeloid leukaemia 
(CML) and of gastrointestinal stromal tumor (GIST). However, the treatment must be taken 
indefinitely and is not devoid of inconvenience and toxicity. Moreover, resistance or escape from 
disease control occurs. Considering the large interindividual differences in the function of the 
enzymatic and transport systems involved in imatinib disposition, exposure to this drug can be 
expected to vary widely among patients. Among those known systems is a cytochrome P450 
(CYP3A4) that metabolizes imatinib, the multidrug transporter P-glycoprotein (P-gp; product of 
the MDR1 gene) that expels imatinib out of cells, and α1-acid glycoprotein (AGP), a circulating 
protein binding imatinib in the plasma. 
The aim of this observational study was to explore the influence of these covariates on 
imatinib pharmacokinetics (PK), to assess the interindividual variability of the PK parameters of 
the drug, and to evaluate whether imatinib use would benefit from a therapeutic drug monitoring 
(TDM) program. A total of 321 plasma concentrations were measured in 59 patients receiving 
imatinib, using a validated chromatographic method developed for this study (HPLC-UV). The 
results were analyzed by non-linear mixed effect modeling (NONMEM). 
A one-compartment pharmacokinetic model with first-order absorption appropriately 
described the data, and a large interindividual variability was observed. The MDR1 polymorphism 
3435C>T and the CYP3A4 activity appeared to modulate the disposition of imatinib, albeit not 
significantly. A hyperbolic relationship between plasma AGP levels and oral clearance, as well as 
volume of distribution, was observed. A mechanistic approach was built up, postulating that only 
the unbound imatinib concentration was able to undergo first-order elimination. This approach 
allowed determining an average free clearance (CLu) of 1310 l/h and a volume of distribution 
(Vd) of 301 l. By comparison, the total clearance determined was 14 l/h (i.e. 233 ml/min). Free 
clearance was affected by body weight and pathology diagnosis. The estimated variability of 
imatinib disposition (17% for CLu and 66% for Vd) decreased globally about one half with the 
model incorporating the AGP impact. Moreover, some associations were observed between PK 
parameters of the free imatinib concentration and its efficacy and toxicity. Finally, the functional 
influence of P-gp activity has been demonstrated in vitro in cell cultures. 
These elements are arguments to further investigate the possible usefulness of a TDM 
program for imatinib. It may help in individualizing the dosing regimen before overt disease 
progression or development of treatment toxicity, thus improving both the long-term therapeutic 
effectiveness and tolerability of this drug. 
iv Résumé 
 
Résumé 
 
L’imatinib (Glivec®) a révolutionné le traitement et le pronostic de la leucémie myéloïde 
chronique (LMC) et des tumeurs stromales d’origine digestive (GIST). Il s’agit toutefois d’un 
traitement non dénué d’inconvénients et de toxicité, et qui doit être pris indéfiniment. Par 
ailleurs, une résistance, ou des échappements au traitement, sont également rencontrés. Le 
devenir de ce médicament dans l’organisme dépend de systèmes enzymatiques et de transport 
connus pour présenter de grandes différences interindividuelles, et l’on peut s’attendre à ce que 
l’exposition à ce médicament varie largement d’un patient à l’autre. Parmi ces systèmes, on note 
un cytochrome P450 (le CYP3A4) métabolisant l’imatinib, la P-glycoprotéine (P-gp ; codée par le 
gène MDR1), un transporteur d’efflux expulsant le médicament hors des cellules, et l’α1-
glycoprotéine acide (AAG), une protéine circulante sur laquelle se fixe l’imatinib dans le plasma. 
L’objectif de la présente étude clinique a été de déterminer l’influence de ces covariats sur la 
pharmacocinétique (PK) de l’imatinib, d’établir la variabilité interindividuelle des paramètres PK 
du médicament, et d’évaluer dans quelle mesure l’imatinib pouvait bénéficier d’un programme de 
suivi thérapeutique (TDM). En utilisant une méthode chromatographique développée et validée à 
cet effet (HPLC-UV), un total de 321 concentrations plasmatiques a été dosé chez 59 patients 
recevant de l’imatinib. Les résultats ont été analysés par modélisation non linéaire à effets mixtes 
(NONMEM). 
Un modèle pharmacocinétique à un compartiment avec absorption de premier ordre a permis 
de décrire les données, et une grande variabilité interindividuelle a été observée. Le 
polymorphisme du gène MDR1 3435C>T et l’activité du CYP3A4 ont montré une influence, 
toutefois non significative, sur le devenir de l’imatinib. Une relation hyperbolique entre les taux 
plasmatiques d’AAG et la clairance, comme le volume de distribution, a été observée. Une 
approche mécanistique a donc été élaborée, postulant que seule la concentration libre subissait 
une élimination du premier ordre. Cette approche a permis de déterminer une clairance libre 
moyenne (CLlibre) de 1310 l/h et un volume de distribution (Vd) de 301 l. Par comparaison, la 
clairance totale était de 14 l/h (c.à.d. 233 ml/min). La CLlibre est affectée par le poids corporel et 
le type de pathologie. La variabilité interindividuelle estimée pour le devenir de l’imatinib (17% 
sur CLlibre et 66% sur Vd) diminuait globalement de moitié avec le modèle incorporant l’impact de 
l’AAG. De plus, une certaine association entre les paramètres PK de la concentration d’imatinib 
libre et l’efficacité et la toxicité a été observée. Finalement, l’influence fonctionnelle de l’activité 
de la P-gp a été démontrée in vitro dans des cultures cellulaires. 
Ces divers éléments constituent des arguments pour étudier davantage l’utilité potentielle d’un 
programme de TDM appliqué à l’imatinib. Un tel suivi pourrait aider à l’individualisation des 
régimes posologiques avant la progression manifeste de la maladie ou l’apparition de toxicité, 
améliorant tant l’efficacité que la tolérabilité de ce médicament. 
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L’imatinib (un médicament commercialisé sous le nom de Glivec®) a révolutionné le 
traitement et le pronostic de deux types de cancers, l’un d’origine sanguine (leucémie) et l’autre 
d’origine digestive. Il s’agit toutefois d’un traitement non dénué d’inconvénients et de toxicité, et 
qui doit être pris indéfiniment. De plus, des résistances ou des échappements au traitement sont 
également rencontrés. Le devenir de ce médicament dans le corps humain (dont l’étude relève de 
la discipline appelée pharmacocinétique) dépend de systèmes connus pour présenter de grandes 
différences entre les individus, et l’on peut s’attendre à ce que l’exposition à ce médicament varie 
largement d’un patient à l’autre. Parmi ces systèmes, l’un est responsable de la dégradation du 
médicament dans le foie (métabolisme), l’autre de l’expulsion du médicament hors des cellules 
cibles, alors que le dernier consiste en une protéine (dénommée AAG) qui transporte l’imatinib 
dans le sang. 
L’objectif de notre étude a été de déterminer l’influence de ces différents systèmes sur le 
comportement pharmacocinétique de l’imatinib chez les patients, et d’étudier dans quelle mesure 
le devenir de ce médicament dans l’organisme variait d’un patient à l’autre. Enfin, cette étude 
avait pour but d’évaluer à quel point la surveillance des concentrations d’imatinib présentes dans 
le sang pourrait améliorer le traitement des patients cancéreux. Une telle surveillance permet en 
fait de connaître l’exposition effective de l’organisme au médicament (concept abrégé par le 
terme anglais TDM, pour Therapeutic Drug Monitoring). 
Ce projet de recherche a d’abord nécessité la mise au point d’une méthode d’analyse pour la 
mesure des quantités (ou concentrations) d’imatinib présentes dans le sang. Cela nous a permis 
d’effectuer régulièrement des mesures chez 59 patients. Il nous a ainsi été possible de décrire le 
devenir du médicament dans le corps à l’aide de modèles mathématiques. Nous avons 
notamment pu déterminer chez ces patients la vitesse à laquelle l’imatinib est éliminé du sang et 
l’étendue de sa distribution dans l’organisme. Nous avons également observé chez les patients 
que les concentrations sanguines d’imatinib étaient très variables d’un individu à l’autre pour une 
même dose de médicament ingérée. Nous avons pu aussi mettre en évidence que les 
concentrations de la protéine AAG, sur laquelle l’imatinib se lie dans le sang, avait une grande 
influence sur la vitesse à laquelle le médicament est éliminé de l’organisme. Ensuite, en tenant 
compte des concentrations sanguines d’imatinib et de cette protéine, nous avons également pu 
calculer les quantités de médicament non liées à cette protéine (= libres), qui sont seules 
susceptibles d’avoir une activité anticancéreuse. Enfin, il a été possible d’établir qu’il existait une 
certaine relation entre ces concentrations, l’effet thérapeutique et la toxicité du traitement. 
Tous ces éléments constituent des arguments pour approfondir encore l’étude de l’utilité d’un 
programme de TDM appliqué à l’imatinib. Comme chaque patient est différent, un tel suivi 
pourrait aider à l’ajustement des doses du médicament avant la progression manifeste de la 
maladie ou l’apparition de toxicité, améliorant ainsi tant son efficacité que son innocuité. 
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Abbreviations 
ABL Abelson’s leukemia virus gene (in chromosome 9) 
ACN Acetonitrile 
AcOEt Ethyl acetate 
AGEP Acute generalized exanthematous pustulosis 
AGP α1-acid glycoprotein 
AL Alkaline lysis 
ALL Acute lymphoblastic leukemia 
ANOVA Analysis of variance (used in statistics) 
AUC Area under the curve (used in pharmacokinetic modeling) 
BCA Bicinchonic acid 
BCR Breakpoint cluster region (in chromosome 22) 
BCRP Breast cancer resistance protein 
bid Twice daily 
bp Base pair (unit of length for nucleic acid sequences) 
CAM Cell-adhesion molecules 
cDNA Complementary DNA 
CHUV Centre hospitalier universitaire vaudois (i.e. Lausanne University hospital) 
c-Kit Mast/stem cell growth factor receptor (also termed CD117) 
CGP Ciba-Geigy Product 
CID Collision-induced dissociation 
CL Clearance 
CML Chronic myeloid leukemia 
CNS Central nervous system 
CPT Cell preparation tube 
CRF Case report form 
CV Coefficient of variation 
CYP Cytochrome P450 
DAD Diode array detector 
DESS Diplôme d’études supérieures spécialisées (i.e. Master of advanced studies) 
Nomenclature ix 
 
DHPLC Denaturing-High performance liquid chromatography 
DMSO Dimethyl sulfoxide 
dNTP Desoxyribo-nucleotide triphosphate 
Dox Doxorubicin 
EC Extracellular 
EDTA Ethylene-diamine-tetra-acetic acid 
EGF Epidermal growth factor 
EORTC European Organisation for Research and Treatment of Cancer 
EtOH Ethanol 
FACS Fluorescent-activated cell sorting 
FCS Fetal calf serum 
FDA Food and Drug Administration (in the United States) 
FISH Fluorescence in situ hybridization 
FO First order (NONMEM estimation method) 
FOCE First order conditional estimation (NONMEM estimation method) 
FORTRAN FORmula TRANslator (a computer programming language) 
GC Gas chromatography 
GF Growth factor 
GHz Giga-hertz (speed-unit for computers’ processors) 
GIST Gastrointestinal stromal tumor 
GR Grade (index of high purity for chemicals) 
HBSS Hanks’ balanced salt solution 
HL-60 Human leukemic cells 
hOCT1 Human organic cation transporter 1 (cation uptake transporter) 
HP Hewlett-Packard® (now Agilent Technologies®) 
HPLC High performance liquid chromatography 
HSP Heat shock proteins 
HUG Hôpitaux universitaires de Genève (i.e. Geneva University hospitals) 
IC Intracellular 
IC50 Inhibitory concentration 50% 
id Internal diameter (for chromatography columns) 
IS Internal standard (in analytical chemistry methods) 
IU International unit 
iv Intravenous (for drug administration) 
x Nomenclature 
 
KIT Mast/stem cell growth factor receptor CD117 gene 
LC Liquid chromatography 
LCC Clinical Chemistry Laboratory (at CHUV) 
LLC-PK1 Porcine kidney epithelial cell line 
LLOQ Lower limit of quantification 
LOD Limit of detection 
Log P Partition coefficient (measure of drug lipophilicity) 
LOQ Limit of quantification 
MAP Mitogen-activated protein 
mAU Milli-absorbance unit (used in UV detection) 
MDR Multi-drug resistance gene 
MeOH Methanol 
MRM Multiple reaction monitoring 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
NADH Nicotinamide adenine dinucleotide reduced form 
NCI National Cancer Institute (in the United States) 
NH4Ac Ammonium acetate 
NM-TRAN NONMEM translator 
NONMEM NONlinear Mixed Effects Model 
OCT Organic cation transporter 
OF Objective function (in NONMEM, corresponding to -2 log likelihood) 
p53 Protein 53 kDa (a tumor suppressor protein) 
PBGD Porphobilinogene deaminase (reference gene used to quantify cDNA amount 
of another gene) 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate-buffered saline 
PCL Division of Clinical Pharmacology & Toxicology (at CHUV) 
PCR Polymerase chain reaction 
PD Pharmacodynamics 
PDGF Platelet-derived growth factor 
PET Positron emission tomography 
P-gp P-glycoprotein (xenobiotic efflux transporter) 
Ph Philadelphia chromosome (landmark of CML) 
Nomenclature xi 
 
PK Pharmacokinetics 
pl Picoliter (i.e. a trillionth of liter = 10-12 l) 
PMU Policlinique Médicale et Universitaire (i.e. Lausanne University policlinic) 
PREDPP PREdiction for Population Pharmacokinetics (subroutine for NONMEM) 
QALY Quality-adjusted-life-years (in pharmacoeconomic studies) 
qd Daily 
QD Once a day 
qMSF Quantitative Mass Spectrometry Facility (at CHUV) 
RECIST Response evaluation criteria in solid tumors 
RNAi RNA interfering pathway 
RP Reversed phase (for chromatography columns) 
RPMI Roswell Park Memorial Institute 
RT Room temperature 
SAR Structure activity relationships 
SB Sleeping Beauty (a synthetic transposon derived from some fish species) 
SD Standard deviation 
SFSTP Société Française des Sciences et Techniques Pharmaceutiques 
si-RNA Small interfering RNA 
SLC Solute liquid carriers 
SNP Single nucleotide polymorphism 
SOP Standard operating procedure 
SPARC Scalable Processor ARChitecture (a computer microprocessor from Sun®) 
SPE Solid-phase extraction 
STI Signal transduction inhibitor 
t1/2 Half-life of elimination 
t1/2a Half-life of absorption 
TBE Tris/borate EDTA buffer 
TDM Therapeutic drug monitoring 
TSQ Triple stage quadrupole 
UCR Urinary cortisol ratio 
Vd Volume of distribution 
VEGF Vascular endothelial growth factor 
VIS Visible light 
wt Wild-type 
xii Nomenclature 
 
Symbols 
Latin letters 
A Adenine (in nucleic acid) 
C Concentration (used in pharmacokinetics); Cytosine (in nucleic acid) 
d Deuterium isotope 
E Effect (used in pharmacodynamics) 
F Forward (for PCR primers); Bioavailability (in pharmacokinetics) 
G Guanine (in nucleic acid) 
h Human 
m Mass (in mass spectrometry) 
M Molar 
n Number 
p Short arm (for chromosomes) 
q Long arm (for chromosomes) 
R Reverse (for PCR primers); Receptor 
T Temperature; Thymine (in nucleic acid) 
u Continuous variable in regression analyses 
v Volume 
y Observation used in NONMEM (typically the plasma concentration of a drug) 
y Discrete variable in logistic regression analyses 
z Fixed effect used in NONMEM (e.g. age, height) 
z Charge (in mass spectrometry) 
Greek letters 
α Alpha: letter used to characterize a residue position on chemical structures 
β Beta: letter used to characterize a residue position on chemical structures 
Δ  Delta: difference 
ε Epsilon: residual error of an observation y, also called random effect parameter 
φ Phi: parameters generated by NONMEM, such as clearance, function of fixed 
effect z and fixed effect parameters θ 
η Eta: interindividual error in NONMEM models 
θ Theta: fixed effects parameters generated by NONMEM 
ω Omega: standard deviation parameters generated by NONMEM 
Nomenclature xiii 
 
Script 
Subscript 
a Absorption 
d Dissociation 
i Observation 
j Subject (i.e. individual) 
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matinib mesylate (Glivec®), a new drug marketed in 2001, has revolutionized the treatment of 
two types of cancers, namely chronic myeloid leukemia (CML) and gastrointestinal stromal tumor 
(GIST). The present thesis focuses on a prospective pharmacokinetic study initiated in 2002 at 
the “Division de Pharmacologie et Toxicologie cliniques” (PCL) in Lausanne, during my Master 
of Advanced Studies (DESS) in Hospital pharmacy [1]. 
The aim of this study is to describe the population pharmacokinetics of imatinib, to identify 
the relevant factors likely to influence imatinib disposition, and finally to examine whether poor 
tolerance or resistance to imatinib treatment could be explained in some instances by alterations 
in its pharmacokinetics. Gaining such knowledge is determinant to evaluate if imatinib could be a 
candidate for a therapeutic drug monitoring (TDM) program. 
This introducing chapter comprises an overview of the general concepts necessary for 
understanding the pathophysiology of the major cancers treated with imatinib, as well as the 
therapeutic options existing before and after the marketing of Glivec®. After a presentation of 
relevant biochemical and pharmacological informations on the drug itself, some underlying 
principles of drug disposition in the body will be described from a pharmacokinetic and 
pharmacogenetic point of view. Finally, this introduction will present a more detailed description 
of the aim of this work. 
Various chemical, biochemical and computational analytical techniques have been used during 
this study. The background and theoretical informations concerning them will be given in the 
related chapters of this manuscript. 
1.1 Cancer 
1.1.1 Epidemiology 
Cancer (also referred as malignant neoplasia1) is characterized by uncontrolled division of cells 
and by the ability of these cells to invade other tissues, either by direct growth into adjacent tissue 
(invasion) or by implantation into distant sites (metastasis). Cancer represents the second leading 
cause of death in the Swiss population, at the same rank as in Europe and in the United States. In 
                                                
1 A neoplasia is a disorganized cell growth in a tissue or organ, usually forming a distinct mass. A neoplasia can be 
benign or malignant (i.e. characterized by local invasion or metastasis, and leading a priori to death). 
I 
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Switzerland, cancers account for 26% of all death cases, after cardiovascular diseases, which 
account for 40% [2]. In the United States, it is expected that the number of American citizens 
diagnosed with cancer each year will double in the next 50 years, notably because of the 
population aging. Cancer represents thus an enormous challenge to handle by physicians and 
scientists in the 21st century. Moreover, the social burden and costs of this disease are 
consequently anticipated to increase, with important socio- and pharmaco-economical 
implications that our health systems will have to tackle. To reduce this cancer burden, it is 
therefore especially important to put much emphasis on the prevention to lower all behavioral 
and environmental factors known to increase the cancer risks. Sustained efforts must be made so 
that high-quality screening services and evidence-based treatments, including pharmacotherapy, 
are accessible to everyone [3]. 
1.1.2 Biological mechanisms 
After a quarter century of relatively rapid advances, cancer research has generated a rich and 
complex body of knowledge. For the next quarter of century, some scientists foresee that cancer 
research will develop into a logical science, where the complexities of the disease, described in the 
laboratory and clinics, will become understandable in terms of a small number of underlying 
principles. They forecast that one day cancer biology and treatment –at present a patchwork of 
cell biology, genetics, histopathology, biochemistry, immunology and pharmacology– will become 
an integrated science with a conceptual structure and logical coherence rivaling that of chemistry 
and physics [4]. 
This paragraph will briefly present a conceptual view of cancer mechanisms recently 
developed by Hanahan and Weinberg [4]. They indeed suggested that the vast catalog of cancer 
genotype –more than 100 distinct types of cancer have been described at present– is a 
manifestation of only six essential alterations in cell physiology that collectively dictate malignant 
growth (Figure 1.1): 
1. Self-sufficiency in growth signals: Normal cells require exogenous mitogenic growth signals from 
their environment to proliferate. On the other hand, tumor cells themselves generate many 
of their own growth signals. To achieve this autonomy, cells can acquire the ability to 
synthesize their own growth factors (GF; e.g. PDGF, platelet-derived growth factor and 
EGF, epidermal growth factor). GF receptors of the cells (e.g. c-Kit receptor) can also be 
upregulated, which makes them hyperresponsive to ambient GF levels. Finally, alterations  
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in components implicated in the intracellular transmission of the growth signal (e.g. Ras 
protein) can occur. 
2. Insensitivity to antigrowth signals: Within a normal tissue, antiproliferative signals operate to 
maintain cellular quiescence and tissue homeostasis. Alterations in this process can be due 
to the loss of function of proteins (e.g. retinoblastoma protein) necessary to suppress 
mitotic progression. They can also result from the avoidance of the terminal differentiation 
of cells by overexpression of proteins (e.g. Myc protein) shifting the differentiation-
inducing signals. 
3. Evading apoptosis: Cell death (apoptosis) program is present in latent form in virtually all cell 
types throughout the body. Once triggered by a variety of signals, this program unfolds in 
precise steps. The p53 tumor suppressor protein (a DNA damage sensor) is a key 
component of the apoptotic signaling circuitry. Mutations involving its related gene 
represent the most common cause of cancer cell resistance to apoptosis. 
 
Figure 1.1. Acquired capabilities of cancer (Reprinted from Cell, 100, Hanahan D et al, The Hallmarks of Cancer, 
57-70, Copyright 2000, with permission from Elsevier) 
4. Limitless replicative potential: Even the acquisition of the three previous capabilities does not 
ensure expansive tumor growth to a macroscopic extent. Mammalian cells carry indeed an 
intrinsic, cell-autonomous program that limits their multiplication. This appears to be due 
to the progressive erosion of the ends of chromosomes (telomeres), leading to the almost 
inevitable cell death. Maintenance of these telomeres by telomerase enzymes provides a 
cause of cell immortalization when these enzymes are upregulated. 
4 Chapter 1 
General introduction 
 
5. Sustained angiogenesis: The oxygen and nutrients supplied by the blood vessels are crucial for 
cell function and survival. The growth of these vessels in a new tissue is called angiogenesis. 
In general, the tumor cells initially lack angiogenic abilities and must develop them. The 
overexpression of the angiogenesis signals (e.g. VEGF, vascular endothelial growth factor), 
as well as the downregulation of endogenous inhibitors (e.g. interferon-β), represent 
strategies to activate the angiogenetic switch. Loss of the p53 upregulation function of the 
thrombospondin-1, a known angiogenesis inhibitor, is a well-documented example of this 
situation. 
6. Tissue invasion and metastasis: Distant settlements of tumor cells (metastasis) are the cause of 
90% human cancer death. The capability to colonize new terrains in the body allows cancer 
cells to reach area where nutrients and space are initially not limiting. Two main processes 
coexist in order to achieve such dissemination. The first one involves changes in the 
physical coupling of cells to their environment (e.g. alteration of CAMs, cell-cell adhesion 
molecules). The second one involves activation of extracellular proteases that facilitate the 
invasion into the tissue framework (e.g. induction of urokinase in some carcinomas). 
These six capabilities should be shared in common by most and perhaps all types of human 
tumors. Most of them are acquired, directly or indirectly, through changes in the genomes of 
cancer cells. However, mutations are by themselves an inefficient process because of various 
DNA monitoring and repair systems that are available in our cells. It’s thus rather the 
malfunction of these genomic “caretakers” that could explain why genomic instability leads to the 
three existing cancer types (epithelial, mesenchymal and hematological). 
1.2 Chronic myeloid leukemia & gastrointestinal stromal tumor 
1.2.1 Leukemias 
Leukemias are cancers characterized by a malignant proliferation of bone marrow cells (blood 
cell lines or precursors). Each leukemia type may progress differently, but generally proliferative 
cells initially replace the normal bone marrow, interfering with its function. Malignant cells can 
subsequently invade other organs, with a fatal consequence if the leukemia is not treated [5]. 
Characterization of the first chronic leukemias was done by Bennett in 1845 [6]. Acute leukemias 
were discovered later in 1870. The term leuxaimia means “white blood” in Greek, because of the 
blood color of patients autopsied by Virchow in the middle of the 19th century [7]. 
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1.2.1.1 Acute leukemias 
These leukemias are characterized by an abrupt onset of clinical signs (infection, hemorrhage, 
pale skin) and symptoms (tiredness, arthralgia and bone pains), followed by a rapid death within a 
few months in the absence of treatment. They can affect adults, as well as children [5]. 
In this case, a minimum of 30% of all nucleus marrow cells consists of blasts (myeloid2 or 
lymphoid3 immature cells). Peripheral white cells number is typically raised, but it is also common 
to observe anemia and neutropenia, and generally thrombocytopenia too [5]. 
1.2.1.2 Chronic leukemias 
Apparition of clinical signs (pale skin, spleen and/or liver hypertrophy, weight loss) and 
symptoms (tiredness, weakness, depression) is insidious, and death does not occur until many 
years after diagnosis of the disease. These leukemias mainly affect adults, but chronic myeloid 
leukemia forms have also been observed in children [5]. 
The peripheral white blood cells count is usually superior to the one observed in acute 
leukemias, and the bone marrow is invaded by massive amounts of immature cells. Contrary to 
the acute forms, the thrombocytes level is normal if not higher than normal, and thrombopenia 
only occurs late in the disease. On the other hand, anemia is frequently observed [5]. 
1.2.2 Chronic myeloid leukemia 
1.2.2.1 Clinical characteristics 
Chronic myeloid leukemia (CML) is a chronic myeloproliferative disorder, characterized by an 
important occurrence of myeloid constituent in bone marrow, peripheral blood, and other 
tissues [5]. Usually, a chronic phase of 3 to 5 years can be observed, followed by an accelerated 
phase of 6 to 18 months, and finally a blast phase (or blastic crisis) of 3 to 6 months [5,8,9]: 
1. Chronic phase: Stage of myeloid hyperplasia with a marked leukocytosis and the presence of 
immature granulocytes in the blood. Thrombocytosis and, to a various extent, basophilia, 
neutrophilia and eosinophilia can be commonly observed at this stage. Leukemic cells are 
normally unable to differentiate themselves, but 50% of patients are asymptomatic at the 
time of diagnosis and are only identified during routine laboratory tests. Figure 1.2 shows 
an example of a chronic phase patient’s blood film. 
                                                
2 Myeloid cells are circulating cells produced and maturated in the bone marrow (muelos in Greek). These cells are 
either erythrocytes, thrombocytes, monocytes or polynuclear cells (i.e. neutrophils, eosinophiles, basophiles). 
3 Lymphoid cells are circulating cells maturated in the lymphatic system (i.e. lymphe node, thymus, etc). Two typical 
lymphoid cells are the white cells lymphocytes T and lymphocytes B. 
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Figure 1.2. Peripheral blood film of a chronic phase CML patient (courtesy of Hematology Service, CHUV) 
2. Accelerated phase: Intermediate stage with a progression of the disease characterized by an 
increase in blast cells count (15-30%) and basophiles count (>20 %), without meeting 
however the criteria of an acute leukemia. 
3. Blastic crisis: Increase of myeloid immaturity and evolution to an acute leukemia. 
CML can occur at any age, but is more common after the age of 45, with a median age at 
diagnosis close to 60 years. This disease represents 20% of all cases of leukemias and has an 
incidence of 1-1.5 new case for 100’000 inhabitants, each year. Before the introduction of 
imatinib, the average age of death was 66 years [5,9]. 
1.2.2.2 Molecular mechanism 
Tyrosine kinases are enzymes that are able to phosphorylate (using ATP) various cellular 
proteins bearing tyrosine residues. Toward this end, they first have to phosphorylate themselves 
(autophosphorylation). In fact, a number of diseases, including cancer, diabetes, and 
inflammation, is linked to perturbation of protein kinase-mediated cell signaling pathways4. The 
importance of signaling in the development of cancers has already been discussed in the item 
no. 1 of § 1.1.2. Some of the tyrosine kinases are receptor kinases (initiating intracellular 
signaling) and others are cytoplasmic kinases [10]. The CML cells are characterized by the 
expression of an altered cytoplasmic tyrosine kinase named Bcr-Abl. 
The presence of this altered tyrosine kinase is due to a reciprocal translocation between the 
long arms of chromosome 9 and 22. Chromosome 22 is thus shortened and named Philadelphia 
chromosome (Ph), which is the landmark of CML. This has been discovered as early as in 1960 
                                                
4 It is noteworthy that the human genome encodes some 518 protein kinases. 
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by Nowell and Hungerford [11] and provided the first proof of the association of a genetic 
modification with a human cancer [12]. Figure 1.3 shows the cytogenetic impact of this 
translocation. 
 
Figure 1.3. Caryotype of the t(9;22)(q34;q11) translocation, the landmark of CML (Reprinted from European 
Journal of Cancer, 37, Mughal TI et al, Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma, 561-
8, Copyright 2001, with permission from Elsevier) 
The molecular consequence of this translocation is the creation of an oncogene BCR-ABL 
coding for the oncoprotein Bcr-Abl. This gene results from the fusion of the oncogene ABL 
(Abelson’s leukemia virus) of chromosome 9 with a sequence of chromosome 22 named 
“breakpoint cluster region” (BCR) [13]. Figure 1.4 schematizes this molecular event. 
Comparatively to the normal Abl protein, the Bcr-Abl protein shows an important increase of its 
tyrosine kinase activity. Its size depends on the break point in BCR, and the two most common 
sizes are 185 kDa (p185 Bcr-Abl) and 210 kDa (p210 Bcr-Abl). The p210 protein is found in 
95% of CML patients and up to 20% of adult acute lymphoblastic leukemia (ALL) patients. 
Conversely, the p185 is observed in 10% of adult ALL and in the majority of pediatric Ph+-ALL 
patients [9]. 
 
Figure 1.4. Reciprocal translocation between chromosome 9 and 22 
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Constitutive activation of those tyrosine kinase results in the activation of various intracellular 
signal transduction pathways, leading to alterations of proliferative, adhesive and survival 
properties of the cells, and thus to the clonal expansion characterizing cancers (see also § 1.1.2). 
1.2.3 Gastrointestinal stromal tumor 
1.2.3.1 Clinical characteristics 
Gastrointestinal stromal tumors (GISTs) are rare tumors originating from mesenchymal stem 
cells of the gastrointestinal tract. Such tumors represent however the most common non-
epithelial neoplasm of the gastrointestinal tract5. From a clinical and pathological point of view, 
GISTs represent a wide range of indolent tumors to aggressive malignant cancers. GISTs appear 
mainly in the stomach (60-70%) and subsidiarily in the intestine, or even in the rectum or 
esophagus. The clinical presentation is variable and the tumor is often silent before it reaches a 
large size. At presentation, the most common symptoms are abdominal pain and presence of a 
palpable abdominal mass. Many patients develop recurrent GIST, in spite of initial surgical 
resection. Recurrence usually occurs in the peritoneum or in the liver. After resection of the 
recurrent tumor, the average survival was usually only 15 months [14,15], prior to the imatinib 
era. Figure 1.5 shows the positron emission tomography (PET) of a patient with a metastatic 
GIST prior to (left-hand picture) and after (right-hand picture) a successful imatinib 
treatment [16]. 
 
Figure 1.5. PET-scan of a metastatic GIST before and after treatment with imatinib (Copyright 2001 Massachusetts 
Medical Society. All rights reserved. Reproduced with permission from The New England Journal of Medicine, 344, 
Joensuu H et al, Brief report: effect of the tyrosine kinase Inhibitor STI571 in a patient with a metastatic 
gastrointestinal stromal tumor, 1052-6) 
                                                
5 GIST is in fact a type of sarcoma (i.e. a cancer of connective or supportive tissue) and represents 5% of all cancer 
in this class. 
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GISTs are characterized by a highest incidence in the 5th to 7th decades, with a median 
occurrence age of 58. Fortunately, incidence is rather low with about 0.3 new cases per year for 
100’000 inhabitants. 
1.2.3.2 Molecular mechanism 
Constitutive activation of the tyrosine kinase receptor c-Kit (CD117) is a key event in the 
pathogenesis of most GISTs. It usually results from point mutations in extra- or intracellular 
domains of this receptor. From a cytogenetic point of view, these mutations are often 
accompanied by a deletion of chromosome 14 or 22, or by a 1p deletion [17]. However, they can 
also occur with a normal caryotype and only point mutations. In mice, for instance, deletion of 
the valine in c-Kit position 558 is sufficient to induce GIST [18]. The most common site of KIT 
(i.e. coding gene of c-Kit) mutation is located at the 5’ end of the exon 11, which encodes the 
juxtamembrane domain. KIT exon 9 mutation occurs in 10-15% of patients, defining a distinct 
subset of GISTs that are often located in the small bowel and have an aggressive clinical 
behavior [19]. These mutations on c-Kit could possibly be responsible per se for the neoplasic 
process, while the biological and clinical progression of the tumor may result mainly from the 
cytogenetic aberrations [17]. Alternately, some GISTs are characterized by another profile of 
mutations (KIT exon 13 or 17 or PDGFRA exon 12 or 18 mutations) or by no detectable 
mutations (especially in the pediatric patients) [19]. 
Mutations may affect the modulation domain of the receptor, as well as its enzymatic domain 
itself, and confer to the receptor the ability to phosphorylate numerous proteins. This results in 
the activation of a number of transduction signal pathways, which control cell proliferation, 
apoptosis, chimiotactism and adhesion (see also § 1.1.2 for more information on signaling) [17]. 
1.2.4 Treatments: an overview 
1.2.4.1 Chronic myeloid leukemias 
Before the imatinib era, standard treatments of this cancer in chronic phase were allogenic 
transplant of stem cells, or the use of hydroxyurea or interferon-α [9]. 
1. Hydroxyurea: Usually used for initial cytoreductive chemotherapy, but a cytogenetic 
response6 is rare. 
2. Allogenic transplant: Only curative therapy to date, with a success rate of 70-80% for young 
patients (< 40 years old). 
                                                
6 A cytogenetic response corresponds to a reduction of Ph+ cells in blood or bone marrow. 
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3. Interferon-α: Standard treatment since the 1980s with a hematological response observed in 
80% of patients. However, a complete cytogenetic response is observed in only 10-20% of 
them. Adjunction of cytarabin increases response level and its coadministration 
represented, despite its toxicity, the gold standard when no transplant was possible. 
1.2.4.2 Gastro-intestinal stromal tumor 
Surgery represents the most valued treatment for the initial phase of GIST. Before imatinib 
introduction, the available options for the metastatic or unresectable stages comprised [15]: 
1. Surgery: When used initially the survival rate at 5 years was 54%. 
2. Adjuvant after initial surgery: Chemo- or radiotherapy used only when the resection was at 
risk. 
3. Systemic chemotherapy: Since the response rate to chemical agents is very low (<10%), it was 
difficult to recommend any treatment. Compounds like doxorubicin were however tried. 
4. Intraperitoneal chemotherapy: To improve the results of peritoneal resection, locoregional 
administration of cisplatin and doxorubicin [20], or of mitoxanthrone [21], were used. 
5. Hepatic metastasis surgery: Such a resection allowed a survival rate of 58% at 3 years. 
6. Chemoembolization: Option for hepatic metastasis consisting in an occlusion of the hepatic 
arterial bed by polyvinyl alcohol, with or without a cytotoxic agent. 
7. Radiotherapy: Only rarely used because of the usually diffuse localization of metastases. 
Following the imatinib revolution, such therapies (especially surgery) are mainly used when 
resistance to imatinib occurs. However, at present, new approaches aim at preventing resistance 
development, even before it occurs, using surgery. Furthermore, some ongoing trials are 
assessing imatinib as adjuvant or neoadjuvant7 to improve the outcome of surgery in primary 
resectable or metastatic GIST [22]. 
1.3 Imatinib and its characteristics 
Imatinib (Glivec®, or Gleevec® in the USA), previously known as STI571, was rationally 
designed to inhibit the Bcr-Abl tyrosine kinase previously described [12]. Imatinib was also found 
to potently inhibit the autophosphorylation of two additional tyrosine kinases: c-Kit, involved in  
 
                                                
7 Adjuvant therapy refers to additional treatment, usually given after the main treatment (e.g. surgery) where all 
detectable disease has been removed, but where there remains a statistical risk of relapse. Neoadjuvant therapy, in 
contrast, is given before the main treatment. 
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the oncogenesis of GIST [23], and the platelet-derived growth factor receptor (PDGFR), 
involved in the pathogenesis of the hypereosinophilic syndrome [24]. 
This “blockbuster” drug was approved by the FDA (United States regulatory agency) for CML 
within an unprecedented short time of 72 days (May 10, 2001) because of the impressive results 
obtained during the initial phase I and II clinical trials [8], with an impressive 90% complete 
response rate [25]. A phase III trial confirmed the very high percentage responses induced by 
imatinib in chronic phase CML [26]. However, these studies showed less impressive responses 
with patients in accelerated phase and blastic crisis [12]. In addition, other clinical trials have also 
showed an important anti-tumor activity of imatinib for GIST and the hypereosinophilic 
syndrome [23,24]. The drug was thus approved in the USA on February 1st, 2002 for the 
treatment of recurrent GIST. Swissmedic also quickly approved the drug in Switzerland for CML 
and GIST. For the latter cancer, imatinib was even accepted on an orphaned drug status. 
Remarkably, the 2-year survival of patients with metastatic GIST is now about 70% [27]. This led 
the chief executive officer of Novartis (the manufacturer of Glivec®) to name this drug a “magic 
cancer bullet8” [28]. 
1.3.1 Imatinib in the general context of cancer chemotherapy [29,30] 
Imatinib constitutes one of the first examples of what is considered now as the revolution of 
targeted-therapy of cancer. As such, it is therefore certainly of interest to put imatinib on the 
more general historical context of anticancer drugs development [29]. Figure 1.6 presents a 
schematic view of the timeline of this history, beginning indeed in the early 1940s. 
In 1942, Goodman and Gilman, two pharmacologists working for the U.S. Department of 
Defense, discovered that nitrogen mustards –deriving from toxics developed for chemical 
warfare– were able to induce tumor regression by forming alkylated intermediates covalently 
bonding double stranded DNA. Some years later, Farber, a pathologist at the Boston Children 
Hospital, discovered the benefit of antifolates (e.g. methotrexate; acting by inhibiting pyrimidines 
and purines synthesis) in acute lymphoblastic leukemia (ALL), and in various epithelial cancers. 
Afterwards, other antileukemic drugs came to clinical trials in the 1950s (especially 
6-mercaptopurine and Vinca alkaloids) and the National Cancer Institute (NCI) began in 1955 a 
program for systematic drug screening. Most of the pharmaceutical companies were indeed not 
interested in developing anticancer drugs at that time. Then, in 1956, a combination of several 
                                                
8 The term “magic bullet” was used by the bacteriologist Paul Ehrlich to describe his goal: a specific cure for syphilis 
which would attack the syphilis spirochaete while having no effect whatsoever on human tissue. It is still used today 
to characterize wished-for drugs. 
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agents proved to be efficient in ALL and launched the concept of combination chemotherapy (like in 
antibacterial therapy). In 1975, a combination of an alkylating agent and 5-fluorouracil (a 
modestly effective drug inhibiting DNA synthesis) proved to extend survival when used after 
surgical resection of breast tumors. This observation initiated the concept of adjuvant chemotherapy 
(see note 7 on page 10). In 1978, the FDA approved cisplatin (a compound inhibiting DNA 
synthesis by covalent bounding) for the treatment of ovarian cancer, a drug also effective against 
a wide variety of solid tumors. Many years before, in 1956, Zubord, working for the NCI, 
discovered paclitaxel, a mitotic spindle poison, in the Pacific Yew tree (Taxus brevifolia L.). It was 
however not until 1992 that the FDA approved this compound, which then became as Taxol® 
the first “blockbuster” oncology drug. 
 
Figure 1.6. Timeline of the history of chemotherapy (Reproduced with permission from Nature Reviews Cancer, 5, 
Chabner BA et al, Chemotherapy and the war on cancer, 65-72, Copyright 2005 Macmillan Magazines Ltd.) 
Following all these developments of cytotoxic drugs, a revolution occurred in the late 1980s. 
Molecular and genetic approaches uncovered entirely new signaling networks regulating cellular 
activities, as important as proliferation and survival. Researchers in small biotechnology firms set 
out to repair these molecular defects and thus initiated the era of “targeted therapy”. Most of the 
new targets are related to the mechanisms that have been presented in § 1.1.2 (e.g. growth 
factors, signaling molecules, apoptosis modulators and angiogenesis promoters). In the early 
1990s, this transformed cancer drug development from a low-budget government research into a 
multi-billion research industry, using combinatorial chemistry, high throughput screening, and  
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high tech in silico9 methods (e.g. SAR, structure-activity relationships methods). Among the 
properties that the drug would ideally possess, attention was given to greater specificity to the 
target it was designed to, and to oral bioavailability. In that perspective, one of the landmark 
events in this revolution has been the development by Novartis (formerly Ciba-Geigy) of 
imatinib, a relatively simple structure possessing apparently all the desired features of the “ideal” 
targeted compound. Additional first-generation signal transduction inhibitors comprise those 
interfering with EGF receptor (gefitinib, inhibiting the ATP-binding function of the receptor, or 
cetuximab, a monoclonal antibody against the receptor extracellular domain). A third important 
class of compounds that is being developed consists of antiangiogenic molecules that inhibit the 
VEGF receptor (e.g. sunitinib, also targeting c-Kit receptor) or anti-VEGF antibodies 
(bevacizumab). 
The next decade will probably present the challenge of designing trials aiming at combining 
targeted drugs and cytotoxics in a more effective manner to better treat oncologic patients. 
However, the pharmacoeconomic challenge of paying for all of these new agents (395 new agents 
are in development…) will certainly become an important issue. The total worldwide market for 
oncology products was approximately 46.5 billions Swiss francs in 2003, representing almost 10% 
of the total market of pharmaceutical, and is projected to exceed 75 billions by 2008 [29]. All 
these important pharmacoeconomical issues will thus have to be considered with the emergence 
of this targeted-therapy of cancer, but they certainly lie beyond the scope of the present 
introduction. 
1.3.2 Development of imatinib 
Back to imatinib, it is worth mentioning that the first tyrosine kinase inhibitors, tyrphostins, 
were already described as early as in 1988 [31]. Later on, researchers at Ciba-Geigy, under the 
direction of Lydon and Matter, identified a new lead compound by the screening of protein 
kinase C inhibitors. This compound, a 2-phenylaminopyrimidin derivative, was subsequently 
optimized by structure-activity relationships [9,32]. This resulted (1992) in the synthesis of the 
best compound with respect to activity, selectivity, and bioavailability [12]. It was initially named 
CGP57148B (CGP for Ciba-Geigy Product) and then STI571 (STI for Signal Transduction 
Inhibitor). It is chemically designed as 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]-amino]phényl]benzamide methanesulfonate (Figure 1.7). 
                                                
9 The term in silico applies to computer simulations that model natural or laboratory processes (in all the natural 
sciences). It usually does not refer to calculations done by computer generically. 
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Figure 1.7. Chemical structure of imatinib mesylate 
Imatinib was initially marketed as 100-mg capsules. More recently, 100- and 400-mg tablets 
have also been made available, with an attested bioequivalence [33]. The recommended dosing 
regimen is 400 mg daily for chronic phase CML patients, 600 mg daily for accelerated and blast 
phases CML patients, and 400 mg for GIST patients. The dose can be raised in case of lack of 
efficacy (if no side effects are observed) [34]. 
1.3.3 Pharmacodynamics 
1.3.3.1 Chronic myeloid leukemia 
In the general situation, tyrosine kinase inhibitors bind directly to the catalytic site of the target 
enzyme. Selective inhibitors, such as imatinib, occupy the catalytic site, recognizing a limited 
sequence variation near the ATP-binding site, as well as conformational differences between 
active and inactive kinases. Furthermore, imatinib binding to the enzyme also decreases its ATP 
binding capacity [35]. Figure 1.8 presents a schematic view of the mechanism concerning imatinib 
and Bcr-Abl. 
 
Figure 1.8. Proposed mechanism of action of imatinib: Bcr-Abl phosphorylation of a substrate in the absence (left 
panel) or presence (right panel) of imatinib (Copyright 2001 Massachusetts Medical Society. All rights reserved. 
Reproduced with permission from The New England Journal of Medicine, 344, Goldman JM et al, Targeting the 
BCR-ABL tyrosine kinase in chronic myeloid leukemia, 1084-6) 
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Imatinib captures in fact a specific inactive conformation of the activation loop of Bcr-Abl. It 
mimics ATP, but blocks the conformational change of the protein normally required for 
substrate phosphorylation [36]. Figure 1.9 depicts imatinib bound in the Abl moiety of the 
enzyme and freezing the kinase in its inactive conformation. 
 
Figure 1.9. Structure of the Abl kinase domain in complex with imatinib (A: ribbon representation, with the 
activation loop and the van der Waals surfaces corresponding to the inhibitor colored blue; B: schematic diagram of 
the interactions made by imatinib, with protein residues labeled and shown in stick representation) (Reprinted from 
Cancer Research, 62, Nagar B et al, Crystal structures of the kinase domain of c-Abl in complex with the small 
molecule inhibitors PD173955 and imatinib (STI-571), Copyright  2002, with permission from the American 
Association for Cancer Research) 
By altering the binding affinity of Bcr-Abl for ATP and substrate proteins, imatinib prevents 
the subsequent phosphorylation of a number of cellular proteins [37]. This results in an inhibition 
of the constitutive activation of several proteins involved in signal transduction pathways, thus 
blocking the proliferation and clonal expansion of cancer cells [38]. 
1.3.3.2 Gastro-intestinal stromal tumors 
Inhibition of the c-Kit oncoprotein by imatinib was also hypothesized, and in fact verified 
with the knowledge that the structure of the catalytic domain of this protein is very close to that 
of PDGFR, another target of imatinib [39]. The drug thus appeared to bind to the intracellular 
tyrosine kinase catalytic site of c-Kit by a mechanism similar to that of Bcr-Abl. 
Modulation of this pathway has been experimentally demonstrated to significantly inhibit the 
growth of c-Kit expressing cells [39]. 
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1.3.4 Pharmacokinetics 
1.3.4.1 Absorption 
Upon oral administration, imatinib is well absorbed and its bioavailability is about 98%. The 
maximum plasma concentration (Cmax) is reached after 2 to 4 h [8]. 
1.3.4.2 Distribution 
At clinically relevant concentrations, plasma protein binding is about 95%, mainly to α1-acid 
glycoprotein (AGP), as well as to albumin [8,40]. The typical volume of distribution (Vd) of 
295 l [41] expresses an affinity of imatinib for the tissular constituents beyond the average affinity 
for plasma components. 
Of importance, imatinib was found to have a limited penetration into some profound body 
compartments, and this may have important clinical consequences. A recent study on mice has 
shown that the central nervous system (CNS) becomes a sanctuary site when animal harboring 
BCR-ABL transfected hematopoietic cells are maintained on imatinib for several months. 
Imatinib has been reported to cross only marginally the blood-brain barrier (possibly because of 
the high levels of P-gp in the blood-brain barrier; see § 1.4.3) [42]. This low penetration in the 
brain compartment was indeed found to influence the therapeutic response of a CML patient 
who unexpectedly experienced a blastic crisis of the CNS, although having achieved a complete 
cytological remission in his bone marrow. The levels of imatinib and of its active metabolite in 
this patient were 40-fold lower in the cerebrospinal fluid than in plasma [43]. 
1.3.4.3 Elimination 
Imatinib is mainly metabolized by cytochrome P450 isoenzyme 3A4 (CYP3A4), and its 
elimination half-life is about 14 to 18 h. Its main metabolite, N-desmethylimatinib (or 
CGP74588) is still active with a similar in vitro potency and a half-life of about 20 to 40 h. It 
represents however no more than 10% of the dose [8,44,45] after a single oral dose and no more 
than 20% at steady state [42]. 
The drug is also metabolized, to a minor extent, by the CYP isoenzymes 1A2, 2D6, 2C9 and 
2C19 [46]. Alternately, imatinib is a weak CYP2C9, 2C19 and 3A4 inhibitor [34] while its main 
metabolite is an inhibitor of CYP2D6 [8]. 
The mean total clearance (CL) value of about 10 l/h determined to date [8,47,48], and 
associated with the bioavailability of almost 100 %, means that imatinib is not a drug  
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characterized by a high extraction factor. The determinant factors for its elimination are thus the 
intrinsic hepatic clearance and the free fraction. 
1.3.5 Safety 
Even if imatinib was initially considered as a “magic bullet”, it has been observed that most 
patients experienced adverse drug events during the various clinical trials. For CML-, as for 
GIST-patients, the most frequent adverse events reported are fluid retention, nausea, skin rash, 
asthenia and muscle cramps, with an incidence of more than 50% (grades 1 to 4). There is a trend 
suggesting increased incidence of grade 3/4 adverse events during the advancing phase of the 
disease, but this rarely leads to a discontinuation of the therapy [8,49]. However, the severity of 
the adverse drug reactions encountered with imatinib is generally not comparable with those 
usually observed with the standard cytotoxic chemotherapy agents. 
1.3.6 Label-use 
In Switzerland, imatinib has received the Swissmedic approval for [34]: 
1. Treatment of Ph+-CML patients in chronic, accelerated and blast phases (in adults and 
children). 
2. Treatment of malignant non-resectable or metastatic-GIST (in adults). 
It is noteworthy that Glivec® therapy constitutes an oncologic treatment that must be taken 
indefinitely. Even in good responders, interruption of the treatment cause a relapse within only a 
few weeks [50]. 
1.4 Mechanism of resistance to imatinib 
Despite the impressive efficacy identified in the initial clinical trials, resistance to imatinib 
develops in variable proportions of patients, especially for CML in accelerated or blast 
phase [12,51], and in up to 20% of GIST patients [52]. Bcr-Abl signal reactivation appears to 
represent the principal cause of acquired resistance to imatinib in CML patients. In 2002, 
Nimmanapali et al published a review of all potential resistance mechanisms in CML [51]. These 
mechanisms are summarized in Table 1.1. 
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Table 1.1. Mechanisms of resistance to imatinib in CML 
Leukemic cells modification  
 Bcr-Abl dependent  
 Mutations in Bcr-Abl (T315I, E255K, M351T, G250E, F317I)  
 Bcr-Abl amplification  
 Bcr-Abl independent  
 Other mutations  
 Signal perennisation by Lyn and MAP kinases  
 Drug efflux by P-glycoprotein  
Host variability  
 α1-acid glycoprotein binding  
 Metabolism (e.g. CYP3A4)  
 
The next paragraphs will briefly describe some important aspects concerning the mechanisms 
of resistance to imatinib. Focusing on this specific issue is certainly relevant in the context of our 
efforts to better understand the relationships between imatinib plasma levels and resistance to 
treatment. 
1.4.1 Point mutations in Bcr-Abl and c-Kit 
In August 2001, Sawyer et al have reported the identification of a point mutation in six of the 
nine patients subject to a relapse after imatinib treatment, and a gene overexpression in the three 
other patients. This mutation was a substitution of threonin by isoleucin in position 315 of the 
ATP-binding site of the kinase Abl domain (T315I; see Figure 1.9 for the exact position), at the 
exact position where imatinib binds [53]. All patients had previously presented a complete 
remission during 2 to 6 months. Since then, several other mutations have been described in 
resistant patients (more than 20 indeed, among more than 30 described overall [32]). It is 
noteworthy that BCR-ABL mutations have been reported to pre-exist to the onset of treatment. 
Imatinib treatment thus appears to select the mutant clones [54]. 
The mechanisms given in Table 1.1 have been identified in cell cultures while clinical 
resistance (i.e. relapses) reported in the literature concerned mainly patients in blast crisis [12,51]. 
This could in fact be expected considering the initial low response rate to the treatment observed 
in these patients [55]. 
In § 1.2.3.2, we have reported that there were two main types of GIST, those with KIT exon 
11 mutations and those with exon 9 mutations or wild-type KIT. Recent data suggest that tumors 
characterized by an exon 11 mutation may benefit from a better response to imatinib compared 
to the other subset of tumors [56]. On the other hand, the mechanism of acquired resistance 
(i.e. arising during the course of imatinib treatment) is however less well defined than in CML.  
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In 2003, Weisberg and Griffin have published a comprehensive review of this field reporting 
some specific mechanisms of resistance in GIST patients characterized by c-Kit and PDGFR 
point mutations. [57]. Last year, Antonescu et al have also shown that about half of the imatinib-
resistant GIST patients they studied presented acquired mutations in the kinase domain of c-
Kit [19]. All these mutations appeared in patients having a primary KIT exon 11 mutation and 
were all substitutions located in the first (exon 13 or 14) or especially second (exon 17) KIT 
kinase domain. It is however still unclear whether a pre-existing clone is responsible for such 
resistances. 
1.4.2 Amplification of the BCR-ABL  gene 
Several articles have addressed the important issue of BCR-ABL and KIT mutations, and their 
influence on the cellular resistance to imatinib [58-61]. In the case of BCR-ABL gene 
amplification, the extra copies of the gene overwhelm the imatinib cytostatic action by producing 
more enzymes than can be blocked by the agent. Thus, intracellular levels of imatinib may not be 
sufficient to effectively inhibit the large amount of coded Bcr-Abl enzyme present within the cell. 
In this case, for instance, the resistance may be possibly overridden by increasing imatinib levels 
at the intracellular site of action through a modulation of systemic and/or intracellular 
concentrations. Indeed, a recent study involving 54 CML patients, who were refractory to 
imatinib, or who had relapsed since first receiving standard dose of imatinib, was published. It 
showed that 65% of the subjects who had hematological resistance or relapse achieved a 
complete or partial hematological response when administered higher-than-conventional doses of 
imatinib [62]. 
1.4.3 Role of cell transporters 
1.4.3.1 P-glycoprotein (P-gp) 
Drug transporters are increasingly recognized as another key determinant of drug disposition 
and response [63-65]. The P-glycoprotein (P-gp) transporter is a 170-kDa transmembrane protein 
(shown in Figure 1.10), which is the product of the Multiple Drug Resistance gene MDR1 
(named at present ABCB110 [66]). P-gp and related multiple-resistance protein-1 (MRP-1) are 
ATP-binding cassette carriers that expel anticancer (as well as various other drugs or 
environmental xenobiotics) out of cells. They thus lower intracellular concentrations, conferring 
or increasing resistance to these agents. Physiologically, P-gp functions as an efflux pump 
                                                
10 ATP-binding cassette (ABC) transporter genes are a superfamily of genes encoding transmembrane proteins that 
function in the transport across cell membranes of a wide variety of substrates (lipids, ions, drugs, etc). 
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expressed in various tissues and compartment interfaces, like the blood-gut barrier, the blood-
brain barrier and the blood-testes barrier. Its main purpose is to protect the whole organism and 
sensitive tissues from potentially harmful xenobiotics. 
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Figure 1.10. P-glycoprotein function and tissue distribution (courtesy of Buclin T) 
1.4.3.2 Human organic cation transporter 1 (hOCT1) 
A range of broad-specificity transporters is present in various compartments of the body for 
the elimination of environmental toxins and metabolic waste products. They are generally present 
in the liver, kidney, and intestine. Among them, the organic cation transporters OCT1, 2, and 3 
mediate the facilitated transport of a variety of structurally diverse organic cations, including 
many drugs, toxins, and endogenous compounds. They belong to the superfamily of solute liquid 
carriers (SLC). OCT1 and OCT2 are mainly found in the basolateral membrane of hepatocytes, 
enterocytes, and renal proximal tubular cells. OCT3 has a more widespread tissue distribution, 
and is especially responsible for the peripheral elimination of monoamine neurotransmitters [67]. 
1.4.3.3 Imatinib and P-gp 
Since the initiation of the present study in summer 2002, various authors have been able to 
demonstrate that imatinib is a substrate of P-gp [12,68], and that some aspects of resistance to 
imatinib treatment may therefore be caused by an increase in P-gp activity [69,70]. We indeed 
confirmed that P-gp expression has a marked impact on imatinib intracellular concentrations (see 
Chapter 6) [71]. 
Thus, imatinib efflux from cancer cells by the drug transporter P-gp is now seriously 
considered among the various mechanisms of resistance to therapy. Its clinical effectiveness may 
be significantly hampered in cells over-expressing P-gp. This seems to be particularly the case of 
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CML in blast phase [69,72]. Previous studies have demonstrated the emergence of intrinsic 
resistance in vitro (i.e. amplification of the BCR-ABL gene) on exposure of cells to increasing 
concentrations of imatinib. This indicates that the equilibrium of extra- and intracellular imatinib 
concentrations certainly plays a critical role in the emergence of a resistant clone [73,74]. 
As already mentioned, most published reports on imatinib resistance mainly focused on 
resistance mediated by point mutations of BCR-ABL [73,74]. However, the conditions favoring 
the occurrence of mutations are largely unknown. Several mutations in the tyrosine kinase 
domain of Bcr-Abl were identified in resistant patients and were found in some instance to be 
present prior to the initiation of the imatinib treatment [54]. Alternately, the development of 
cellular resistance in cells initially sensible to imatinib may be caused by P-gp efflux, which 
reduces intracellular disposition to levels that would not allow to completely block the replication 
of cells harboring BCR-ABL. These cells may subsequently undergo mutations, thus favoring the 
selection of resistant clones. In other words, P-gp may indirectly participate in the selection of 
cell clones harboring BCR-ABL mutation and amplification. Moreover, the fact that P-gp may be 
responsible for the appearance of cellular resistance to imatinib offers the opportunity of a 
pharmacological modulation of this transport system. It has been shown that doxorubicin-
resistant K562 cells, which are resistant to doxorubicin through overexpression of the MDR1 
gene, are cross-resistant to imatinib, but regain imatinib sensitivity in the presence of the P-gp 
inhibitors verapamil or valspodar (PSC833) [70]. 
P-gp is not the only transporter involved in the efflux of imatinib. Two research groups have 
indeed recently shown that breast cancer resistance protein (BCRP, ABCG2) may play an 
important role in imatinib disposition [75,76]. By contrast, Houghton et al have reported that 
imatinib transport was unaltered between ABCG2 and non-ABCG2 expressing cells, rather 
suggesting that imatinib inhibits the function of BCRP, but was perhaps not a substrate of this 
transporter [77]. 
1.4.3.4 Imatinib and hOCT1 
A recent study indicates that active influx-transport process also occurs and does affect 
imatinib exposure in leukemia cells. Imatinib has been demonstrated to be a substrate of hOCT1 
(but not hOCT2 and 3) [78]. This suggests that differential expression of this influx transporter in 
target cells may be a critical determinant of intracellular drug levels and, hence, resistance to 
imatinib treatment. Interestingly, it has been recently found that cellular hOCT1 expression levels 
were much lower in nonresponders CML patients as compared to responders, in line with the  
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above considerations [79]. The functional consequence of the active influx transport expression 
on imatinib cellular levels, and its clinical relevance certainly deserves further evaluation. 
1.4.4 Variability in imatinib metabolism 
As previously mentioned, imatinib is mainly metabolized by the CYP3A4 and is a weak 
competitive inhibitor of this cytochrome. Alternately, the simultaneous administration of CYP3A 
inhibitors such as itraconazole or erythromycin is able to significantly increase imatinib plasma 
levels, whereas CYP3A inducers (rifampicin, St John’s Wort, i.e. Hypericum perforatum L. extracts) 
tend to reduce them. In a clinical study with healthy volunteers, rifampicin was found to decrease 
imatinib exposure, and this could potentially lead to subtherapeutic plasma concentrations of 
imatinib [80]. Among the cytochrome P450 isoenzymes present in the liver and in the gut wall, 
CYP3A4/5 are the most important isoenzymes, corresponding to approximately 30% of the total 
content in hepatic cytochromes. CYP3A activity is known to present a wide interindividual 
variability, which may be furthermore influenced by a number of inhibitory or inducing 
compounds present in the environment (see also § 1.5.1). Consequently, the variability in the 
CYP3A-mediated pharmacokinetics of imatinib may put some patients at risk of suboptimal 
imatinib exposure. This could increase the probability of appearance of resistant cell clones with 
potential consequences in term of response to anticancer treatment. Moreover, high levels of 
expression of CYP3A in cancer cells have been reported to be responsible for the resistance to 
the cytotoxic drug paclitaxel, a known CYP3A substrate [81]. However, no observations are 
available at present to suggest that such a mechanism is also involved in imatinib resistance. 
1.4.5 Modulation of imatinib free fraction by α 1-acid glycoprotein 
Other mechanisms of resistance have also been incriminated [12,68], including host-
dependent factors such as modulation of imatinib binding to the plasma protein named α1-acid 
glycoprotein (AGP) [51]. AGP binds imatinib in vitro at physiological concentrations [40], and is 
able to reverse imatinib inhibition of Bcr-Abl [82]. In another study, higher-than-normal levels of 
AGP were found in the plasma from CML patients, yet such concentrations of AGP were unable 
to inhibit the effect of imatinib on the growth of Ph+ cells in vitro [83]. Moreover, no correlation 
was found between the elevated AGP levels and resistance to imatinib [84]. However, patients 
showing high levels of AGP had a slower response to imatinib. 
Total plasma concentration of imatinib comprises the AGP-bound fraction, in equilibrium 
with free imatinib, the latter being the only species likely to penetrate intracellularly to interact 
with its intracellular target and exert its pharmacological action. This suggests that total plasma 
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concentrations may only be an imperfect surrogate of target-site concentrations of imatinib. An 
interaction study was carried out in patients on imatinib who also received clindamycin, which 
competes with imatinib binding to AGP. Coadministration of both drugs resulted in a rapid 
decrease in plasma levels of imatinib. The authors explain this observation by a fast tissular 
distribution following displacement from AGP [85]. It has been therefore suggested that 
clindamycin may restore imatinib intracellular concentration and activity by avoiding the 
exposure to marginally active drug concentrations (which could favor the selection of resistant 
cells) [86]. The role of AGP in this context must however be counterbalanced by the fact that 
therapeutic concentrations of imatinib exceed in general the total binding capacity of this plasma 
carrier protein. 
1.4.6 Alternative strategies to overcome imatinib resistance 
Beside the above-mentioned strategies devised to overcome the resistance due to P-gp, 
CYP3A4 and AGP, alternate approaches are being attempted to associate imatinib with other 
substances to counteract some further aspects of resistance mechanisms. 
Heat shock proteins (HSP) are a class of intracellular proteins, named chaperones11, helping 
other altered proteins to remain functional in spite of inhibition. As Bcr-Abl is client of HSP90, 
regimens combining imatinib with the recent drugs that act as HSP inhibitors (i.e. geldanamycin 
and derivatives) are currently considered [87,88]. It is premature at present to determine whether 
such an approach may be translated into potential clinical applications. 
Alternately, imatinib was also shown to induce another signaling pathway mediated by MAP 
(mitogen-activated protein) kinase. Lonafarnib is a farnesyl protein transferase inhibitor, which 
prevents the post-transcriptional addition of a farnesyl moiety to the Ras protein involved in this 
MAP pathway (see also the description of cancer mechanisms in § 1.1.2). Combination of 
lonafarnib and imatinib allowed to inhibit resistant cell colonies [51]. In addition, lonafarnib was 
found in vitro to be a potent P-gp inhibitor that could certainly be of interest in a regimen 
associating it with imatinib [89]. 
1.4.7 Looking beyond imatinib 
Further strategies developed to overcome imatinib resistances are the use of new targeted 
drugs. This is particularly important since imatinib buys time for most patients rather than 
provides a cure. The relapse rate in CML patients after 4.5 years is about 16% overall. The new 
                                                
11 Chaperones are proteins that bind to and stabilize other proteins in order to allow their correct folding or 
transport. 
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compounds have been designed to inhibit Bcr-Abl proteins harboring the point mutations 
previously described to confer resistance to imatinib. The two principal drugs that are emerging 
at present are dasatinib (BMS354825), developed by Bristol-Myers Squibb, and nilotinib 
(AMN107), developed by Novartis [90,91]. 
Dasatinib, structurally unrelated to imatinib, is 325 times more potent than imatinib, and 
possesses activity against 18 Bcr-Abl mutations. At present, dasatinib demonstrates significant 
efficacy in both imatinib-resistant and intolerant patients (6-month data from the multicentric 
phase II study START-C) [91]. Alternately, nilotinib is a new derivative based on imatinib 
structure and inhibiting 32 mutant forms of Bcr-Abl. It is 20-fold more potent than its 
predecessor and shows a 60% hematological response rate in imatinib-resistant CML 
patients [91]. However, neither dasatinib nor nilotinib inhibit the T315I mutant form of Bcr-
Abl [90]. 
1.5 Potential importance of pharmacokinetics and pharmaco-
genetics in clinical response variability of imatinib 
The pharmacokinetics of many drugs considerably differs between individuals, largely because 
of variations in the expression of metabolizing enzymes in the liver, intestine and other tissues. In 
particular, the cytochrome P450 enzyme system is involved in the metabolism and elimination of 
almost half of the drugs on the market [92]. In addition, drug transporters such as P-glycoprotein 
(P-gp) are recognized as key determinants of drug disposition and response [93]. As previously 
detailed, the activity of these systems is different from person to person. This leads to highly 
variable drug elimination rates, hence to interindividual differences in circulating drug 
concentrations and in therapeutic response. 
Pharmacogenetics is the study of genetic variations underlying differential responses to drugs. 
Inherited differences in the metabolism, transport and disposition of drugs, and in the drug 
targets, greatly affect the efficacy and toxicity of medications (Figure 1.11). The existence of 
genetic polymorphisms12 of drug-metabolizing enzymes and drug-transporters proteins has thus 
provided an explanation as to why some patients do not obtain the expected drug effects, or 
show an exaggerated drug response and serious toxicity after taking standard doses of a drug [94]. 
                                                
12 Polymorphisms are variations in an organism's DNA sequence, which accounts for all naturally occurring alleles 
(i.e. viable coding sequences of a gene). 
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Figure 1.11. Genetic variability of CYP and P-gp affecting imatinib activity, and potential targets for PK 
optimization  (courtesy of Decosterd LA, with modifications) 
1.5.1 Pharmacogenetics of CYP3A4/5 
Although no polymorphisms modifying the enzyme structure and activity have been formally 
identified to date, some polymorphisms are known to affect the gene promoter and hence the 
expression and inducibility of CYP3A4. In fact, there is roughly a 10-fold variability in CYP3A4 
activity among different subjects, and this is one of the most important factors responsible for 
the large intra- and interindividual pharmacokinetic variability observed during drug 
treatments [92]. Moreover, CYP3A5, a closely related isoenzyme of CYP3A4, displays a 
significant polymorphism with about 75% of Caucasian subjects harboring an inefficient allele. 
This polymorphism has been shown to affect the disposition of CYP3A substrates [95]. 
The determination of the CYP3A enzymatic activity (phenotyping) in patients may be 
clinically useful and has been notably used in the present study. The CYP3A4/5 activity can be 
assessed using various tests (erythromycin breath test, plasma clearance of midazolam, 
6β-hydroxycortisol/cortisol urinary ratio). Among them, the measurement of the endogenous 
levels of 6β-hydroxycortisol/cortisol13 in urine (UCR) is an attractive approach, as it does not 
require the administration of any exogenous probe substance [96]. This non-invasive test only 
requires the collection of a single urinary spot, which can be analyzed by LC-MS/MS after solid-
liquid phase extraction. 
                                                
13 6β-hydroxycortisol is the product of cortisol metabolization by CYP3A4. The product to parent ratio has been 
therefore proposed as a marker of CYP3A4 activity. 
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Besides being variable, CYP3A activity may be inhibited or induced by numerous drugs, as 
well as by environmental and dietary substances. This results in elevated plasma levels of 
substrates of this enzyme such as imatinib, associated with possible adverse drug reactions, or 
alternately leading to a lowering of plasma levels with potential consequences on the clinical 
response. The phenotyping of CYP3A has the advantage of reflecting both the acquired 
modulation (by environmental factors) and the genetic determinant of enzyme activity. 
1.5.2 Polymorphism of the MDR1  and hOCT1  gene 
There is a large interindividual variability in the expression and activity of the drug efflux 
transporter P-gp, in part due to the polymorphism of the MDR1 gene, notably the C3435T single 
nucleotide polymorphism (SNP) at exon 26, with functional [97,98] and clinical [99] 
consequences. This polymorphism has been reviewed in detail [93,100]. In childhood ALL, a 
7.1% reduction of CNS relapse was observed in patients harboring the MDR1 3435 TT or CT 
genotype, associated with a reduced expression and function of P-gp [101]. Similarly, in a study 
performed in Lausanne, this same C3435T SNP has been found to be a factor influencing the 
immune recovery of HIV patients at the initiation of their antiretroviral therapy [99]. In fact, HIV 
protease inhibitors, like imatinib, are substrates of P-gp. Individuals with the 3435 TT genotype 
have low expression of P-gp in their peripheral blood mononuclear cells (PBMCs)14 as compared 
to the case of wild-type 3435 CC patients. It was thus hypothesized that the MDR1 C3435T 
polymorphism would influence the intracellular accumulation of P-gp substrates such as HIV 
protease inhibitors, thereby explaining the immunological benefits observed in HIV patients with 
the MDR1 3435 TT genotype. Indeed, it was confirmed that patients with the MDR1 3435 TT 
genotype, associated with reduced P-gp expression, had a more than 2-fold increase in PBMCs 
intracellular levels of the protease inhibitor nelfinavir, a P-gp substrate [66]. 
As far as hOCT1 is concerned, genetic polymorphic variations have also been identified, but 
their functional and clinical consequences have been until now the focus of less intense 
investigations, in comparison to MDR1. It seems that the transporter variants with the A61C, 
C88A, G220V, G401S, G465A mutations result in a reduced uptake, whereas the S14P variant 
results in increased uptake activity [67]. In fact, much remains to be learned from this transporter 
genetic. 
                                                
14 PBMCs are circulating mononuclear cells, i.e. lymphocytes and monocytes. 
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It thus appears that both genetic and environmental factors are likely to affect the expression 
and function of P-gp and hOCT1, with possible clinical consequences on the outcome of 
treatment with a P-gp and hOCT1 substrate such as imatinib. 
1.5.3 α 1-acid glycoprotein polymorphism 
Two genes arranged in tandem control the expression of AGP: AGP1 and AGP2. They are 
closely linked on chromosome 9, and encode two ORM proteins (ORM1 and ORM2, 
respectively). While the ORM2 locus is monomorphic in most populations, at the ORM1 locus, 
three codominants alleles (ORM1*F1, ORM1*F2 and ORM1*S) have been characterized. 
ORM1*F1 and ORM1*S are observed worldwide, while ORM1*F2 is rare and is limited to 
Caucasians and West Asians. Although these two proteins are generally measured at a molar ratio 
of about 3 : 1, the relative concentrations of the ORM variants can largely vary [102]. However, 
the functional implications of the relative occurrence of these alleles –either on AGP plasma 
levels or on drug binding– is still essentially unknown. 
In the present work, the influence of the diverse genetic variants has not been considered. We 
only measured the total AGP plasma levels. 
1.6 Population pharmacokinetics 
All drugs exhibit pharmacokinetic (PK) variability to a greater or lesser extend. Population 
pharmacokinetics aims at describing this variability in terms of a number of factors [103]. 
1. Fixed effects: population average values of PK parameters, which may be function of 
various patient characteristics (demographical variables such as weight or gender; 
physiological variables such as creatininemia; external influences such as comedications). 
2. Random effects: they quantify the amount of pharmacokinetic variability that is not 
explained by the previous effects (i.e. inter- and intraindividual variability). 
Estimation of these effects allows designing dosage regimens for specific populations of 
patients (e.g. elderly or patients with renal impairment), and the individualization and 
optimization of these regimens integrated in a TDM program (see following paragraph). All new 
drugs, as well as all drugs for which a therapeutic range has been identified, should ideally be 
subjected to such an analysis. This was done for imatinib, but such a modeling was barely 
mentioned in literature at the time of marketing [8]. Only recently more extensive data were 
published on population pharmacokinetics in GIST patients [47], and in CML patients [104]. 
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Our study thus aimed mainly at assessing further imatinib pharmacokinetics variability and its 
relationship to various demographical and biological covariates (especially MDR1 polymorphism, 
CYP3A4 activity and AGP plasma levels). In order to achieve such an analysis, the NONMEM 
(which stands for NONlinear Mixed Effects Model) approach was used (see Chapter 3). 
1.7 Imatinib and therapeutic drug monitoring strategy 
1.7.1 Therapeutic drug monitoring 
During the past decades, it has been established that the therapeutic use of selected drugs 
could be optimized by an individualization of their dosage, based on blood concentrations 
measurement. Such a feedback strategy, termed TDM (for Therapeutic Drug Monitoring), is now 
current practice for drugs such as digoxin, lithium, aminoglycosides, vancomycin, cyclosporine 
and antiepileptics [105]. In the anticancer chemotherapy, the follow-up of methotrexate plasma 
levels decay in patients is used for the adjustment of folinic acid dose required for the 
rescue [106]. More recently, monitoring of HIV protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors has also been progressively adopted in our hospital. The therapeutic 
benefit of the TDM of antiretrovirals on the outcome, quality of life and survival of HIV patients 
is currently under evaluation [107,108]. This approach seems both to increase the probability that 
a consistent therapeutic effect is reached in the treated patient, and to decrease the risk of toxic 
side-effects. For some drugs, TDM has been shown cost-effective in economic evaluations, 
provided that blood levels are subjected to expert interpretation [109]. At the “Centre hospitalier 
universitaire vaudois” (CHUV), TDM is performed by clinical pharmacologists and hospital 
pharmacists at the Clinical Pharmacology Division. 
Generally, suitable drugs for a TDM program are those with large interindividual but low 
intraindividual pharmacokinetic variability, with both consistent concentration-response and 
concentration-toxicity relationships, and for which no easily measurable markers are available to 
evaluate efficacy and to precociously detect toxicity. Table 1.2 represents in details the common 
criteria a drug should own to benefit from a TDM approach [110,111]. 
Various indications exist for the measurements of drug concentrations, such as for instance a) 
individualizing therapy (at time of early therapy or dosage change); b) avoiding toxicity; c) 
monitoring drug interactions; and d) monitoring compliance [112]. 
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Table 1.2. Components of the target concentration strategy 
Analytic  
  An appropriate drug assay is available  
Pharmacokinetic  
  Documented and significant interindividual variability in drug disposition  
  Adequate pharmacokinetic data available concerning the drug (including 
  in the specific subpopulation considered)  
  Unpredictable pharmacokinetic parameters (intrinsic variability or 
  confounding factors)  
Pharmacodynamic  
  Pharmacological effect proportional to the plasma drug concentration  
  A narrow therapeutic range (i.e. range between efficacious and toxic 
  concentration) exists  
  A constant pharmacological effect over an extended period of time exists  
Clinical  
  Therapeutic range has been clinically established  
  No easily measurable clinical markers are available (e.g. intraocular 
  pressure for glaucoma)  
  Duration of drug therapy sufficient for the patient to benefit from TDM  
  TDM will provide more information than sound clinical judgment only  
 
1.7.2  Imatinib and TDM 
As previously mentioned, imatinib is mainly metabolized by cytochrome P450 3A4 [8], whose 
enzymatic activity presents a large interindividual variability and is susceptible to induction or 
inhibition. Thus, a given dose of imatinib may yield circulating concentrations departing in 
selected patients from those expected based on the average pharmacokinetic data established in 
stringent phase I and II clinical studies. Imatinib could therefore be a suitable candidate for an 
individualization of dose prescription based on TDM. The follow-up of imatinib circulating 
concentrations could play an appreciable role in delaying the appearance of tumor resistance, 
which seems to be favored by repeated exposure to subtherapeutic drug levels of imatinib both in 
vitro [73,112] or in vivo [113]. 
Just recently, Judson et al have presented data indicating that imatinib clearance tends to 
increase (i.e. plasma levels are decreasing) over time upon Glivec® treatment. Imatinib levels in 
patients in which the dosage was increased (upon progression) were substantially lower than at 
the beginning of the treatment [47]. Conversely, a 25% decrease in imatinib clearance has been 
reported in another study in CML patients, albeit followed up for one month [104]. Such 
uncertainties on the pharmacokinetics of imatinib suggest a potential clinical interest to monitor 
imatinib peripheral blood levels. 
30 Chapter 1 
General introduction 
 
The present thesis work will address only some of the steps necessary to evaluate the potential 
benefit of a TDM program. The analytical method development is given in Chapter 2. The 
pharmacokinetic evaluation is reported in Chapter 3. Some aspects of the pharmacokinetic-
pharmacodynamic analysis are addressed in Chapter 4. Finally, examples of applications of 
imatinib plasma levels monitoring in selected clinical situations are presented in Chapter 5. 
1.8 Aims of this work 
Considering the above mentioned issues, the overall purpose of the work presented in this 
thesis has been formally to describe the population pharmacokinetics of imatinib, to identify 
factors likely to influence it, and finally to examine whether poor tolerance or resistance to 
imatinib treatment could be explained in some patients by alterations in its pharmacokinetic 
characteristics. The specific goal of our research study and its ancillary projects were as follows: 
1.8.1 Main aims of the study 
1. To study imatinib pharmacokinetic interindividual and residual intraindividual variability in 
CML- or GIST-patients, using a population pharmacokinetic approach. 
2. To assess the influence of MDR1 polymorphism in imatinib pharmacokinetics in this 
patient population. 
3. To evaluate CYP3A4 enzyme activity in the same patients by measuring the urinary 
6β-hydroxycortisol/cortisol ratio. 
4. To determine the role of α1-acid glycoprotein on imatinib pharmacokinetic variability in 
this patients’ population. 
1.8.2 Subsidiary aims of the study 
1. To study in vivo the intracellular disposition of imatinib in patients. 
2. To study the relationship between imatinib plasma concentrations, possibly modulated by 
AGP levels, and the clinical outcome (relapses, initial/secondary failure, side effects). In 
short, to ascertain whether relapses are more frequent in patients with low imatinib plasma 
concentrations, and alternately whether adverse drug reactions are more prevalent in 
patients with high imatinib concentrations. 
3. As the PK-PD relationship may be obscured, or confounded, by the cancer genetic 
heterogeneity, to distinguish the importance of tumor genotypes on response to imatinib 
therapy. 
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4. As a complement to this study, to assess in vitro (in cellular models) the functional 
consequence of MDR1 gene expression, or siRNA-mediated silencing, on intracellular 
concentrations of imatinib. 
The full protocol of the clinical part of this study is presented in Appendices 1.1 to 1.5 and 
will be detailed further in Chapter 3. 
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Chapter 2   Analytical methods 
 
his chapter will provide a description of the various analytical procedures that have been 
developed and/or applied during the population pharmacokinetic study (see Chapter 3). 
Special attention will be given to the methods to which I have contributed mostly, namely the 
development of a HPLC-UV method used for the determination of imatinib concentrations in 
plasma from patients (and intracellularly for some of our in vitro studies). Attention will be given 
as well to the analysis of our patient’s MDR1 genotype (one of the biological covariate of our PK 
study) using a procedure available at the Clinical Chemistry Laboratory (LCC) of our hospital. 
The initial development of the measurement of urinary cortisol and 6β-hydroxycortisol (a 
second biological covariate) by LC-MS/MS [1], as well as of the setting up of the intracellular 
measurements of imatinib in peripheral blood mononuclear cells (PBMCs) by LC-MS/MS [2], 
have been the subject of two Pharmacist diplomas presented at the Faculty of Sciences at the 
University of Lausanne. Application of these methods during the present study was performed by 
a laboratory technician at the Division of Clinical Pharmacology. The α1-acid glycoprotein plasma 
levels (the third main biological covariate evaluated) were measured at the Laboratory of Clinical 
Biochemistry and Psychopharmacology Unit in the Cery hospital. 
2.1 Determination of imatinib in human plasma by LC-UV 
The setting up and the validation of the HPLC-UV method, as well as its application for the 
measurement of imatinib in patients’ plasma samples, is the principal analytical chemistry 
development of this thesis work. It has been published in a peer-reviewed journal in 2004 [3], and 
has also been applied for the intra- and extracellular measurement of imatinib in in vitro cell 
cultures during a side-study on the functional influence of P-gp expression (see Chapter 6). 
2.1.1 Theoretical introduction 
2.1.1.1 Chromatography 
Chromatography is a physico-chemical technique used for the separation, identification, 
isolation (preparative) and/or quantification (analytical) of the different chemical components of 
a –most often– complex mixture. These mixtures may be a pharmaceutical formulation of a drug 
(see for example, the quantification of captopril in an oral solution, which was developed as a 
part of a previous project at the hospital pharmacy of our hospital [4]), or a complex biological 
T 
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matrix (i.e. patients’ plasma samples, such as in the present study). Most chromatographic 
methods imply the use of a mobile phase, which can be a gas (GC, gas chromatography) or a 
liquid (LC, liquid chromatograpy) [5] distributed through a stationary –either solid or liquid– 
phase. The various components of a given mixture are carried out by the mobile phase through 
the stationary phase. Depending on their relative distribution in the mobile and stationary phase, 
and their respective affinity (i.e polarity, lipophilicity, affinity, and size) to the stationary phase, a 
difference in the delay of elution of the various components of a mixture out of the 
chromatographic column will occur. This difference in turn results in their physical separation, 
which can be exploited for their isolation and/or quantification. 
2.1.1.2 High-performance liquid chromatography with UV detection (HPLC-UV) 
HPLC is a chromatographic technique using a liquid mobile phase, which is distributed at high 
pressure (several hundred bars) through a stationary phase. This latter phase consists of a solid 
material contained in a stainless tube and characterized by a very high specific area (e.g. silica-
derived or synthetic polymers). HPLC can be coupled with a variety of detectors, such as single 
MS or tandem MS (see infra), or spectrofluorimetry. Spectrophotometric UV detectors measure 
the ultraviolet or visible light absorption of compounds eluted from the chromatography column. 
It is also possible to couple HPLC with a UV diode array detector (DAD), which allows the 
online recording of the entire UV or visible spectra of analytes during their passage trough the 
photometer cell. This provides additional information on compounds identity and analytical 
method selectivity [5]. At present and because of its robustness, UV detection remains the more 
frequently used method in the routine practice of hospital pharmacy and clinical pharmacology 
laboratories. In fact, HPLC is generally considered to be the “reference” method, when alternate 
analytical methods are developed. However, LC-MS or LC-MS/MS technologies certainly tend to 
be increasingly applied in more recent analytical methods developments. 
It is generally necessary to eliminate from sample as many matrix constituents as possible  
–likely to interfere with the analytes measurements–, prior to the sample injection into the 
chromatographic system. This is typically made by precipitation or extraction. A commonly used 
extraction method is solid-phase extraction (SPE). It consists in the purification and 
concentration of analytes from a complex mixture by adsorption onto a disposable solid-phase 
cartridge, followed by selective elution of the analyte with an appropriate solvent [6,7]. 
The above-mentioned techniques were applied for the measurement of imatinib 
concentrations in plasma from the patients participating in the present clinical study. 
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2.1.2 Materials and methods 
2.1.2.1 Chemicals 
Imatinib mesylate was kindly provided by Novartis (Basel, Switzerland). Clozapine (IS, 
Internal Standard) stock solution (250 mg/ml) in methanol (MeOH) was obtained by extraction 
with MeOH of a Leponex® (Novartis, Basel, Switzerland) tablet. This solution was diluted before 
use. MeOH for chromatography LiChrosolv® and ammonium acetate (NH4Ac) GR for analysis 
were from E. Merck (Darmstadt, Germany). All other chemicals were of analytical grade and 
used as received. Ultrapure water was obtained from a Milli-Q® UF-Plus device (Millipore). 
2.1.2.2 Chromatographic system 
The chromatographic system consisted of a Hewlett-Packard 1050 pump connected to a 
spectrophotometric UV-VIS DAD 1050 detector set at 261 nm (Agilent, formerly Hewlett-
Packard, Böblingen, Germany). This wavelength corresponds to the maximal absorption of 
imatinib under the chromatographic analysis conditions. The separation was performed at room 
temperature (RT) on a ChromCart® cartridge column (125 mm length x 4 mm id) filled with 
Nucleosil 100-5 µm C18 AB (Macherey-Nagel, Düren, Germany), and equipped with a guard 
column (8 mm length x 4 mm id) filled with the same packing material. The injection volume was 
50 µl. 
The HP-ChemStation A.06.03 software (Hewlett-Packard, Böblingen, Germany) was used to 
pilot the HPLC instrument and to process the data. Baselines were visually inspected and were 
manually adjusted using peak start and end features of the HP-ChemStation software. 
2.1.2.3 Mobile phase solutions 
Solvent A consisted of water containing 0.05% w/v of NH4Ac and solvent B was MeOH 
containing also 0.05% w/v of NH4Ac. The mobile phase was delivered at 1 ml/min and the 
gradient program conditions are given in Table 2.1. 
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Table 2.1. Gradient elution program 
Time 
(min) 
Solvent A 
(%) 
Solvent B 
(%) 
Flow 
(ml/min) 
0 80 20 1.0 
20 50 50 1.0 
36 40 60 1.0 
36.5* 0 100 2.0 
40.5* 0 100 2.0 
41* 80 20 1.0 
45* 80 20 1.0 
*Rinsing / re-equilibration program. 
 
2.1.2.4 Stock and working solutions, plasma calibration and control samples 
The stock solution of imatinib mesylate was prepared at a concentration of 1 mg/ml 
(calculated as base) in 100% MeOH and was appropriately diluted with 50% MeOH for the 
preparation of working solutions at concentrations of 2-200 µg/ml. Plasma calibration samples at 
0.1, 0.3, 0.9, 2.5, 5.0, 10.0 µg/ml, together with plasma control samples at 0.2, 4.5, 9.0 µg/ml, 
were prepared by 1 : 20 dilution of the respective working solution to blank plasma (total added 
volume ≤ 10% of the biological sample volume), in accordance with the recommendations on 
bioanalytical method validation [8-10]. 
The working solutions were stored at -20°C and the calibration and control samples were 
prepared on the day of the analysis. The IS stock solution at 250 mg/ml was diluted to 
105 µg/ml with 50% MeOH prior use. 
2.1.2.5 Samples preparation 
750-µl samples of plasma (calibration, control) were diluted with 200 µl H2O and 50 µl of 
diluted IS solution (thus providing a clozapine plasma concentration of 7.0 µg/ml) in an 
Eppendorf microvial. The resulting solution was vortexed and centrifuged for 10 min in a 
centrifuge at 20’000 g (14’000 rpm) (Benchtop Universal 16R, Hettich, Bäch, Switzerland). 
Plasma samples from patients were processed similarly. 
The clean-up procedure of diluted plasma samples was performed by solid-phase extraction 
(SPE) using a 24-tube vacuum manifold Macherey-Nagel (Düren, Germany). The C18 cartridges 
of 100 mg packing with 40-45 µm diameters and 60 Å porosity (Supelclean LC-18, Supelco, 
Buchs, Switzerland) were conditioned with 2 ml of methanol (in two 1-ml aliquots) followed by 
2 x 1 ml water. An aliquot (900 µl) of the diluted plasma sample was applied onto the cartridge 
and drawn through completely under vacuum (ca 2.5 mm Hg). 
The cartridge was washed twice with 1000 µl H2O and a light vacuum (about 10 mm Hg) was 
applied thereafter for 5 min. Imatinib and clozapine were subsequently eluted with 1500 µl 
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methanol (in three aliquots of 500 µl), followed by a final drying step (about 10 mm Hg vacuum). 
The eluted solutions were evaporated to dryness under nitrogen steam at RT for approximately 
45 min, and the residue was reconstituted in 180 µl of 50% methanol. The resulting solutions 
were carefully vortexed and centrifuged at 20’000 g for 10 min. Aliquots (80 µl) of the 
supernatants were introduced into 200 µl HPLC microvials (Hewlett-Packard, Böblingen, 
Germany) and a volume of 50 µl was injected onto the HPLC column. 
2.1.2.6 Calibration curves 
Quantitative analysis of imatinib was performed using the Internal Standard (IS) method. The 
calibration curves were obtained by 1/x weighted least-squares linear regression of the peak-area 
ratio of imatinib to clozapine (IS), versus the ratio of the injected amount of imatinib to IS, in each 
standard sample. The calibration was established over the range 0.1-10.0 µg/ml, where the 
response ratio / amount ratio was linear. 
Clozapine was chosen as the internal standard because it shares some structural similarity with 
imatinib (heterocyclic base with a piperazinyl group). It has already been used as an IS for the 
dosage of other basic drugs [11,12]. 
2.1.2.7 Analytical method validation 
The validation of the method was based on the recommendations published as Conference 
Reports of the Washington Conference on “Analytical methods validation: Bioavailability, 
Bioequivalence and Pharmacokinetic studies” [8] and of the Arlington Workshop “Bioanalytical 
methods validation – A revisit with a decade of progress” [9]. Recent SFSTP (Société Française 
des Sciences et Techniques Pharmaceutiques) recommendations were also considered [13]. 
Each level of the calibration curve was measured with two sets of calibrators: one set at the 
beginning and a second set at the end of the HPLC run. When series of patients’ analyses were 
performed, control samples at three concentration levels (low, medium and high; i.e. 0.2, 4.5 and 
9.0 µg/ml) were assayed every seven samples. 
Quality control samples were used for the precision and accuracy determination. The 
precision was calculated as the coefficient of variation (CV %) within a single run (intra-assay) 
and among different assays (inter-assays). The accuracy (i.e. in fact, the inaccuracy, or bias) was 
the percentage of deviation between nominal and measured concentrations. 
The limit of quantification (LOQ) in plasma was experimentally chosen as the minimal 
concentration in plasma samples which could be confidently determined in accordance with the 
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Arlington Workshop (recommending a deviation between measured and nominal concentrations 
at LOQ that do not exceed ± 20%) [9]. The limit of detection (LOD) was considered as the 
concentration of imatinib that provides a signal corresponding to 3 times the background signal. 
2.1.2.8 Stability of imatinib 
1. Stability of plasma samples kept frozen at -20°C: Imatinib levels of aliquoted quality control plasma 
samples (i.e. at 0.2, 4.5 and 9.0 µg/ml) were measured each month during 12 months. The 
variations of imatinib concentrations were expressed in percentages of the initial levels 
measured on the first day of storage. 
2. Stability of imatinib in plasma and blood samples left at room temperature (RT): The concentration of 
imatinib in QC plasma samples was measured immediately after preparation and after being left 
at RT for 24 h and 48 h. 
Anticoagulated (citrate or EDTA) blood samples spiked with 0.2, 4.5 and 9.0 µg/ml imatinib 
were left at RT. Aliquots (2 ml) were taken at 0 h, 24 h, 48 h, 72 h and 96 h, and immediately 
centrifuged at 1850 g for 10 min at +4°C. The plasma was collected and analyzed for imatinib, 
according to the above-described procedure. 
3. Stability of plasma samples after multiple freeze-thaw cycles: Aliquots of plasma spiked with 0.2, 4.5 
and 9.0 µg/ml of imatinib underwent three freeze-thaw cycles: frozen samples were allowed to 
thaw at ambient temperature for 2 h and were subsequently refrozen for approximately 24 h. 
The imatinib levels were measured in aliquots from the three consecutive freeze-thaw cycles. 
The variations of imatinib concentrations were expressed in percentages of the initial levels 
measured at the beginning of the stability study. 
4. Stability of plasma extracts into HPLC vials at RT: Processed samples (i.e. reconstituted in 50% 
MeOH) containing imatinib at low, medium and high concentrations were analyzed 
immediately after preparation and after being left for 24 h, 48 h and 72 h at RT in the 
autosampler rack. 
2.1.2.9 Recovery 
The efficiency of the solid phase extraction was determined with control samples at 0.2, 4.5 
and 9.0 µg/ml imatinib. The absolute recovery of imatinib from plasma was obtained as the peak-
area response of imatinib in the processed samples. It was expressed as a percentage of the 
response of the same amount of imatinib (contained in the 50-µl injection volume) directly 
injected onto the HPLC column. The absolute recovery was similarly calculated for the IS 
clozapine. 
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2.1.2.10 Selectivity 
The selectivity of our analytical method was determined by injecting onto the HPLC column 
22 drugs frequently prescribed to CML- or GIST-patients at our hospital: acetylsalicylic acid 
(Aspirin®), diclofenac (Voltaren®), acetaminophen (Panadol®), tramadol (Tramal®), tizanidin 
(Sirdalud®), diltiazem (Dilzem®), verapamil (Isoptin®), atenonol (Tenormin®), torasemide 
(Torem®), acenocoumarol (Sintrom®), ranitidin (Zantic®), omeprazol (Antra®), metoclopramid 
(Primperan®), fluconazole (Diflucan®), voriconazole (Vfend®), prednisone (Prednisone®), 
fluoxetine (Fluctine®), citalopram (Seropram®), lorazepam (Temesta®),  oxazepam (Seresta®), 
zolpidem (Stilnox®), allopurinol (Zyloric®). 
The selectivity was also evaluated with the above-mentioned extraction procedure using blank 
plasma samples from six healthy subjects [8] to ascertain that no endogenous peak would 
interfere with the imatinib signal. 
2.1.3 Results and discussion 
2.1.3.1 Chromatograms 
The proposed HPLC method allows the measurement of imatinib in plasma with UV 
detection set at 261 nm. With the gradient program used (Table 2.1), the retention times for 
imatinib and clozapine are 23 min and 33 min, respectively. The gradient elution program yields 
sharp peaks without any significant drift of the baseline. 
Figure 2.1 shows the chromatogram of blank plasma, using the gradient program reported in 
Table 2.1. Figure 2.2 presents the chromatogram of the same blank plasma spiked with 2.5 µg/ml 
imatinib and 7.0 µg/ml clozapine (IS), which represents concentration commonly encountered in 
our patients’ population. Finally, Figure 2.3 shows the chromatographic profile of another blank 
plasma spiked with 0.2 µg/ml imatinib and 7.0 µg/ml clozapine (IS). It is at the same scale as 
Figure 2.2 and corresponds to the lowest quality control concentration. Even at this low 
concentration, the peak has a sharp shape and is easily detectable. 
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Figure 2.1. Chromatographic profile of blank plasma 
 
Figure 2.2. Chromatographic profile of a blank plasma spiked with 2.5 µg/ml imatinib and 7.0 µg/ml clozapine 
 
Figure 2.3. Chromatographic profile of the lowest QC plasma (0.2 µg/ml imatinib and 7.0 µg/ml clozapine) 
A HPLC run of 45 min duration (including the rinsing and re-equilibration steps) can be 
considered lengthy. Nevertheless, it is necessary to achieve a satisfactory separation of imatinib 
from signals arising from endogenous plasma components and from drugs likely to be taken by 
this population of patients. It is noteworthy that the small peak appearing at 21.5 min is observed 
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in all samples (including blank MeOH/H2O solutions subjected to SPE), and arises from the 
packing material smearing from the SPE cartridge during water rinsing and MeOH elution. It 
does not interfere with the imatinib signal at 23 min. 
2.1.3.2 Mobile phase composition 
Peak tailing is a common phenomenon observed with basic nitrogen-containing molecules 
eluted on reversed-phase columns by HPLC [14,15]. Thus, a Nucleosil 100-5 µm C18 AB column 
(i.e. a base deactivated column specifically designed for minimizing the peak tailing of base 
compounds [16]) was used. Furthermore, NH4Ac was added to the mobile phase (solvent A  
and B) to reduce peak tailing by saturation of the stationary phase residual silanols [17]. 
2.1.3.3 Calibration curves 
The standard curves for imatinib are satisfactorily described by 1/x weighted least-squares 
linear regression. The slope of the calibration curves is stable, with values averaging 1.25 (± 2.9%; 
n = 6) during the validation steps. Over the concentration range 0.1-10.0 µg/ml, the 
determination coefficient r2 of the calibration curves remained always greater than 0.998. 
There was originally some concern that the calibration samples prepared with citrated plasma 
(collected from blood from outdated transfusion bag) may not fully reflect the plasma matrix 
from CML and GIST patients collected on EDTA Monovettes® (polypropylene tubes known for 
minimal components adsorption). However, getting blood on EDTA from volunteers only for 
the purpose of calibration samples preparation is impracticable and ethically difficult to justify. A 
few reports have indeed been published, showing significant differences in concentrations 
measured for some drugs, related to the medium (serum versus plasma) or to the anticoagulant 
used [18-20]. For the sake of validation, the cross-validation was performed among 3 series of the 
three QC levels and 3 series of calibration samples (citrate versus EDTA). The results of the head-
to-head comparison show that the anticoagulant significantly influences the imatinib results 
(p < 0.05, multi-way ANOVA). This difference was however quantitatively low and highly 
reproducible at every level (with a mean of 5.0% and a SD of 0.04%). Consequently, if the 
analysis of EDTA samples rather than of citrate samples is performed with a citrate calibration, it 
is recommended to correct the results accordingly. This correction has been done in our study as 
patients’ blood samples were collected on EDTA. 
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2.1.3.4 Validation: precision, accuracy and LOQ/LOD 
Precision and accuracy determined with the control samples are given in Table 2.2. The levels 
of control samples (0.2, 4.5 and 9.0 µg/ml) were selected to encompass the range of 
concentrations expected in the patients’ plasma. 
Table 2.2. Precision and accuracy of the imatinib assay in plasma 
*(Found—nominal)/nominal x 100.  
 
The mean intra-assay precision is similar over the whole concentration range and always less 
than 2.5%. Overall, the mean inter-day precision is good with average CVs within 1.1 - 2.4%. The 
intra-assay deviation (bias) from the nominal concentrations of imatinib is between -1.5 and 
+0.4% and the range of inter-day deviation is always lower than 1.0%. 
Calibration curves were established up to the highest pharmacologically relevant concentration 
of imatinib at 10 µg/ml, and at 0.0125, 0.025 and 0.050 µg/ml for the lowest calibration levels. 
This allows experimentally determining the lower limit of quantification (LLOQ) at 0.05 µg/ml. 
With a calibration between 0.05 µg/ml and 10.0 µg/ml, the precision (CV) of the calibration 
sample at 0.05 µg/ml is 6.4% and the accuracy (i.e. bias, calculated by back-calculation) at this 
lowest calibration level is 15.5%. Both values are thus included within the ± 20% limit 
recommended by the Conference Report [9]. The limit of detection (LOD) of imatinib with this 
assay is 0.01 µg/ml, which corresponds to a signal (0.31 mAU) equal to about three times the 
blank background signal at the retention time of imatinib (0.12 mAU; Figure 2.1). 
2.1.3.5 Samples stability 
1. Stability at -20°C: No evidence of imatinib decomposition was found during plasma samples 
storage in the freezer at -20°C for up to 1 year. After 24 months, a slight decrease can be 
observed as imatinib at low, medium and high quality control levels corresponds to 90.5 %, 
95.4 % and 91.9 % of the respective initial values (Table 2.3). This is in fair agreement with 
the good stability over 9 months observed for imatinib prepared in EDTA plasma [21]. This 
Nominal conc. Concentration found Precision Accuracy* 
(µg/ml) (µg/ml) CV % Bias % 
A. Intra-assay (n=6) SD (±)   
     0.200 0.199 0.003 1.3 -0.6 
4.500 4.433 0.092 2.1 -1.5 
9.000 9.034 0.199 2.2 0.4 
     
B. Inter-assay (n=6) SD (±)   
     0.200 0.201 0.002 1.1 0.7 
4.500 4.474 0.098 2.2 -0.6 
9.000 9.042 0.217 2.4 0.5 
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indicates that patients’ plasma samples can be confidently stored at –20°C for a long period 
before HPLC analysis. In our study, the majority of samples were analyzed within 12 months 
after blood collection (and for a few samples within 22 months). 
Table 2.3. Stability of imatinib in plasma samples kept frozen at –20°C (concentration variations expressed as % of 
the starting levels) 
Nominal concentration (µg/ml) Duration 
(months) 0.2 4.5 9.0 
1 -0.8 -3.8 -4.0 
2 -1.5 -2.2 -2.1 
3 2.5 2.0 4.7 
4 -1.6 -2.1 4.1 
5 2.8 -2.4 1.5 
6 0.4 3.6 0.9 
9 0.8 0.5 3.5 
12 -3.4 -2.6 -2.8 
18 -1.7 -9.3 -4.5 
24 -9.5 -4.6 -7.4 
 
2. Stability at RT in plasma and in blood samples: The stability of plasma samples left at RT was 
ascertained up to 48 h. At the concentrations of 0.2, 4.5 and 9.0 µg/ml, the variations of 
imatinib levels over time were always less than ± 5% (Table 2.4) indicating that the plasma 
samples are stable at RT for at least 48 h. 
Table 2.4. Stability of imatinib in plasma, blood and extracts samples left at RT for 24 h, 48 h, 72 h or 96 h 
(concentration changes expressed as % of the initial concentration; NA: not available) 
Nominal concentration (µg/ml) Duration 
(h) 
Medium at RT 
0.2 4.5 9.0 
24 Plasma -1.7 -4.4 -2.3 
 Blood (citrated) -1.8 -4.0 -1.2 
 Blood (EDTA) 1.0 0.9 -3.5 
 Extract 1.7 1.4 1.0 
48 Plasma -2.8 -4.4 -4.7 
 Blood (citrated) -1.4 -0.9 -2.7 
 Blood (EDTA) 2.7 2.1 0.8 
 Extract 3.9 1.8 1.1 
72 Plasma NA NA NA 
 Blood (citrated) -2.5 0.4 -4.0 
 Blood (EDTA) 3.3 2.4 2.0 
 Extract 2.9 3.1 3.4 
96 Plasma NA NA NA 
 Blood (citrated) -2.3 0.6 -1.9 
 Blood (EDTA) 3.3 4.7 4.9 
 Extract NA NA NA 
 
The stability of imatinib in blood samples left at RT for 96 h was checked. The variations of the 
levels of imatinib, at the concentrations of 0.2, 4.5 and 9.0 µg/ml respectively, was always less 
than ± 5% (Table 2.4) for at least 96 h, irrespectively of the anticoagulant used (citrate or  
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EDTA). This is important when shipment of blood samples is considered (e.g. in the case of 
multicentric studies). 
3.  Stability after one, two and three freeze-thaw cycles: The variations of imatinib concentrations in QC 
samples subjected to successive freeze-thaw cycles are reported in Table 2.5. The results 
indicate that no significant loss of imatinib is to be expected after up to three freeze-thaw 
cycles. 
Table 2.5. Stability of imatinib in plasma samples after multiple freeze-thaw cycles (concentration change expressed 
as % of the starting concentration) 
 Nominal concentration (µg/ml) 
Cycles 0.2 4.5 9.0 
1 2.3 -2.6 -4.2 
2 -0.6 -2.0 -3.3 
3 0.2 -1.7 -2.8 
 
4. Stability of extract samples in HPLC vials at RT: The stability of plasma extracts (i.e. reconstituted 
in MeOH/H2O 50 : 50) submitted to HPLC analysis was checked at RT for 72 h and is 
reported in Table 2.4. The variations over time of imatinib, expressed as percentage of the 
initial level, were again within ± 5%. These results indicate that, taking into account the 
analytical variability, the processed samples are stable throughout HPLC analysis performed 
within up to three days. 
2.1.3.6 Recovery 
The mean absolute recovery of imatinib measured with the low, medium and high quality 
controls are 96.4 ± 2.8%, 96.6 ± 2.3% and 96.0 ± 1.9%, respectively. The clean-up procedure by 
SPE is reliable in eliminating interfering material from plasma, with high absolute recovery and 
low recovery variability. 
The internal standard is fully recovered at the concentration spiked (7.0 µg/ml), and most 
importantly is characterized by a low variability: 101.7 ± 4.4 %. 
2.1.3.7 Selectivity 
At 261 nm, six different blank plasmas gave no significant interfering peaks at the retention 
time of imatinib. The small peak sometimes observed at about 34.5 min, i.e. near the retention 
time of clozapine (Figure 2.1), accounts for only a negligible part of the total area of IS (< 0.5%). 
The analysis of 22 drugs prescribed for CML- and GIST-patients at our hospital confirmed 
the method selectivity. All drugs are eluted at retention times not interfering with imatinib 
determination, except for three psychotropic drugs (oxazepam, lorazepam and zolpidem; 
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ΔRT < 0.9 min). For these three potentially interfering compounds, the entire extraction process 
was also conducted with plasma samples containing these drugs at their highest concentrations 
(Cmax) [22]: 1.17 µg/ml, 0.04 µg/ml, 0.14 µg/ml, for oxazepam, lorazepam and zolpidem, 
respectively. The peak area for these compounds at their Cmax may not be considered negligible, 
especially for oxazepam. However, since these drugs are mostly administered in the evening, their 
dosages are quite small by comparison with those of imatinib, and their concentrations 
presumably low at the time of sampling on the next day. Consequently, they should not interfere 
to any significant extent with imatinib measurements. More generally, online spectra provided by 
diode-array detection should be carefully examined at the time of imatinib elution (in order to 
exclude the presence of coeluting peaks arising from other unusual comedication taken by the 
patients). As far as the potentially interfering drugs are concerned, all samples from patients 
included in our clinical study were sent to the laboratory with the previously mentioned 
formulary, where all other drugs taken by patient during the latest week are indicated. The three 
concerned psychotropic drugs, or any unusual drug, can thus be straightforwardly identified. 
2.1.4 Conclusion 
This HPLC method provides a fairly robust procedure for determining imatinib in patients’ 
plasma. Adapted from previously described more sophisticated MS-methods [21,23,24], it has 
been developed using instruments available in conventional hospital laboratories, requesting only 
a UV detector set at 261 nm. UV detection has been shown to provide the required level of 
sensitivity for measuring pharmacologically relevant concentrations of imatinib in patients. The 
increase of selectivity provided by the diode array feature is of help to exclude the possible 
interference of compound eluted at the retention time of imatinib or the IS. Despite the relatively 
prolonged time required for each analysis and the higher risk of interferences as compared to MS 
detection, this method provides a readily available, practicable, cheap and robust technique for 
hospitals. More sophisticated detection technologies such as LC-MS or MS/MS are indeed not 
always available for routine application in such a clinical environment. At the same time as our 
method validation was completed, a LC-UV procedure was also published for the analysis of 
imatinib and some of its impurity products in bulk drug [25], as well as in Glivec® capsules [26]. 
However, our method was the first to enable the measurement of imatinib by HPLC-UV using a 
solid phase extraction from plasma. While our publication was in press, a report just appeared 
also describing an assay of imatinib in human biological fluids using a valve switching technique 
and UV detection [27]. Since then, another LC-UV procedure for the assay of imatinib after 
protein precipitation as purification technique was published as a short communication. It 
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described a rapid and sensitive method that furthermore allowed to determine the lipophilicity of 
imatinib (log P = 1.198 at 25°C and 1.267 at 37°C) [28]. 
Since plasma extract samples are stable at RT in the autosampler rack, the duration of the run 
is not a limitation of our method and the assay can be fully automated, requiring no tedious 
technical supervision. In our studies, batches of samples have been analyzed over 30 h in a row 
without any problem. Using one single HPLC apparatus, it is possible to analyze more than 
20 patient samples per run sequence. This was fairly enough for our clinical study. However, in 
case of the implementation of a routine dosage for imatinib –as part of a TDM program– further 
optimization may be probably warranted. Just recently indeed, a French group has published a 
description of a LC-MS/MS method that they are using for clinical monitoring of imatinib, in 
order to evaluate adherence to therapy, drug-drug interaction and PK-PD relationships [29]. 
2.2 Determination of imatinib in PBMCs by LC-MS/MS 
During our study, a whole-day pharmacokinetic study was achieved with 5 consenting 
patients. On this occasion, peripheral blood mononuclear cells (PBMCs) were also collected from 
these 5 patients every 2 h for the measurement of the intracellular imatinib concentration in vivo 
by a LC-MS/MS technique. PBMCs were used as a surrogate of the cells involved in the 
considered pathologies (i.e. PNML, polymorphonuclear leucocytes for CML, and tumor cells for 
GIST). 
2.2.1 LC-MS/MS: Theoretical principles 
2.2.1.1 Mass spectrometry and LC-MS 
Mass spectrometry (MS) is an analytical technique enabling to determine the molecular mass 
of ionized molecules accelerated into magnetic or electric fields. Mass spectrometers are now 
widely used in modern analytical laboratories, and the mass spectra they provide enable analysts 
to determine the molecular masses. Additionnaly, when using high resolution technology, 
structural information of compounds in complex samples can be obtained [1,2]. 
Being able to couple MS to LC was a technological challenge because of the critical step of 
eliminating the aqueous mobile phase during the ionization process. Among the possible 
interfaces and ionization sources that have been developed for that purpose, the electrospray 
interface has been chosen for the present study. The application of a high electrical potential at 
the surface of the liquid flowing through the extremity of a capillary is necessary for the 
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production of charged droplets. They disintegrate upon drying by an intense heat source to 
ultimately generate ions that are accelerated into the detector [1,2]. The produced ions are then 
guided by a quadripole detector, onto which an electrodynamic field of a given radiofrequency is 
applied for the selection of ions with specific m/z ratio. 
2.2.1.2  Tandem mass spectrometry 
Tandem mass spectrometry (MS/MS) implies the selection by the first analyzer (i.e. quadripole 
in our case) of a parent ion (generally the molecular ion), which is directed by magnetic fields into 
the so-called collision cell (ie. in fact a second quadripole). This cell contains a neutral gas (argon) 
into which the ion disintegrates to produce a number of fragments (daughter or product ions). 
One product ion of enough intensity is then selected by a second analyzer (third quadripole) 
before its detection by a photomultiplier [1]. 
2.2.2 Materials and methods 
2.2.2.1 PBMC isolation from blood 
The PBMCs isolation procedure is based on the method previously developed in our 
laboratory for the intracellular measurement of the anti-HIV drugs by Colombo et al [30]. On the 
study day, samples were immediately taken (within 10 min) to the laboratory and processed. 
PBMCs were isolated using Vacutainer® CPT (Cell Preparation Tubes, Becton Dickinson, 
Allschwil, Switzerland), according to the manufacturer’s recommended procedure [31]. These 
tubes contain citrate as anticoagulant, a polyester gel layer and a Ficoll1 solution enabling the 
direct separation of mononuclear cells from other blood components. One tube per patient 
(approximately 8 ml of blood) was collected, gently inverted 8-10 times for careful 
homogenization with the anticoagulant, and centrifuged within 5 min (1650 g for 20 min at RT 
without brake; Centrifuge J-6B, Beckman, Fullerton, USA). The thin mononuclear cell layer was 
carefully mixed with plasma and transferred into a polypropylene tube (15 ml) pre-chilled at 4°C 
on an ice bath. The entire cell washing procedure was performed using pre-chilled PBS 
(phosphate-buffered saline) kept at +4°C. The centrifuge (Benchtop Universal 16R, Hettich, 
Bäch, Switzerland) was also maintained at +4°C to inhibit enzymatic activity and to prevent 
active drug efflux out of cells. 
The collected cells suspended into the plasma were first centrifuged at 4°C for 10 min, and 
after discarding the supernatant, they were washed with 10 ml cold PBS solution containing 2% 
                                                
1 Ficoll is a neutral highly branched, high-mass, hydrophilic polysaccharide. 
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FBS (fetal bovine serum). After careful cell homogenization, the tube was centrifuged for 10 min 
at 650 g (+4°C) and the supernatant discarded. The washing procedure was repeated twice. The 
third (final) supernatant wash solution was completely aspirated off and an exact volume of 
1.0 ml of PBS was added to the cell pellet. Cells were carefully homogenized and suspended, and 
a 20-µl aliquot was taken out from them and diluted 1 : 10 with 180 µl PBS in a 0.5-ml 
Eppendorf tube. This aliquot was homogenized for cell counting within 10 min, allowing the 
total number of PBMC contained in each patient’s pellet sample to be calculated, and used for 
normalizing the intracellular drug concentration determined by LC-MS/MS. The Laboratory of 
Hematology of our hospital performed the cell counting with a Coulter counter. 
The remaining 980-µl cell suspension was centrifuged at 650 g for 10 min at 4°C. The 
supernatant was aspirated off, leaving the PBMCs pellet at the bottom of the vial which was 
immediately stored at –20°C up to the day of the analysis. 
2.2.2.2 Imatinib measurement in PBMCs pellets 
The development of the LC-MS/MS methodology used for quantifying imatinib levels in 
PBMCs was carried out by an assistant-pharmacist2 during her Pharmacy diploma [2]. It was 
based on various publications of LC-MS measurement of imatinib in plasma [21,24,32], as well as 
on publications on the intracellular quantification of cytotoxic [33] and anti-HIV drugs [30]. 
It is also worth noting that this LC-MS/MS analysis has been applied for the quantification of 
imatinib levels in liver biopsies. This measurement was carried out as part of a collaborative work 
with the Institute of Clinical Pharmacology of the University of Bern, in a study aiming at 
assessing the antifibrotic effect of imatinib in rat livers. This study was not directly related to the 
present thesis work, and is therefore not presented here, but can be found in an article recently 
published in the Journal of Hepatology [34]. Moreover, such a technique was also used to measure 
imatinib inside cultured cells that have been knocked down for P-gp by an Austrian research 
group (see § 6.2 for details). 
The analysis of PBMCs samples collected during our clinical study was performed by the 
Principal Laboratory technician3 in charge of the LC-MS/MS instrument of the Division of 
Clinical Pharmacology. 
                                                
2 Aurélie Fayet 
3 Alexandre Béguin 
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1. PBMCs extraction procedure: 100-µl PBS buffer was added to the PBMCs pellets, as well as 100 µl 
acetonitrile (ACN, containing 0.05 µg/ml clozapine as IS) in order to denature and inactivate 
proteins and enzymes. The resulting suspensions were vortexed to ensure adequate mixing 
and were subsequently incubated at 37°C for 1 h. The mix was finally sonicated for 5 min in 
an ultrasound bath for cell lysis and centrifuged for 10 min at 20°C and 20’000 g (Benchtop 
Universal 16R centrifuge, Hettich, Bäch, Switzerland). 
100 µl of supernatants diluted with 100 µl mobile phase A (NH4Ac buffer 10 mM + 1% acetic 
acid) were introduced into 200-µl HPLC microvials (Agilent, Böblingen, Germany) and a 
volume of 10 µl was used for LC-MS/MS analysis. 
2. LC-MS/MS quantification: The LC-MS/MS system consisted of a TSQ Quantum Discovery 
tandem triple-stage quadripole (Thermo Finnigan, San Jose, USA), coupled with an Agilent 
1100 liquid chromatography system (Agilent, Böblingen, Germany) equipped with a binary 
pump, an autoinjector and an on-line degaser system. The temperature of the autoinjector was 
set at 20°C during the operation. HPLC vials were maintained at 20°C in the autosampler. 
Chromatographic separations were performed on a Symmetry Shield RP8 3.5 µm, 30 mm 
length x 2.1 mm id column (Waters, Milford, USA), thermostated at 30°C. The binary solvent 
system was NH4Ac buffer 10 mM + 1% acetic acid (A), and MeOH + 1% acetic acid (B) used 
in gradient mode and followed by a rinsing and re-equilibration program for up to 16 min. 
The LC-elute was introduced into the electrospray source without splitting. An adequate 
MS/MS tune settings for imatinib/metabolites/clozapine (IS) was chosen [2]. A desolvation 
temperature of 350°C, a spray voltage of 4000 V, a source CID (collision-induced 
dissociation) of 10 V, a sheath gas flow rate of 40 units, an auxiliary gas flow rate of 10 units 
and a collision gas (argon) of 1.0 mTorr were used. Multiple reactions monitoring (MRM) was 
selected in the positive ions mode for all analytes. 
It is noteworthy that this LC-MS/MS method allows the intracellular measurement of 
imatinib, its main metabolite N-desmethylimatinib (CGP74588) and of some oxygenated 
metabolites of imatinib (as yet unidentified). 
3. Imatinib levels calculation: After PBMC extracts quantification, imatinib levels in PBMCs may be 
expressed either in ng per 106 cells, taking into account the number of cells determined in the 
sample at Hematology Laboratory, or in ng/ml (“intracellular” concentration), assuming a 
0.4 pl PBMC volume [35]. 
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The limit of quantification of the assay was 10 µg/l. Mean intra-day and inter-day precision for 
intra-PBMC imatinib was 2.9 and 6.3%, respectively. Finally, the mean intra-day and inter-day 
accuracy was 1.9 and 5.9%, respectively. 
2.3 MDR1  genotyping 
Since the MDR1 3435C>T polymorphism is known to influence P-gp expression in vivo, with 
potential consequence on the disposition of its substrates [36-38], and since P-gp markedly 
affects the imatinib intracellular concentration (see Chapter 6), the genotyping of the MDR1 gene 
was considered as a biological covariate in the present clinical study. The 3435C>T 
polymorphism was therefore assessed in consenting patients using a restriction length 
polymorphism method previously established at the Clinical Chemistry Laboratory of our 
hospital4. 
2.3.1 Theoretical introduction 
Examination of the exon 26 of MDR1 gene reveals that the SNP 3435C>T is located at 
position 176 [39], with the 3435T variant resulting in the disappearance of a restriction site 
(GATC between positions 172 and 176) recognized by three restriction enzymes (DpnII, MboI 
and Sau3AI). 
To assess the genotype of a patient, the procedure implies the extraction of DNA from the 
buffy coat of patients’ blood samples and subsequent purification using a suitable solid-phase 
extraction kit for DNA. A sequence of MDR1 exon 26 contained in this DNA is then amplified 
using a polymerase chain reaction (PCR)5 method, before being restricted by the MboI enzyme 
(i.e. cutting amplicons if the restriction site is recognized). In our case, the expected restriction 
enzyme-digested fragments are 143- and 46-bp for the CC genotype at nucleotide 3435; 189-, 
143- and 46-bp for CT; and 189 bp for TT. Finally, the fragments are visualized as bands on an 
agarose gel after electrophoresis and subsequent ethidium bromide staining. 
                                                
4 References: “Genomic DNA preparation” and “Restriction fragment length polymorphism MDR1 C3435T” SOPs 
issued by the Clinical Chemistry Laboratory at CHUV. 
5 As a reminder: PCR is a process in which a particular DNA fragment from a mixture of DNA chains is rapidly 
replicated, producing a large, readily analyzed sample. 
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2.3.2 Materials and methods 
2.3.2.1 DNA purification from pellet samples 
Purification of patients’ genomic DNA was carried out using QIAamp® DNA kits (Qiagen, 
Basel, Switzerland). A 200-µl aliquot of solid cellular pellet samples (obtained after plasma 
collection and containing buffy coat) were added to Eppendorf tubes containing 20 µl 
Proteinase K, prior to the addition of 200 µl alkaline lysis buffer (AL buffer, containing a 
chaotropic salt). After mixing by pulse-vortexing for 15 s, the tubes were incubated at 56°C for 
10 min and briefly centrifuged at 13’000 g (Genofuge® 16M, Techne, Cambridge, UK) to remove 
any drop present on the inside of the lid. A 200-µl volume EtOH was added and the mixes were 
vortexed again for 15 s and briefly centrifuged. 
The mixtures were then carefully applied to SPE columns specifically designed for DNA 
extraction (QIAamp Spin columns), placed into 2-ml collection tubes, and centrifuged at 10’000 g 
for 1 min. The columns were then put into clean 2-ml collection tubes while the previous tubes 
containing the filtrate were discarded. 500 µl of a first wash buffer (also containing a chaotropic 
salt with large amount of EtOH) was added, and the same procedure was repeated 
(centrifugation and discarding of collection tubes). 500 µl of a second wash buffer (containing 
EtOH) were subsequently added, followed by a centrifugation at 13’000 g for 1 min. The 
collection tubes were finally replaced by 1.5-ml Eppendorf tubes (without lids) before the 
addition of 200 µl water in the columns and incubation for 5 min. The columns were centrifuged 
at 10’000 g for 1 min to eluate DNA out of them. DNA concentration in Eppendorf tubes was 
finally checked by photometry (260 nm). 
2.3.2.2 PCR mix preparation 
The PCR mix was prepared in a specifically assigned protection hood (for preventing cross-
contamination). Various reagents were mixed in the following order: 5.0 µl incubation buffer 
15 mM MgCl2 x 10, 1.0 µl nucleotides 10 mM (dNTPs from Q-Biogene, Basel, Switzerland), 
2.0 µl primers (F2 and R2 M29445), 0.5 µl Taq DNA polymerase 5 U/µl from Q-Biogene (all 
quantities for one sample). The mix was vortexed and 45-µl aliquots were distributed in PCR 
tubes. The primers’ sequences were as followed: forward (F2) 5'-TGGCAAAGAAATAAA 
GCGAC-3'; and reverse (R2) 5'-GACTCGATGAAGGCATGTA-3'. 
Outside of the hood, 5 µl of patients’ genomic DNA were added to each PCR tubes, together 
with two drops of paraffin. The mixtures were finally vortexed and briefly centrifuged at 
13’000 g. 
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2.3.2.3 PCR amplification 
PCR amplification was done with a Touchgene gradient thermal cycler (Techne, Cambridge, 
UK) with the program described in Table 2.6. The above-mentioned primers (F2 and R2) are 
shown on Figure 2.4. 
Table 2.6. Touchgene PCR program 
Phases Cycles # T [°C] Duration Purpose 
1 1 94 2 min Denaturation 
94 15 s Denaturation 
58 30 s Hybridation 2 10 
72 40 s Elongation 
94 15 s Denaturation 
58 30 s Hybridation 
3 25 72 1st cycle: + 20 s 
25th cycle: + 6 min 
Elongation (for 
increasing amount of 
materials) 
4 1 72 7 min End of elongation 
5 1 4 ∞ Cooling 
 
 1 GATCTGTGAACTCTTGTTTTCAGCTGCTTGATGGCAAAGAAATAAAGCGACTGAATGTTC 
 61 AGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCCATCCTGTTTGACTGCAGCA 
121 TTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTGTCACAGGAAGAGATCGTGA 
181 GGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCACTGCCTAATGTAAGTCTCT 
241 CTTCAAA 
 
C C3435T mutation GATC  Restriction site 
NNNN… Exon 26 sequence NNNN… Forward primer (F2) NNNN… Reverse primer (R2) 
Figure 2.4. GenBank sequence # M29445 
2.3.2.4 Restriction 
10-µl aliquots of the 189 bp PCR product (obtained after amplification) were pipeted into 
500-µl Eppendorf tubes before the addition of 1 µl MboI enzyme and one drop of paraffin. The 
mix was vortexed, briefly centrifuged and incubated overnight at 37°C. In the absence of 
mutation, MboI was able to cut the amplified sequence at the restriction site (Figure 2.4). 
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2.3.2.5 Agarose gel electrophoresis 
The DNA fragments produced during the above-mentioned experiments were finally 
separated by electrophoresis with a high-resolution agarose gels consisting of 3% MetaPhor® in 
TBE buffer (Tris/borate EDTA, pH 8.0). MetaPhor® (Cambrex,, Verviers, Belgium) is an 
intermediate melting temperature agarose. Three gels were prepared by microwave dissolution 
according to the manufacturer’s recommended procedure. 
Before migration, 2 µl DNA loading buffer 6x were added to the restriction mixes. Each 
sample was charged onto the gels, as well as a DNA molecular mass marker from the laboratory 
(no. VIII). A CC control sample and a blank control (water) were also charged. The migration 
was carried out for 2 h under a 75-V voltage. 
After migration, the gels were incubated with ethidium bromide 0.5 µg/ml for 30 min and 
washed with distilled water. They were then scanned with a fluorimetry densitometer Typhoon 
(Amersham Biosciences, Piscataway, USA) and the fragments were identified by comparison with 
the DNA molecular mass markers. 
2.4 Urinary 6β-OH-cortisol/cortisol measurement by LC-MS 
2.4.1 Background 
As previously stated (see § 1.5.1 and 1.8.1), the 6β-hydroxycortisol/cortisol ratio, used as a 
putative index of CYP3A4 activity (one of the biological covariate of our study), was determined 
in urine spots collected from patients simultaneously to the blood sample. A laboratory 
technician6 at PCL has carried out the analysis using a method previously developed by an 
assistant-pharmacist7 during his Pharmacy diploma [1]. It is noteworthy that an HPLC-UV 
method had previously been evaluated in our laboratory [40], but this technique lacked the 
required level of sensitivity and specificity, because both compounds are frequently present at 
very low levels in the collected urine. The liquid intake and time of urine collection was not 
controlled in the study and the concentrations of 6β-hydroxycortisol and cortisol in urine 
collection were thus highly variable. The development of the present LC-MS/MS method was 
therefore required for the measurement of endogenous cortisol and 6β-hydroxycortisol 
measurements in patients’ urine. Theoretical considerations on such a technique have already 
been exposed. 
                                                
6 Alexandre Béguin 
7 Hugo Figueiredo 
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2.4.2 Materials and methods 
2.4.2.1 Extraction from urinary samples 
Urinary samples were purified using a solid-liquid SPE technique with Chromabond® XTR 
(Macherey-Nagel, Düren, Germany) based on a publication by Ohno et al [41]. A 3-ml urine 
aliquot was centrifuged for 5 min at 1800 g (Centrifuge J-6B, Beckman, Fullerton, USA) to 
eliminate the precipitate, which can appear over time during the storage at -20°C. A 1-ml aliquot 
of the clear supernatant was taken and vortexed in an Eppendorf vial with 100 µl of a solution of 
cortisol-d4 (IS) at 250 ng/ml. Finally, 1 ml of this solution was directly loaded on the 
Chromabond® XTR cartridge, which does not require any pre-conditioning step. 
The sample was absorbed into the solid phase and maintained for 10 min onto the cartridge, 
before elution with 2 x 4 ml of ethyl acetate (AcOEt). This eluted AcOEt phase was evaporated 
to dryness under a nitrogen stream. The solid residue was reconstituted with 200 µl of 
MeOH/H2O 50 : 50 (v/v). A 50-µl aliquot of this reconstituted sample was diluted with 75 µl of 
water to attain the desired MeOH/H2O 20 : 80 (v/v) final solvent composition (similar to the 
solvent composition at the beginning of the gradient program). 20 µl of this last solution was 
injected on the LC-MS/MS system. 
2.4.2.2 LC-MS/MS quantification 
The chromatographic method used for the separation of cortisol and 6β-hydroxycortisol is an 
adaptation of various previously published methods [41,42]. The same instrument as for the 
intracellular measurement of imatinib was used (TSQ Quantum Discovery tandem triple-stage 
quadripole; Thermo Finnigan, San Jose, USA), coupled to an Agilent 1100 liquid chromatography 
system (Agilent, Böblingen, Germany). The mobile phase consisted of 0.1% formic acid (A) and 
MeOH + 0.1% formic acid (B). The chromatographic column was Nucleosil 100-3 µm C8 HD 
(Macherey-Nagel, Düren, Germany). A stepwise gradient was used at a typical flow rate of 
0.3 ml/min. These conditions provided a good separation of the two compounds 
(6β-hydroxycortisol eluted in 3.2 min, and cortisol and IS in 9.0 min). An adequate MS/MS tune 
settings for cortisol/6β-hydroxycortisol/cortisol-d4 (IS) was chosen [1]. A desolvation 
temperature of 350°C, a spray voltage of 4500 V, a source CID (collision-induced dissociation) of 
10 V (6β-OH-cortisol) and 15 V (cortisol and IS), a sheath gas flow rate of 60 units, auxiliary gas 
flow rate of 5 units and a collision gas (argon) of 1.0 mTorr were used. 
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The limits of quantification of the assays were 1 µg/l for cortisol and 10 µg/l for 
6β-hydroxycortisol. Mean inter-day precision and accuracy were 7.4 and 7.2%, and 9.1 and 3.7% 
for cortisol and 6β-hydroxycortisol, respectively. 
2.5 Plasma α 1-acid glycoprotein measurement 
2.5.1 Theoretical introduction 
The third main biological covariate of our PK analysis (AGP plasma level) was measured at 
the Laboratory of Clinical Biochemistry and Psychopharmacology Unit in Cery. The principle of 
the method implies the precipitation of AGP with a specific rabbit antiserum that can then be 
analyzed by turbidimetry [43]. 
Turbidimetry is an analytical method based on a phenomenon whereby the intensity of light, 
passing through a medium with dispersed particles, is attenuated by scattering. It is worth noting 
that, in turbidimetry, the intensity of transmitted light (i.e. unscattered) is measured, whereas in 
nephelometry the scattered light is measured. 
The limit of quantification of the assay was 0.16 g/l. Mean intra-day and inter-day precision 
were 1.9 and 2.4%, respectively, for a 0.62 g/l concentration, and 1.0 and 1.5%, respectively, for a 
2.22 g/l concentration. 
2.5.2 Materials and methods 
The automate instrument used was a COBAS INTEGRA 400 system (Roche Diagnostics, 
Basel, Switzerland). A 100-µl aliquot of patients’ plasma samples was pipeted into suitable tubes 
in our laboratory. After reception at Cery and dilution, polyethyleneglycol (used as reaction 
accelerator) and rabbit antiserum T were added. The rabbit antiserum precipitated AGP, which 
could then be quantified by turbidimetry at 340 nm, using a calibration method (with 
Serumproteins T standards). The results are given in g/l. 
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Chapter 3   Population pharmacokinetic study 
 
his chapter will first provide a detailed description of the overall procedure used for clinical 
data collection from patient medical files and their gathering into a suitable database. Their 
integration into the population pharmacokinetic modeling performed with the NONMEM® 
software will then be largely presented. 
The results of a subsequent pharmacokinetic-pharmacodynamic (PK-PD) analysis will be 
exposed in a specific chapter (i.e. Chapter 4). 
3.1 Theoretical introduction 
3.1.1 Imatinib pharmacokinetics 
Our current knowledge of imatinib pharmacokinetics previously given in § 1.3.4 has been 
gathered during the phases I, II and III of the clinical development of imatinib, which have been 
recently published [1-6]. Among the two stringent studies applying a population approach [2,4], 
one of them [4] has indicated that imatinib clearance tends to increase upon Glivec® treatment in 
GIST patients, followed over 12 months. Accordingly, imatinib levels in patients whose dosage 
was increased (upon progression) were substantially lower than those at the beginning of the 
treatment. By contrast, a 25% decrease in imatinib overall clearance was reported in another 
study with CML patients [2], albeit followed up for only one month. As recently stated by 
Leveque et al, the clinical relevance of imatinib PK variability deserves investigation, as well as the 
identification of individual kinetic determinants that could modulate the clinical response [7]. 
Weight, creatininemia, albuminemia, hemoglobinemia and some other covariates have already 
been assessed [2,4]. To our knowledge however, no formal study assessed the effects of the three 
important covariates mentioned above –namely MDR1 expression, CYP3A4 activity and AGP 
plasma levels– on imatinib PK parameters. Only one study, published in an abstract form, has 
correlated MDR1 single nucleotide polymorphism (SNP) and CYP3A4 activity to imatinib area 
under the curve (AUC) [8]. Finally, no data are available about the intracellular levels of imatinib 
into patients’ cells, and a single study only had assessed in vitro the intra/extracellular ratio of this 
drug in human plasma [3]. 
As previously stated (§ 1.8), the major goals of our clinical pharmacokinetic study were thus 
(1) to characterize the population PK profile of imatinib in CML and GIST patients, (2) to 
T 
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evaluate the influence of various demographic and biological covariates on imatinib absorption 
and disposition, (3) to assess the specific role of AGP on imatinib PK, and (4) to further explore 
the intracellular uptake of imatinib in vivo. 
3.1.2 The NONMEM approach 
As mentioned in § 1.6, population pharmacokinetics aims at describing the pharmacokinetic 
variability in terms of a series of interrelated factors [9]. They can be evaluated, for instance, using 
the NONMEM approach. 
3.1.2.1 General principles 
NONMEM stands for “NONlinear Mixed Effects Model”. It is a computer program, written 
in FORTRAN1 77, and designed to fit general statistical (nonlinear) regression-type models to 
data. This program was developed by the NONMEM Project Group at the University of 
California at San Francisco, a group of researchers in the Division of Clinical Pharmacology. The 
first version appeared at the beginning of the 1980s. It was able to analyze data described by a 
regression model with both fixed and random effects, and was thus notably developed for 
analyzing population pharmacokinetic data [10,11]. NONMEM® is now the most widely used 
software for this type of analysis and has been employed for numerous drugs, such as phenytoin 
(yielding the well-known “orbit plot”  [12]) and angiotensin antagonists (e.g. in a study realized at 
the Division of Clinical Pharmacology at Lausanne PCL Division [13]). 
This regression software describes the observed concentration-time data in terms of 
deterministic and probabilistic parts [9,13]: 
1. Deterministic part: Several fixed effects parameters θ, which may include the mean values of 
the pharmacokinetic model parameters φj or parameters relating the model to the 
demographical, physiological or external variables described above. 
2. Probabilistic part: Two types of random effect parameters characterizing the variability 
around the fixed effects: 
• ω2: variance of θ, i.e. the interindividual variability. Thus, an individual has his own 
parameter value θj = θ + ηj, where ηj follows a centered normal distribution with a 
ω2 variance. 
                                                
1 Fortran (also FORTRAN; FORmula TRANslator) is a computer programming language originally developed by 
IBM in the 1950s and still used for scientific computing and numerical computation. It is sometimes considered as 
the earliest "cross platform" programming language. 
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• σ2: residual intraindividual variability due to random fluctuations in an individual’s 
parameter values, measurement errors and all sources of errors not accounted for by the 
other parameters. An ih observation in the jth individual (yij) thus differs from the 
corresponding prediction ŷ by a residual error of εij (following a centered normal 
distribution with a σ2 variance). 
The function of NONMEM is thus to estimate the average values of these three parameters. 
3.1.2.2 The general model 
A general model in NONMEM can be written in the following generic form [13]: 
 
  
! 
y ij = f (x ij ," j )+ #ij           where    
! 
" j = g(z j ,#)+ $ j  (1) 
As previously stated, yij is the ith observation (typically the plasma concentration) from the jth 
individual, f is a specified pharmacokinetic (or even pharmacodynamic) model, which is function 
of known quantities xij (e.g. dose, time) and parameters φj (e.g. clearance, distribution volume). 
The parameters φj are functions of fixed effects zj (e.g. age, height) and fixed effects parameters θ 
previously cited. As already mentioned, εij corresponds to the residual error and ηj to the 
interindividual error. 
By using NONMEM, the aim is to determine the best model to fit the experimental data, in 
order to obtain estimates of the average values of θ, ω2 and σ2. The fitting method used by 
NONMEM is the one based on the extended least squares criterion [14]. The model has to be 
selected among classical PK models such as one compartment, two compartments, linear or 
nonlinear kinetics for PK variables (e.g. concentration), or among PD models such as Emax for 
effect variables. 
3.1.2.3 NM-TRAN and PREDPP 
Two additional components are distributed with NONMEM: NM-TRAN and PREDPP. The 
first one stands for “NONMEM translator” and is a language processor and data preprocessor 
that translates commands and data files in NONMEM input files. The second one stands for 
“Prediction for Population Pharmacokinetics”. Whereas NONMEM is a general nonlinear 
regression tool, PREDPP is specific to the types of predictions that arise in pharmacokinetic 
models. It is an extensive library of Fortran subroutines, corresponding to various predefined 
models (e.g. ADVAN and TRANS subroutines) [13,14]. 
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3.2 Materials and methods 
3.2.1 General study procedure 
These paragraphs summarize the main logistical and practical aspects of the study protocol 
and its amendment presented in Chapter 1 (and which can also be found in Appendices 1.1 to 
1.5). The study was approved in 2002 by the Ethics Committee of the Lausanne Faculty of 
Medicine (see Appendices 1.3 and 1.5). 
At the occasion of a scheduled medical visit for the usual follow-up of their conditions, the 
patients were given oral and written informations on the objectives and on the logistical details of 
the study (see “Feuille d’information aux patients” in Appendix 1.2). After obtaining the written 
informed consent, a 5-ml blood sample was drawn together with the standard routine sampling 
(chemistry, hematology). For practical reasons, one blood sample was taken per visit, if possible 
during the imatinib elimination phase (i.e. at least 4 h after the latest dose intake). It had been 
anticipated that each patient would provide at least two samples at 3-month intervals (to assess 
intra- and interindividual variability). Moreover, as previously mentioned, plasma and intracellular 
(i.e. intra-PBMC) imatinib pharmacokinetics was also studied for a small number of consenting 
patients (i.e. 5 subjects) over a whole dosing interval in the Clinical Research Unit at the Division 
of Clinical Pharmacology. This ancillary study has required an amendment of our protocol 
(Appendices 1.4 and 1.5). 
Clinicians had to report on a specific Case Report Form (CRF, see Appendix 3.1) the exact 
time of blood sampling, the daily regimen, as well as the dose, the date and the exact time of the 
last intake of Glivec®. Comedication taken by the patient during the last week and relevant 
information such as side effects and clinical evolution (at the time of blood collection and during 
the preceding month) also had to be reported in details. Cancer progression markers were 
considered (hematological, cytogenetic and molecular response for CML, and tumor evolution 
criteria (RECIST) [15] for GIST). All these data were reported at each routine medical visit, and 
were checked and validated, at the end of the study, by direct access to the medical files of each 
patient. Laboratory test results (such as creatininemia) were obtained from the central computer 
system of our hospital (Molis®), gathering all routine laboratory results at CHUV. All data have 
been introduced in an Access® database (version 2000, Microsoft Co., Redmond, USA), designed 
in collaboration with the PCL Data manager2. For the whole-day study, a special CRF 
(Appendix 3.2) was elaborated. It was directly filled at PCL Clinical Research Unit. 
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In addition, patients were asked to provide a spot of urine sample (ca 10 ml), for the 
determination of the 6-β-hydroxycortisol/cortisol ratio. These blood and urine samples were 
taken at each of the patients’ routine medical visit. Blood samples (5 ml) were collected in 
Monovettes® (Sarstedt, Nümbrecht, Germany) with K-EDTA as anticoagulant and brought or 
sent together with urine samples (Monovettes®) to the Laboratory of Clinical Pharmacology. 
3.2.1.1 Sample storage 
Blood samples were immediately centrifuged (1800 g, +4°C, 10 min) at the laboratory 
(Centrifuge J-6B, Beckman, Fullerton, USA). The plasma was separated and transferred into 
polypropylene test tubes before storage, together with urinary sample at -20°C, prior to LC-UV 
analysis. During the whole-day pharmacokinetic study, PBMC samples were immediately 
processed after collection and cells pellet were stored at -20°C before LC-MS/MS analysis (§ 2.2). 
The cellular (erythrocytes and buffy coat) bottom layer obtained after blood centrifugation has 
been kept for subsequent PCR analysis of P-glycoprotein (P-gp) polymorphism, relevant 
cytochromes P450 polymorphism analysis, or for the analysis of BCR-ABL and KIT expression 
and mutation in patients. 
DNA samples have been coded to preserve patients’ anonymity. The remaining samples or 
the non-analyzed samples will be eliminated one year after the end of the study, but in January 
2007 at the latest. 
3.2.1.2 Samples analysis 
Imatinib in plasma was analyzed on a semi-routine basis (batch series of approximately 
20 patients’ samples) by the LC-UV method previously mentioned [16]. 6β-hydroxycortisol and 
cortisol in urinary samples were quantified by LC-MS/MS at the Quantitative Mass Spectrometry 
Facility (qMSF) of CHUV (method reported in § 2.4). Plasma AGP levels were measured by the 
Laboratory of Clinical Biochemistry and Psychopharmacology Unit in Cery (see § 2.5). 
3.2.2 Population pharmacokinetic analysis with NONMEM® 
Population PK analysis was carried out with the previously described NONMEM® program. 
The description of the analysis presented here corresponds to the article that has just been 
accepted for publication by an international journal [17]. 
Data from 59 patients, providing a total of 321 plasma samples, were collected during 3 years 
for the population PK analysis. These patients included 38 with GIST, 20 with CML and 1 with 
ALL, who received imatinib at various dosage regimens (daily doses ranging from 150 to 
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800 mg). All patients were pooled in our analysis, regardless of their medical history. Their 
median age was 55 years (range 20-79), their median body weight was 71 kg (44-110), and their 
median height was 172 cm (152-189); 26 patients were female (Table 3.1). Most peripheral blood 
samples were drawn periodically at 1- to 6-month intervals on follow-up visits, along with routine 
laboratory tests. The median number of measurements for each patient was 4 (range 1-14). All 
samples were obtained under steady state conditions (i.e. unchanged dosage for at least one 
month). Additional measurements were taken in 5 consenting patients over one dosing interval to 
obtain a detailed concentration-time profile, with 9 peripheral blood samples drawn between 0 
and 8 h after drug intake. 
Table 3.1. Characteristics of the 59 patients (corresponding to 321 samples) evaluated in the population 
pharmacokinetics analysis of imatinib 
Characteristic Patients 
Pathology diagnosis (No.) 
 GIST 
 CML 
 ALL 
 
38 
20 
1 
Gender (No.) 
 Men 
 Women 
 
33 
26 
Age (y) 
 Median 
 Range 
 
55 
20-79 
Body weight (kg) 
 Median 
 Range 
 
71 
44-110 
Height (cm) 
 Median 
 Range 
 
172 
152-189 
AGP plasma levels (g/l) 
 Median 
 Range 
 
0.9 
0.4-3.2 
MDR1 genotype (No.) 
 3435CC 
 3435CT 
 3435TT 
 
5 
22 
9 
CYP3A4 ratio (UCR) 
 Median 
 Range 
 
3.6 
0.7-38.5 
CYP3A4 inducers 
 Carbamazepine, rifampicine, dexamethasone 
CYP3A4 inhibitors 
 Verapamil, diltiazem, fluoxetine, fluvoxamine, amiodarone, 
éthinylestradiol, fluconazole, voriconazole 
 
3 
 
9 
                              UCR = urinary cortisol ratio 
 
During this same single-day study, intracellular concentrations of imatinib were also measured 
in peripheral blood mononuclear cells (PBMC; used as a surrogate of target cells) from four 
peripheral blood samples. These samples were drawn before and 2, 4 and 6 h after drug intake 
using Vacutainer® CPT (Cell Preparation Tubes, Becton Dickinson, Allschwil, Switzerland), 
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according to the manufacturer’s recommended procedure and to the method previously 
developed in our laboratory for the intracellular measurement of anti-HIV drugs [18]. All tubes 
were processed at +4°C and the collected cells were washed three times with cold PBS, prior to 
cell counting with a Coulter counter and imatinib measurement using the LC-MS/MS method 
previously described (see § 2.2.2). 
In addition to accurate dosing and sampling time information, the following data were 
recorded for each patient: body weight, gender, age, height, creatininemia (CRT, in µmol/l) and 
concomitant medication intake (Table 3.1). 
Furthermore, the genotype of MDR1 was determined in 36 patients for the 3435C>T single 
nucleotide polymorphism (SNP), known to be associated with P-gp expression level [19]. The 
evaluation of the CYP3A4 function was achieved by measuring the 6β-hydroxycortisol/cortisol 
ratio in a 10-ml spot of urine collected at the same time as 164 peripheral blood samples [20]. 
These urine samples were stored at -20°C until analysis (see below). As previously stated, the 
measurement of endogenous levels of 6β-hydroxycortisol/cortisol in urine represents an 
attractive approach to assess the CYP3A4 activity, as it does not require the administration of any 
exogenous probe substance [20]. Finally, AGP plasma levels were assessed in 278 plasma 
samples. The influence of MDR1 genotype, CYP3A4 activity and AGP plasma levels on imatinib 
PK was thus evaluated in the patient subsets. 
3.2.3 Pharmacokinetic modeling 
3.2.3.1 Demographic covariates analysis 
A one-compartment and a two-compartments model with first-order absorption were tested. 
The first one is described by the following differential equations: 
 
  
! 
dA
1
dt
= "k
a
# A
1
 (2) 
 
  
! 
dA
2
dt
= k
a
" A
1
#CL "C
tot
 (3) 
where A1 and A2 are the amounts of imatinib in the absorption and central compartments, ka 
the first order absorption rate, Ctot the measured drug concentration (corresponding to the A2/Vd 
ratio, and where Vd is the volume of distribution) and CL the clearance. 
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Three demographic covariates (body weight, gender and age), as well as the pathology 
diagnosis, were then sequentially incorporated in the model and tested for significance, leading to 
the following equations (final expressions): 
 
  
! 
CL = "a + "1 #
(BW $BWmean )
BWmean
+ "2 # q $"2 # (1$ q)+ "3 #
(AGE $ AGEmean )
AGEmean
+ "4 # p$"4 # (1$ p) (4) 
   
! 
Vd = "b + "5 # q $"5 # (1$ q) (5) 
where body weight (BW) and age (AGE) are expressed as the relative deviation of the 
individual BW and AGE from the population mean (BWmean = 70 kg and AGEmean = 50 years, 
respectively). Dichotomous variable were used for gender (q = 0 for female and 1 for male) and 
for the pathology diagnosis (p = 0 for CML and 1 for GIST). 
3.2.3.2 Biological covariates analysis 
Several models were tested to assess the effect of AGP on the PK parameters. First, a linear 
relationship between the AGP covariate and the PK parameters was tested: 
 
  
! 
CL  or  Vd = "a + "1 #
(X $ Xmean )
Xmean
 (6) 
where X is expressed as the relative deviation of the individual X from population mean Xmean. 
For AGP plasma levels (AGPtot), the population mean (AGPmean) was equal to 0.95 g/l. This 
equation (5) was also used afterwards for testing some other biological covariates (see below). 
Based on a hyperbolic relationship between AGPtot and CL/Vd was observed on the plots 
(see Results and Figure 3.7), two simple hyperbolic models (Power and Emax-like respectively) 
were also tested on CL and Vd: 
 
  
! 
CL  or  Vd = "
a
+ AGP
tot
#"
1  (7) 
 
  
! 
CL  or  Vd = "
a
#
"
1
$ AGP
tot
"
2
+ AGP
tot
 (8) 
Additionally, a model derived from the expression of the free fraction (fu), proposed by 
Rowland et al [21] (
  
! 
fu =
1
1+ Ka " fup " AGPtot
), was assessed: 
 
  
! 
CL =
"
1
1+ "
2
# AGP
tot
 (9) 
where θ1 represents the unbound clearance (CLu) and θ2 accounts for both the association 
constant (Ka) and the fraction of the number of binding sites unoccupied (fup). Notice that this 
model assumes constant, non-saturable free fraction. 
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Furthermore, a mechanistic approach was built up on the basis of physiological considerations 
(see Figure 3.1). The model given by equation (3) was thus rewritten, postulating that only the 
unbound imatinib concentration Cu was able to undergo first-order elimination through an 
unbound clearance process: 
 
Figure 3.1. Pharmacokinetic model derived from a mechanistic approach (Aa, imatinib amount in absorption 
compartment; ka, absorption constant; Kd, dissociation constant; Cu, free imatinib concentration; Ctot, total imatinib 
concentration; Cbound, imatinib concentration bound to AGP; AGPtot, total plasma AGP levels; CLu, free clearance) 
 
  
! 
dA
2
dt
= k
a
" A
1
#CL
u
"C
u
 (10) 
The values of Cu were related to the predicted concentrations Ctot through the following 
equation, incorporating AGPtot, the AGP dissociation constant for imatinib Kd and a scaling 
factor L: 
 
  
! 
Cu =
Ctot "Kd "L # AGPtot + (Ctot "Kd "L # AGPtot )
2
+ 4 #Kd #Ctot
2
 (11) 
The derivation of equation (11) is detailed in Appendix 3.3. A similar equation had been 
previously proposed for the analysis of sulfonamides PK by Bourne et al [22,23] (we simply used 
the dissociation constant Kd, instead of the association constant Ka). The L constant accounts for 
the difference in concentration unit between Ctot (µg/l) and AGPtot (g/l), assuming a one-to-one 
molar binding ratio [24]. It was fixed to 11.7 (considering a molar mass of 493.6 g/mol for 
imatinib [25], and a mean molar mass of 42’000 g/mol for AGP [26]). 
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On the basis of similar considerations, another hyperbolic equation relating Vd to AGPtot was 
derived (see Appendix 3.4 for details): 
  
! 
Vd =
"{["Kd "L # AGPtot + Ctot
2
+ 2 #Ctot # (Kd "L # AGPtot )+ (Kd + L # AGPtot )
2 ]# (VAGP " Vu )}+ Ctot # (VAGP + Vu )
2 #Ctot
 (12) 
where VAGP represents the volume of distribution of the protein and Vu the volume of 
distribution of the unbound fraction of imatinib. Formally, equation (12) makes Vd dependent 
on the predicted total concentration of imatinib (Ctot). To fit such an equation in NONMEM
®, it 
was however necessary to use the observed concentration instead. 
The demographic covariates (BW, gender and age) and the pathology diagnosis were tested 
again (see equations (4) and (5)), based on the new model incorporating AGP (equations (10) and 
(11)). 
Additionally to this AGP model, the effect of other biological covariates (MDR1 genotype, 
CYP3A4 activity and creatinine clearance) on imatinib PK was assessed. For MDR1, the 
following expression was used: 
 
  
! 
CL  or  Vd = "
a
+ "
1
#MDRT  (13) 
where MDRT is equal to -1 for MDR1 genotype 3435CC, 0 for 3435CT and 1 for 3435TT. 
For CYP3A4 activity (3A4A, expressed as urinary cortisol ratio) and creatinine clearance 
(CLCRT), the linear equation 5 was used with 3A4Amean = 5.4 (6β-hydroxycortisol/cortisol ratio) 
and CLCRTmean = 75 ml/min. CLCRT was calculated according to the Cockcroft and Gault 
formula [27]. 
At last, some derived parameters (elimination half-life t1/2, absorption half-life t1/2a and 
imatinib free fraction fu) were calculated as follows: 
  
! 
t
1/2
=
ln 2 " Vd
CL
, 
  
! 
t
1/2a
=
ln 2
k
a
, 
  
! 
f
u
=
C
u
C
tot
, where 
Cu is the predicted unbound concentration and Ctot the predicted total concentration. 
3.2.4 Statistical model 
A hierarchical model was used to account for inter- and intraindividual variability. The 
individual PK parameters θj were modeled assuming a log-normal distribution among the patients 
and were of the general form (see also equation (1)): 
 
  
! 
" j = "# e
$ j  (14) 
where θ is the population mean of the parameter, and ηj are independent normally distributed 
random effects with mean zero and variance Ω. 
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A proportional model was used to describe intraindividual (residual) variability of imatinib. 
For the generic response Y and the corresponding prediction Yˆ , the ith measurement for the jth 
individual takes the form: 
 ijij
!
"= eYˆY  (15) 
where εij is independent normally distributed with mean zero and a variance σ
2. 
3.2.5 Parameter estimation and model selection 
The analysis was performed using the computer program NONMEM® (version V, with NM-
TRAN version II) [11] running on a mainframe station (Sun Fire® 3800 server with 
UltraSPARC® III processors; Sun, Santa Clara, USA). It uses mixed (fixed and random) effects 
regression to estimate population means and variances of the PK parameters and to identify 
factors that may affect them. The data were fitted using a stepwise procedure and the first-order 
conditional method (FOCE INTERACTION and three significant digits) with the subroutine 
ADVAN 6. To determine the statistical significance between two models, different statistical 
selection criteria can be used that require a minimal decrease of 2 to 10 points in the objective 
function (OF) [28,29]. The decrease in OF corresponds to minus twice the logarithm of the 
linearized maximum likelihood of the model, and is approximately χ2 distributed (based on the 
likelihood ratio test). Therefore, a decrease of more than 3.8 points was considered significant for 
one additional parameter and 5.9 points for two additional parameters. Additionally, regression 
diagnostic plots generated with Excel® (version 11.2, Microsoft Co., Redmond, USA) were used 
for comparison between models. 
The general model was first evaluated with the data from the 5 patients having undergone 
intensive PK investigation. The analysis on the whole population was then conducted starting 
from those initial estimates. The influence of each recorded patient characteristics (i.e. covariates) 
on the Bayesian individual PK estimates of oral clearance (CL) and oral volume of distribution 
(Vd) was visually explored with Excel® (Appendix 3.5). The patient characteristics showing some 
potential influence on the PK parameters were then evaluated with NONMEM® by sequentially 
introducing them in the model. Finally, a simulation based on the final PK parameter estimates 
was performed with Excel® using first-order error propagation formulae to calculate the 90% 
prediction interval (Figure 3.6 and 3.8), encompassing the 5th and 95th expected concentration 
percentiles at each time point. The figures were generated with Prism® (version 4.03, Graphpad 
Software Inc., San Diego, USA). 
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3.3 Results 
The 321 imatinib plasma concentration values measured in the 59 patients ranged between  
67 and 11’221 µg/l. The population description is summarized in Table 3.1. Figure 3.2 shows the 
plot of the concentrations versus time after drug intake for all samples collected during the 3-year 
study. This Figure also integrates the additional measurements of the 5 patients followed at the 
PCL Clinical Research Unit during an entire dosing interval (9 blood samples drawn between 0 h 
and 8 h after drug intake). It is important to note that the analytical results of the 321 samples 
collected on EDTA measured were increased by 5 %, to correct for calibrations prepared in 
citrated plasma, in accordance with the recommendations specified in § 2.1.3.3. 
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Figure 3.2. Concentration versus time plot of the 321 samples collected during the 3-year study 
The P-gp polymorphism assessed in the sub-population of 36 patients (corresponding to 
245 samples) revealed that 5 had the MDR1 3435CC and 9 had TT genotypes, theoretically 
associated respectively with higher and lower P-gp expression as compared to the CT genotype 
found in 22 patients. Figure 3.3 shows an example of one of the electrophoretic gels of the 
digested PCR products obtained after migration and staining with ethidium bromide. 
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Figure 3.3. Electrophoretic gel of 8 patients (subjects 40 to 47), along with DNA molecular mass marker VIII (far 
left), CC control and blank control (H2O; right) 
The CYP3A4 activity (evaluated as the urinary cortisol ratio and determined in 39 patients; 
representing 164 samples) ranged from 0.7 to 38.5 (levels assumed to reflect metabolic activity). 
There are still controversies as to whether the 6β-hydroxycortisol/cortisol ratio reliably reflects 
the CYP3A phenotype. Information available at present suggests that this ratio is probably only 
moderately useful to compare interindividual CYP3A4 activity in a population, whereas the ratio 
may certainly constitute a useful index to assess the intraindividual variability of the CYP3A 
phenotype of a given subject, and its evolution over time. Despite this controversy, the data were 
integrated into the database without a priori, in order not to lose any power in the analysis. 
Finally, the assessment of AGP plasma concentration in 51 patients (corresponding to 
278 samples) provided results ranging from 0.4 to 3.2 g/l. As for the CYP3A4 phenotype, the 
data were not categorized into patient subgroups (i.e. low = 0.4-1.0 g/l, intermediate = 1.0-
2.0 g/l, etc). 
3.3.1 PK Population model 
A one-compartment model with first-order absorption from the gastrointestinal tract 
appropriately described the data (equations (2) and (3)), and a 2-compartment model did not 
improve the fit, with a difference in the objective function (ΔOF) of 0.0. In the absence of 
intravenous data, the mean population bioavailability (F) was fixed to 1, in accordance with the 
almost complete absorption reported for imatinib [30,31]. Significant inter-patient variability 
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could be assigned to both oral clearance (CV = 45%; ΔOF = -123.7) and oral volume of 
distribution (CV = 130%; ΔOF = -30.2), with a covariance between CL and Vd further reducing 
the objective function (ΔOF = -18.4). 
3.3.1.1 Demographic covariates model 
Established on this basic model, individual estimates of CL and Vd were derived for each 
patient and plotted versus all collected covariates to identify potential influences. Among the 
demographic covariates, body weight (BW), height, age, gender, as well as pathology diagnosis, 
showed some influence on imatinib PK. Height, being notably correlated to body weight, was not 
further investigated, assuming that the body weight was instead of interest to predict imatinib PK 
parameters. CL increased significantly with BW (ΔOF = -63.4). The combination of BW and 
gender produced a slight improvement over the model with BW alone (ΔOF = -3.5). The 
addition of age and pathology diagnosis provided some further improvement of the model (ΔOF 
= -4.5 and -4.6 respectively). Finally, gender significantly affected Vd (ΔOF = -5.1). Although 
gender, age and pathology diagnosis were of borderline statistical significance, we kept them in 
the model since they are always recorded for each patient and might be clinically relevant for 
selected patients (global ΔOF = -17.7). 
Coadministration of CYP3A4 inhibitors (ΔOF = -0.8) or inducers (ΔOF = 0.0) did not appear 
to affect imatinib PK to a statistically relevant extent in this population of patients. 
With the use of the Excel® program, it has been possible to generate for each step of this 
model development a diagnostic plot, similar to the one generated for the final demographic 
model retained (Figure 3.4). This latest plot shows a reasonable model that reliably fits the data. 
All concentration data are given in µg/l. 
Chapter 3 
Population pharmacokinetic study 
81 
 
10
10000
10 10000
Observations
P
re
d
ic
ti
o
n
s
 (
in
d
iv
id
u
a
l)
ba
e
c d
10
10000
10 10000
Observations
P
re
d
ic
ti
o
n
s
 (
ty
p
ic
a
l 
s
u
b
je
c
t)
-8000
-6000
-4000
-2000
0
2000
4000
6000
8000
0 1000 2000 3000 4000 5000 6000
Predictions
R
e
s
id
u
a
ls
 (
ty
p
ic
a
l 
s
u
b
je
c
t)
-8000
-6000
-4000
-2000
0
2000
4000
6000
8000
0 1000 2000 3000 4000 5000 6000
Predictions
R
e
s
id
u
a
ls
 (
in
d
iv
id
u
a
l)
-8
-6
-4
-2
0
2
4
6
8
0 1000 2000 3000 4000 5000 6000
Predictions
W
e
ig
h
te
d
 r
e
s
id
u
a
ls
 (
ty
p
ic
a
l 
s
u
b
je
c
t)
 
Figure 3.4. Diagnostic plots of the final demographic PK model: a) observed values versus population predicted 
values; b) observed values versus individual predicted values; c) population predictions versus population residual 
values (i.e. difference between observed and predicted values); d) population predictions versus individual residual 
values; e) population predictions versus population weighted residual values 
The data of the 5 patients having participated in the whole-day study have been useful to 
validate the model by visual examination of the curves fitted to the individual data of these 
patients (see Figure 3.5 for the graphs obtained with the final model). 
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Figure 3.5. Diagnostic plots of the 5 patients participating in the whole-day PK study (continuous lines: population 
average prediction; dashed lines: individual maximum likelihood curve fit) 
The final population estimates of the demographic model were CL 14.3 l/h, and oral Vd 347 l. 
The derived elimination half-life was 17 h, while the absorption half-life was 1.1 h. The 
interindividual variability in CL and Vd (CV = 36% and 63%) remained higher than the residual 
intraindividual variability (CV = 31%). CL increased by 99% on body weight doubling, decreased 
in female compared to male patients by 6%, decreased by 16% on age doubling, and decreased by 
8% in GIST patients compared to CML patients. The building steps of this demographic model 
can be found in Appendix 3.6, and the PK parameter values obtained are given in Table 3.2. The 
observed plasma concentrations of imatinib are presented in Figure 3.6, along with the 
population average and 90%-prediction interval (calculated with Excel® by using the Bateman 
model with log-normal error propagation3 and plotted with Graphpad Prism®). 
                                                
3 Concept developed by Dr Thierry Buclin. 
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Table 3.2. Population pharmacokinetic parameters of imatinib according to the two main models developed (FOCE 
INTERACTION method) 
Population mean Interindividual variability1 Model Parameter 
Estimate 2SE Estimate 2SE 
CL  (l/h) 14.3 7.1% 36% 28.6%3 
Vd  (l) 347 17.9% 63% 39.6%3 
ka  (h-1) 0.61 30.0% -  
Demographic 
σ  (CV %)4 31 % 20.3%3 -  
CLu (l/h) 1310 13.1% 17% 40.7%3 
Vd  (l) 301 7.8% 66% 46.5%3 
ka  (h-1) 0.61 18.9% -  
Kd  (mg/l) 0.090 14.3% -  
AGP 
σ  (CV %)4 23% 20.3%3 -  
             1 Estimates of variability expressed as coefficient of variation (CV%) 
             2 SE, standard error of the estimates, expressed as CV% 
             3 SE, standard error of the variance components, taken as SEestimate / estimate, expressed as a percentage 
             4 Residual intraindividual variability of the plasma concentration, expressed as CV% 
 
 
Figure 3.6. Imatinib plasma concentration observed in patients receiving imatinib, along with the average 
population prediction (solid line) and the 90% prediction interval (dashed lines). The graphs represent a once (right-
hand part) and a twice (left-hand part) daily regimen, based on the demographic covariates model 
3.3.1.2 Biological covariates analysis 
The plots from Figure 3.7 (left panel) clearly suggest a hyperbolic dependency of imatinib oral 
CL and Vd on plasma AGP levels. The use of a linear model to characterize the relationship 
between CL and AGP (equation (6)) improved significantly the fit (ΔOF = -170.5). Only a 
slightly better description of the data was detected when using a power function (equation (7); 
ΔOF = -5.6). The use of an Emax model (equation (8)) allowed an important improvement of the 
fit (ΔOF = -267.2), and the constant free fraction approach of equation (9) an even better fit 
(ΔOF = -271.4). Finally, the mechanistic approach (equations (10) and (11)) provided the best 
improvement of the fit (ΔOF = -284.1), and the plot of CLu versus AGPtot showed an absence of a 
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relationship between these two variables (see Figure 3.7, right panel). As the apparent volume of 
distribution calculated with this model still showed some correlation with AGPtot, we tried to 
model the influence of AGP plasma levels on Vd (using equations (6), (7), (8) and (12)). The 
most significant improvement was obtained using a linear relationship (equation (6); ΔOF = 
-11.7). The Emax-like relationship brought no significant improvement of the fit (equation (8); 
ΔOF = -2.2). Finally, the mechanistic approach (equation (12)) was not superior to the model not 
taking into account AGP (ΔOF = -0.0). This was probably due to the lack of available data with 
very low AGP plasma levels that could have accounted for a residual hyperbolic relationship 
between AGPtot and Vd. As this mechanistic model could not be retained, Figure 3.7 (right panel) 
represents the relationship between AGPtot and total volume of distribution (Vd). 
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Figure 3.7. Pharmacokinetic parameters estimates derived from the demographic covariates model (left panel) and 
from the final AGP model (right panel), plotted according to AGP plasma levels 
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Following the inclusion of AGP in the analysis (equations (10) and (11)), the four 
demographic covariates, found significantly correlated with CL in the previous analysis (see 
above), were again added into the AGP model, to affect CLu (rather than on CL) and Vd (linearly 
correlated to AGPtot by equation (5)). While BW still improved the prediction of CLu (ΔOF = -
27.0; change by 91% on body weight doubling), the addition of age and gender did not 
significantly improve the model as compared to BW alone (ΔOF = -4.7). At last, pathology 
diagnosis appeared to have no significant effect on Vd (ΔOF = -0.5), but significantly decreased 
CLu in GIST patients (ΔOF = -6.8; difference of 10.2% between GIST and CML patients), 
confirming the effect already observed with the demographic covariates model. 
Finally, the influence of three other biological covariates were assessed. MDR1 polymorphism 
was tested in the sub-population of 36 patients for whom both MDR1 genotype and AGP 
plasma levels were available (corresponding to 245 samples). The assignment of this genotype as 
a covariate on either CLu or Vd tended to improve the fit (ΔOF = -1.3 and -1.0), albeit not 
significantly. As compared to the MDR1 3435CC genotype, CLu decreased by 10.6% for the TT 
genotype, while Vd decreased by 29.8%. No clear influence of CYP3A4 activity on CLu or Vd 
could be detected (ΔOF = -0.2 and -1.0) in this limited number of observations (154 samples in 
39 patients). CYP3A4 activity tended to increase CLu by only 1.1% when the marker value 
doubled. Creatinine clearance significantly influenced CLu (ΔOF = -5.7; change of CLu by 29.0% 
on creatinine clearance doubling) and Vd (ΔOF = -7.0; change of Vd by 53.2% on creatinine 
clearance doubling), in the corresponding subpopulation (271 samples in 47 patients). Such 
findings were in line with those obtained with the demographic model (data not shown). 
The final parameters of the AGP model are given in Table 3.2, and Figure 3.8 presents the 
modeled free plasma concentrations of imatinib, along with the population average and 
90%-prediction interval. The in vivo dissociation constant (Kd) of 8.97·10
-2 mg/l (i.e. 
1.82·10-4 mmol/l), corresponds to an association constant of 5.5·106 l/mol and leads to a median 
free fraction (fu) of 1.1% (range 0.3-2.3). The AGP model building steps can be found in 
Appendix 3.7. 
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Figure 3.8. Free imatinib concentration calculated in patients receiving imatinib, along with the average population 
prediction (solid line) and the 90% prediction interval (dashed lines). The graphs represent a once (right-hand part) 
and a twice (left-hand part) daily regimen, based on the AGP covariates model 
3.3.2 Intracellular Pharmacokinetics 
Figure 3.9 shows the intracellular imatinib concentration versus time profiles, with the 
corresponding plasma profiles, observed during the whole-day study carried out for the 
5 consenting patients studied intensively. 
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Figure 3.9. Intracellular and plasma pharmacokinetic profile of imatinib in the 5 patients of the whole-day study 
(each shape represents a different patient; with solid lines: plasma levels; broken lines: PBMC levels) 
As these patients were at steady state on a once-daily regimen, the levels at 0 h (i.e. prior to 
dose intake) were plotted at a time corresponding to the duration elapsed between the previous 
drug intake (i.e. the day before) and the 0 h sampling. This extrapolation allows displaying the 
entire pharmacokinetic profile of imatinib over 24 h. However, this approximation was only done 
for the graphical presentation and was not taken into account for the NONMEM analysis (into 
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which the plasma concentrations were incorporated). Except for one subject, the 
intra/extracellular ratio appeared rather constant, and indicated an average 8-fold accumulation 
of imatinib within cells as compared to plasma levels (Figure 3.10). The atypical appearance of 
the intracellular curve in the subject represented by open triangle shapes is most probably due to 
inaccurate cell counting in the sample corresponding to the 24 h-level. 
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Figure 3.10. Evolution of intracellular/plasma concentrations ratio over time in the 5 patients of the whole-day 
study (each shape represents a different patient) 
3.4  Discussion 
This study enabled the development of two main types of imatinib population PK models. 
The use of a demographic covariates model confirms the large interindividual variability 
characterizing imatinib disposition, which can only be partly explained by the considered 
covariates (body weight, gender, age and pathology diagnosis). Together with the residual intra-
patient variability (31%), this translates into an average 5-fold width of the prediction interval 
around the mean PK curve (or 6-fold at Cmax; Figure 3.6). Our estimates of CL and Vd are in 
good agreement with the study values recently published in GIST [4] and CML [2] patients, as 
well as in healthy volunteers after a single oral dose [6]. These results also confirm that pathology 
diagnosis has only a small clinical impact on total and free clearance, in agreement with the 
manufacturer initial assumption of unchanged kinetics according to the treated disease [7]. The 
elimination half-life of 17 h is also in good accordance with previously reported values of 17-19 h 
in CML patients [1,3,30], 12-16 h in GIST patients [4], and 14 h in healthy volunteers [6]. The 
relationship between CL and BW suggests that it could be useful to adapt imatinib dosage to 
patient body weight. Moreover, the important variability observed implies that a given dose of 
imatinib may yield, in selected patients, circulating concentrations departing markedly from those 
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expected based on the average PK profile (established in stringent phase I and II clinical studies). 
This variability represents one argument in favor of individualizing imatinib dose prescription 
based on a therapeutic drug monitoring (TDM) program. Figure 3.6 provides a first typical 
concentration profile usable for Bayesian-type dosage adjustment in patients receiving imatinib. 
Unlike other previously studied covariates shown to have only a modest influence, AGP 
plasma levels proved to have a marked impact on imatinib PK. AGP plasma levels explained 
indeed about one half of the inter-patient variability in total CL. With the model incorporating 
this biological covariates, the estimates of Vd and ka remained similar, but the 90%-prediction 
interval around the mean PK curve was reduced to a 3-fold width (Figure 3.8). We thus report 
here the first model of the formal impact of AGP plasma levels on imatinib total plasma PK. 
This model is derived from mechanistic considerations assuming a saturable protein binding, 
because of the limited amount of circulating carrier. The disappearance of the effects of gender 
and age in this AGP model can probably be explained by the known intercorrelation of age and 
gender with circulating AGP levels [32]. A role of AGP on imatinib disposition has already been 
discussed [5,33], and the marked relationship observed between protein binding and imatinib PK 
profile might raise again the question as to whether high levels of AGP might represent a 
resistance factor [34-36]. However, imatinib being a drug of low hepatic extraction, a change in 
protein binding should not translate into significant variations in free drug concentration, since 
CLu remains constant as assumed in our model. This implies that the free AUC, and thus the 
cellular exposition to the drug, remains unaffected. Furthermore, it is worth noting that one 
might expect AGP levels to fall in line with the response to imatinib treatment, as the disease 
burden is reduced. 
On the other hand, as protein binding affects the total concentration of the drug, it would 
represent an important issue to take into account when monitoring and interpreting total 
concentrations. Our findings indeed indicate that total plasma imatinib levels do not simply 
reflect the free (and thus the target) concentrations of this molecule [33]. Would imatinib be 
accepted as a drug requiring TDM, either the measurement of free concentration or the 
correction of the total concentration by the actual AGP plasma level should be considered for a 
precise interpretation of the results. Although free drug concentration monitoring might be more 
appropriate, the technology to do so is not widely available (we are however considering the 
development of a liquid chromatography-tandem mass spectrometry method). Using AGP 
plasma levels instead and deducing the free fraction of the drug could thus represent a more 
convenient approach. In day-to-day practice, the determination of total AGP plasma level and 
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total imatinib concentration in a patient would enable to calculate a free concentration of 
imatinib using the equation (11) above. This value could then easily be compared to the typical 
free concentration profile given in Figure 3.8 and provide useful information for clinicians 
regarding a suitable dose adjustment to reach an adequate range of concentration. By combining 
Figures 3.6 and 3.8, we have obtained Figure 3.11, which gives a good illustration of the 
difference between the two approaches (total vs free concentrations). This summarizing 
representation was presented in two recent meetings [37,38]. 
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Figure 3.11. Comparison of imatinib plasma concentrations in patients receiving imatinib, along with the average 
population prediction (solid line) and the 90% prediction interval (dashed lines). The upper part represents the 
observed Ctot and the lower part the estimated Cu 
Our model incorporating AGP also provides interesting estimates of the in vivo dissociation 
(respectively association) constant and fu, regarding this protein binding. Our association constant 
of 5.5·106 l/mol determined in vivo is not very different from the value of 4.9·106 l/mol 
previously reported in vitro [24]. This denotes a very high affinity of imatinib for AGP, and this 
could explain the marked effect observed for this carrier, as previously reported for other 
anticancer agents [39]. The median in vivo free fraction (fu) of 1.1% is of the same order of 
magnitude as the value determined in vitro (3.1% at AGP concentration of 1 g/l and imatinib 
concentration of 0.3-0.5 µg/ml [40]). Such findings clarify in part the in vivo impact of protein 
binding on imatinib disposition, as wished by Peng et al in a recently published review [5]. The 
effect of albumin could also have been assessed. However, as the concentration of this protein 
varies much less than the one of AGP, and as imatinib is known to bind preferentially to 
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AGP [24,40]), albumin level has not been considered in our model. A recent population 
pharmacokinetic study did not observe any significant relationship between albumin levels and 
imatinib PK parameters [4]. 
Concerning other biological covariates, MDR1 polymorphism and CYP3A4 function seem to 
have a limited impact on imatinib disposition, even the 3435C>T SNP known to be correlated to 
imatinib AUC [8]. The use of other CYP3A4 markers, such as erythromycin breath test or 
midazolam clearance, may help to define better any relationship between imatinib 
pharmacokinetics and the activity of this enzyme, as recently demonstrated [8]. However, the use 
of such exogenous markers was beyond the scope of our exploratory study. Despite the 
controversial validity of the urinary cortisol ratio test used, it has the advantage to represent a 
non-invasive test [41]. The lack of apparent effect of CYP3A4 inhibitors or inducers is probably 
due to the limited number of patients exposed to such drugs in our population. Most CML and 
GIST patients were actually outpatients without comedications. On the other hand, the observed 
effect of creatinine clearance on imatinib clearance and volume of distribution might suggest 
some influence, either direct or indirect, of renal function on imatinib disposition, despite its 
predominant hepatic clearance [30]. 
In addition, this study provides the first in vivo assessment of imatinib intracellular 
accumulation. The average 8-fold cell/plasma ratio determined in samples taken simultaneously is 
in agreement with the available in vitro data from the literature (approximate 5-fold factor in 
leukemia cell cultures incubated with imatinib and human plasma [3]). This is in line with the 
recent demonstration that imatinib undergoes active transport inside leukemia cells by the solute 
liquid transporter hOCT1 [42], which may have functional and clinical consequences. 
Interestingly, it has been recently reported that hOCT1 expression level varies between 
responders and non-responders CML patients [43]. The clinical relevance of those observations 
certainly deserves further evaluation. The relative stability of the cell/plasma ratio suggests 
though that measuring plasma concentration (either total, AGP-corrected or free, as discussed 
above) probably provides a good surrogate for intracellular exposure. It is noteworthy that 
intracellular concentration of imatinib should likely be better termed “cell-associated amount”, as 
the drug in its cellular environment may be embedded in membrane lipid bilayers, complexed to 
cytoplasmic proteins or sequestrated in specific subcellular fractions. This has been reported for 
instance with anti-HIV drugs [44,45], and only a fraction of the so-called “intracellular amount” 
of the drug is actually available to exert its pharmacological activity. It is also worth noting that 
during the course of the study, pathologists have sent us, at several occasions, some GIST tumors 
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biopsy specimens taken from patients on imatinib. Thus, the setting-up of an analytical method 
allowing the intra-tissular measurement of imatinib is anticipated before its application to the 
analysis of these samples, as well as of those further collected. This would allow comparing the 
intra-tumoral imatinib penetration in responding or non-responding GIST patients. 
In conclusion, the high inter-patient and rather limited intra-patient variability in imatinib PK 
(along with the potential relationship of exposure with treatment efficacy and toxicity suggested 
by some studies and case reports mentioned above) are arguments to further investigate the 
potential usefulness of a TDM program for this drug. Taking into account protein binding may 
represent an advantage over the rough measurement of total plasma concentration, but protein 
binding may not represent by itself a resistance mechanism. The monitoring of imatinib 
exposure, with consequent dosage individualization, might play an appreciable role in limiting the 
incidence of side effects and delaying the emergence of tumor resistance, which seems to be 
favored by prolonged subtherapeutic drug levels exposure both in vitro [46,47] and in vivo [48]. 
Similar considerations may apply to other signal transduction inhibitors currently under 
development for the treatment of several malignancies. In addition, devoting attention to TDM 
could contribute to optimize the patients’ compliance, considered as an important issue for 
sustained inhibition of target proteins. However, before individualization of imatinib therapy 
based on routine drug concentration monitoring can be recommended, further PK-PD analysis 
in well-controlled trials is required. 
In that perspective, the next chapter will give some insights of a preliminary analysis of the 
PK-PD relationships of imatinib in our patient population. 
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omplementary to the population pharmacokinetic analysis presented in Chapter 3, an 
exploration of pharmacokinetic-pharmacodynamic (PK-PD) relationships was carried out 
and is presented in the following sections. 
As early as 2004, a Phase I trial in CML patients [1] had already shown that an imatinib dose 
of 350 mg or higher was necessary to achieve a median through level of 570 ng/ml (i.e. about 
1 µM) in the studied patients, but was associated, however, with a very high variability (SD = 
± 369 ng/ml). It exceeds the 50% inhibitory concentration (IC50) required to inhibit in vitro 
proliferation of Bcr-Abl leukemic cells (i.e. 0.025 µM and 0.25 µM for inhibition of Bcr-Abl 
substrate phosphorylation and specific tyrosine phosphorylation, respectively [2]). This through 
plasma concentration, and the time during which imatinib plasma levels were above this level, 
appeared to be related to the initial PD effects of imatinib [1]. The sensitivity of Ph+ cell lines 
derived from patients with CML or ALL was subsequently tested. In most of these lines, the IC50 
values were also comprised between 0.1 and 0.5 µM [3]. A target concentration of 1 µM seems 
thus appropriate to maximize the efficacy in CML cells and to limit the toxicity in normal 
mononuclear cells. However, there is still a controversy on whether this concentration does not 
really also affect normal mononuclear cells [4]. Alternately, such a concentration appears to be 
ineffective to obtain fully BCR-ABL-free colonies in vitro [4]. Moreover, no considerations about 
adjustments of concentrations regarding protein binding (in vitro, as well as in vivo) have been 
mentioned in these studies. 
More information on PK-PD relationships between total –and free– plasma levels of imatinib 
and clinical response and toxicity seems thus needed. The present chapter will therefore present a 
first data analysis relating imatinib pharmacokinetics to clinical effects in our patient population. 
Demonstration of a clear PK-PD relationship for a drug is indeed a prerequisite to apply a 
therapeutic drug monitoring (TDM) approach in the management of a treatment. 
4.1 Theoretical introduction 
4.1.1 PK-PD relationships 
Pharmacodynamics has been defined as the study of the biologic effects resulting from the 
interaction between drugs and biological systems [5]. Pharmacodynamics can be considered as  
C 
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“what the drug does to the body”, whereas pharmacokinetics is “what the body does to the 
drug” [6]. Figure 4.1 is an illustration of how pharmacokinetics and pharmacodynamics 
determine the observed pharmacological effect of a drug [5,7]. 
 
Figure 4.1. Pharmacokinetics and pharmacodynamics as determinant of the dose-response relationship 
This Figure also shows that investigating only the pharmacokinetics of a drug, without 
assessing the pharmacological effects (efficacy and toxicity; associated with the biologic 
concentration) has limited clinical relevance. Since the late 1970s, there has thus been an 
increased emphasis on combining pharmacokinetics (PK) and pharmacodynamics (PD) in the 
clinical evaluation of new drugs. Appropriate analysis linking PK and PD information provides a 
rational basis for evaluating the impact of different dosage regimens on the course of 
pharmacological response [6], and is also essential in the evaluation of a TDM approach. 
4.1.2 Logistic regression analysis 
Since the late 1960s, the logistic regression model has become the standard method for 
regression analysis of dichotomous data in many fields, especially in the health sciences. 
Regression methods have become an integral component of any data analysis describing the 
relationship between a response variable (usually discrete) and one or more explanatory variables. 
What distinguishes a logistic regression model from the linear regression model is that the 
outcome variable in logistic regression is binary or dichotomous (i.e. y = 0 or 1) [8]. Logistic 
regression can also be generalized to situations where the response variable has more than two 
ordered response categories (i.e. y1, …, yi) by considering these categories as resulting from 
thresholding an unobserved continuous variable u at a number of cut-points [9]. 
In PK-PD relationships, the response variable (efficacy or toxicity) typically belongs to the 
latter example. This is why logistic regression is often chosen to analyze the relationship between 
PK and PD variables. 
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4.2 Materials and methods 
As previously mentioned in § 3.2.1, a comprehensive set of clinical data has been collected for 
all patients who participated in the clinical pharmacokinetic study. In addition to accurate dosing 
and sampling time information, the following data were also recorded: body weight, gender, age, 
height, creatininemia (CRT, in µmol/l), presence of liver or cardiac impairment, and all 
concomitant medication intake (Table 3.1). Moreover, the current clinical response was 
determined using a 3-point scale for CML/ALL (complete=2, partial=1 and absent=0 
hematological remission), and according to RECIST criteria for GIST [10]. For the efficacy 
analysis, the RECIST criteria were afterwards recoded to match the CML evaluation (i.e. 
complete response=2, partial response or stable disease=1 and progressive disease=0). A 
standardized evaluation of the typical side effects was performed, and the number of side effects 
experienced by patient at each sampling time was summarized in a 4-point scale (0, 1, 2 and 3 or 
more side effects).  
4.2.1 Standard analysis 
Once the NONMEM modeling completed, individual post hoc Bayesian estimates of the PK 
parameters could be derived for all patients, and were used to calculate the individual drug 
exposure, expressed as AUC (area under curve; defined as   
! 
Dose/CL " # , where 
! 
"  is the dosing 
interval). Associations between Dose, AUC or CL and therapeutic response (coded on the 0 to 2 
scale described above), as well as the association with tolerability (count of 0, 1, 2 or 3 and more 
adverse effects), were explored by ordered logistic regression. Beside this per-sample analysis, a 
per-patient analysis was carried out with all different data collapsed in one value for each patient 
(i.e. average Dose, AUC and CL, and median efficacy and side effect scores). This analysis was 
carried out using both total plasma and free AUC and CL, given by the demographic and AGP 
models, respectively. The results were considered statistically significant at p < 0.05, while p ≤ 0.1 
values were regarded as indicative of possible trends. All statistical tests were performed with the 
Stata® software (version 9.1, Stata Co., College Station, USA). 
4.2.2 Analysis incorporating the target mutation profile 
The same above-mentioned approach was used for assessing the influence of the target 
mutation profile in the pharmacodynamics, by incorporating additionally the patient genotypic 
profile, coded on a binary scale (i.e. 1 = presence of mutation known to confer resistance to 
imatinib treatment, and 0 = absence of such mutation). 
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4.2.2.1 CML patients 
The mutation profiles of BCR-ABL in our CML patients have been determined by InPheno 
(Basel, Switzerland), a collaborating spin-off laboratory of the University of Basel, which analyzed 
our frozen cell pellets samples. 
The RNA from the samples was extracted with a phenol-containing reagent (TRI Reagent®, 
Sigma-Aldrich, Buchs, Switzerland). The biological sample was homogenized in the reagent and 
the simultaneous isolation of RNA, DNA and proteins was carried out in a single step by a 
liquid-phase separation. However, it was not anticipated at the initiation of our study to analyze 
the RNA from our patients, and the blood cellular pellet samples collected during the clinical 
study were frozen without cryoprotective agent (e.g. DMSO). This prevented thus InPheno to 
amplify the RNA corresponding to the BCR-ABL gene required for the subsequent cloning of 
the cDNA of this gene. It was thus decided to rather amplify only two exons of this gene directly 
from the DNA fraction. The exons chosen were exon 4 and exon 6 of the ABL moiety [11], 
containing most of the known mutations and the most frequent mutations (namely E225K/V for 
exon 4, and T315I and M351T for exon 6; Figure 4.2). Various reagents were mixed in the 
following order to prepare the PCR mix: 5.0 µl incubation buffer x 10, 1.0 µl nucleotides 10 mM 
(dNTPs), 2.0 µl primers (F and R for exon 4 and 6, respectively), 0.5 µl Hot Star Taq DNA 
polymerase from Qiagen (Basel, Switzerland), and water to 50 µl (all quantities for one sample). 
The mix was vortexed and aliquots were distributed in PCR tubes. The primers sequences were 
as follows: forward (F4) 5'-CTCTGTCCTGTGTGGAGAGCT-3' and reverse (R4) 5'-CATCG 
CCTAATGCCAGCAGACG-3'; and forward (F6) 5'-GAGCACAGTCTCAGGATGCAGG-3' 
and reverse (R6) 5'-CCAAGTGTTGCCAGCACTGAG-3'. PCR amplification was carried out 
with the program described in Table 4.1, using a PCR Sprint cycler (Catalys, Wallisellen, 
Switzerland). 
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58441 gatcttctaa acactctgtc ctgtgtggag agctccttat gtgagatttt gctgtgtagt 
58501 gaattaaggc tcagccaaac tggctcacgt gagctctttg agcttgcctg tctctgtggg 
58561 ctgaaggctg ttccctgttt ccttcagctc tacgtctcct ccgagagccg cttcaacacc 
58621 ctggccgagt tggttcatca tcattcaacg gtggccgacg ggctcatcac cacgctccat 
58681 tatccagccc caaagcgcaa caagcccact gtctatggtg tgtcccccaa ctacgacaag 
58741 tgggagatgg aacgcacgga catcaccatg aagcacaagc tgggcggggg ccagtacggg 
58801 gaggtgtacg agggcgtgtg gaagaaatac agcctgacgg tggccgtgaa gaccttgaag 
 E255K/V 
58861 gtaggctggg actgccgggg gtgcccaggg tacgtggggc aaggcgtctg ctggcattag 
58921 gcgatgcatc tgcctggaag tctacctcct gcctgctgtc cgagggcttc attggcgcca 
 
 
67741 aattgaaaag tttggcccca aaggggaaaa ttctttctgc catcaagttg ctggtcagct 
67801 gtcatggaac ctgtctgcag caatgtggct gtcacaaaac gcagcccagg acgagtatgc 
67861 gctgaagctc cattttgcat taactagtca agtacttacc cactgaaaag cacttcctga 
67921 aataatttca ccttcgtttt tttccttctg caggaggaca ccatggaggt ggaagagttc 
 E279K 
67981 ttgaaagaag ctgcagtcat gaaagagatc aaacacccta acctggtgca gctccttggt 
 V289I 
68041 gagtaagccc ggggctctga agagagggtc tcgcgccgca cccccagggt gacacaggcg 
68101 ctggggaaga cgcacgggcg gctcactgca caaaacctcg ttggaatatt tgtgctctgc 
68161 cgacgttcag ccgcgggtaa aatgaggcct gtatgggatg ggtgtgtgcg tgtgtgcaca 
68221 tatgcacatg tatgtatgag agggagaatg tgattatttt aagtggatac ctaaaagcag 
 
 
68461 ctgcgtaaat tcaagttcac tggcttgaga agaagaaaag agcctggcca tgtccctccc 
68521 acacgagcac agtctcagga tgcaggtgct tgggaccatg ttggaagttg ggcccaggac 
68581 tgaggagcag agtcagaatc cttcagaagg ctttttcttt agacagttgt ttgttcagtt 
68641 gggagcggag ccacgtgttg aagtcctcgt tgtcttgttg gcaggggtct gcacccggga 
68701 gcccccgttc tatatcatca ctgagttcat gacctacggg aacctcctgg actacctgag 
 T315I 
68761 ggagtgcaac cggcaggagg tgaacgccgt ggtgctgctg tacatggcca ctcagatctc 
68821 gtcagccatg gagtacctgg agaagaaaaa cttcatccac aggtaggggc ctggccaggc 
 M351T 
68881 agcctgcgcc atggagtcac agggcgtgga gccgggcagc cttttacaaa aagccccagc 
68941 ctaggaggtc tcagggcgca gcttctaacc tcagtgctgg caacacattg gaccttggaa 
69001 caaaggcaaa cactaggctc ctggcaaagc cagctttggg catgcatcca gggctaaatt 
69061 cagccaggcc tagactctgg accagtggag cagctaatcc ccggagtaag gaatatttca 
 
Figure 4.2. Regions chosen to design primers to amplify Abl genomic DNA (exon 4 = green, exon 5 = yellow, exon 
6 = green; courtesy of Roten T, InPheno, Basel) 
Table 4.1. PCR Sprint cycler program 
Phases Cycles # T [°C] Duration Purpose 
1 1 95 15 min Activation step 
95 30 s Denaturation 
55 30 s Hybridation 2 30 
72 1 min 10 s Elongation 
3 1 72 10 min Final extension 
 
 Following this amplification, the DNA amplicons were sequenced with a 3730 DNA 
Analyzer (Applied Biosystems, Foster City, USA), a fully automated system for medium-to-high 
throughput genetic analysis. This step was performed using the ABI Big-Dye® Terminator 
chemistry (Applied Biosystems, Foster City, USA). The patient sequences were finally compared 
to the respective typical exon sequence, using the dot plots method [12] of CLC Combined 
Workbench (version 1.0, CLC bio A/S, Aarhus, Denmark). 
It was planned that the patients presenting any mutation on one of the two exons would be 
attributed the mutation code 0 and those with wild-type ABL would be attributed the mutation 
code 1 (see above and § 1.4.1). 
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4.2.2.2 GIST patients 
As some of the GIST patients (20/38) followed in Lausanne were selected in a tertiary 
reference center as part of the multicentric EORTC Soft Tissue and Bone Sarcoma trial, their 
tumor genetic profiles were available. Genomic DNA was extracted from sections of paraffin-
embedded tumor blocks. Exons 9, 11, 13 and 17 of the KIT gene were amplified by PCR, and the 
amplicons were analyzed for mutations by a combination of DHPLC prescreening (WAVE 
DHPLC system, Transgenomic, UK) and bidirectional sequencing [13]. Specimens that had no 
detectable KIT mutation (KIT wild-type) were further tested for PDGFRA exons 12 and 18 
mutations. 
The patients presenting mutation on exon 11 were attributed the mutation code 1 and those 
presenting mutation on exon 9 or those that were wild-type were attributed the mutation code 0 
(see above and § 1.4.1). 
4.3 Results 
4.3.1 Standard analysis 
Using Bayesian PK estimates from the demographic covariates model, a pharmacodynamic 
exploration revealed an inverse relationship between Dose (as well as AUC) and therapeutic 
response (p < 0.005 in per-sample analysis, non-significant in per-patient analysis), with disease 
progression patients receiving higher doses than good responders. Similarly, a better response 
was observed with increasing CL (p < 0.005 in per-sample analysis, non-significant in per-patient 
analysis). It is noteworthy that Dose and AUC were highly correlated (p < 0.005) and the type of 
pathology alone was in fact sufficient to predict the response (better scores in CML patient, 
p < 0.005). A similar analysis carried out on side effects’ scores showed that Dose and AUC were 
positively correlated with the amount of side effects (p < 0.005 in per-sample analysis, non-
significant in per-patient analysis), but this was not the case for CL. 
Using the exposure estimates derived from the AGP model (i.e. free drug exposure) made the 
relationship between free AUC and response become positive, albeit non-significant (in per-
sample and per-patient analyses). Concerning the tolerability to the drug, free AUC remained 
positively correlated with the amount of side effects (p < 0.005 in per-sample, and p < 0.05 per-
patient analyses; Stata® generated Figure 4.3, left-hand part). In the same analysis, free clearance 
(CLu) showed some association with tolerability scores (p < 0.05 in per-sample and per-patient 
analysis; Stata® generated Figure 4.3, right-hand part). Interestingly, a multivariate regression 
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including Dose and CLu still showed significant effects for both parameters (p < 0.005 in per-
sample analysis and p < 0.05 in per-patient analysis). 
 
Figure 4.3. Box plot of the pharmacokinetic parameters according to side effects (0 = no side effects, 1 = 1 side 
effect, 2 = 2 side effects, and 3 = 3 or more side effects) 
4.3.2 Analysis including the target mutation profile 
First of all, Table 4.2 presents the results of all the genotypic analysis performed in our patient 
population and Figure 4.4 shows an example of a DNA sequence determined at InPheno. 
Table 4.2. Genotypic profile of our patient population (1 = mutation profile known to confer lower response to 
imatinib; 0 = no deleterious mutations; - = no mutation assessment) 
Patients Profile n  (%) 
CML/ALL patients 
  No. 38, 41, 105, 106 
  No. 33-35, 37, 39-40, 42, 44, 46-47, 51-52, 101-104, 107 
  None 
 
- 
0 
1 
 
4 (7) 
17 (29) 
0 (0) 
GIST patients 
  No. 6, 8-10, 12, 14, 16, 18-19, 24, 29, 31, 36, 43, 45, 48-50 
  No. 2-5, 7, 11, 15, 17, 21, 25-28 
  No. 1, 13, 20, 22-23, 30, 32 
 
- 
0 
1 
 
18 (31) 
13 (22) 
7 (12) 
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Figure 4.4. Example of the chromatogram file, showing the DNA sequence from exon 2 of patient no. 33 (courtesy 
of Roten T, InPheno, Basel) 
No mutations of the BCR-ABL gene (on the two exons analyzed) could be detected (i.e. all 
patients received the code = 0). By contrast, various mutations were detected for the KIT gene: 
deletions, point mutations or mixed mutations: on exon 11 (code = 0), or alternately insertion in 
exon 9 (AY 502-503 duplication) or wild-type profile (code = 1). 
Initially, this second pharmacodynamic exploration was conducted with the whole population 
(CML and GIST patients pooled). As in the standard exploration (§ 4.3.1), it revealed an inverse 
relationship between Dose, AUC and CL and therapeutic response (p < 0.05 in per-sample 
analysis, non-significant in per-patient analysis). It is important to note that this logistic regression 
analysis showed also that the response was significantly correlated with the mutation profile 
(p < 0.05 in per-sample and per-patient analysis), with patients presenting a resistance-related 
profile (i.e. KIT exon 9 mutation or KIT wild-type) being poor responders. The side effects 
analysis showed that Dose and AUC were still positively correlated with the amount of side 
effects when incorporating the mutation profile in the analysis (p < 0.05 in per-sample analysis, 
non-significant in per-patient analysis). 
As in the standard PK-PD analysis, using the exposure estimates derived from the AGP 
model (i.e. free drug exposure) made the relationship between free AUC and response become 
positive. It was even significant when taking into account the pathology diagnosis (p < 0.005 in 
per-sample analysis, non-significant in per-patient analysis). The same was observed with CLu, 
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with a negative relationship when incorporating the pathology diagnosis in the statistical model 
(p < 0.05 in per-sample analysis, non-significant in per-patient analysis), indicating that the greater 
is the free clearance value, the poorer is the response. Concerning the tolerability of the drug, free 
AUC remained positively correlated with the amount of side effects and CLu showed still some 
association with tolerability scores (p < 0.005 in per-sample, and p < 0.05 per-patient analyses). 
Finally, as it appeared that the mutation profile was highly correlated with the pathology 
diagnosis (individuals with resistant genetic profile were indeed only encountered in the GIST 
subpopulation), it was decided to also perform this last analysis focusing only on the GIST 
subpopulation. In this last per-patient analysis including the mutation profile, free AUC tended to 
be correlated with good response (p < 0.1) and CLu proved to be significantly inversely correlated 
to response (p < 0.05). Of importance, CLu appeared even as a better predictor of the response 
than the mutation profile (characterized only by a trend to influence response in this 
subpopulation; p < 0.1). These results are depicted in Figure 4.5, which presents the median free 
AUC and CLu (with the associated box plot; generated by Stata
®) corresponding to the 3 types of 
response (per-sample representation). 
 
Figure 4.5. Box plot of the pharmacokinetic parameters according to response for the two main genotypic profiles 
of GIST patients (0 = progressive disease (n = 15 for exon 9/wt, 11 for exon 11), 1 = partial response/stable disease 
(n = 27 for exon 9/wt, 67 for exon 11), and 2 = complete response (n = 8 for exon 9/wt, 0 for exon 11)) 
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4.4 Discussion 
The preliminary standard PK-PD analysis shows that the occurrence of side effects is more 
frequent at higher imatinib exposure, indicating that monitoring imatinib plasma levels may 
therefore identify patients with excessive levels at risk of developing toxicity. Several cases 
(including a patient case at CHUV, described in detail in § 5.1) have indeed been reported in the 
literature where imatinib treatment had to be discontinued because of the occurrence of serious 
adverse events [14-16]. However, in only one case were plasma drug measurement and dose 
adjustment considered [16]. Conversely, several studies suggest that the administration of higher 
doses than the typical 400 mg daily regimen could improve the response in some patient subsets. 
A better response was indeed observed in accelerated and blast phases of CML with 600 mg 
daily [17], and a 800 mg daily regimen allowed a longer progression-free survival in GIST 
patients [18]. The inverse relationship we have observed between Dose (as well as AUC) and 
therapeutic response could thus be considered paradoxical. However, since this first study was 
only observational, we were in presence of good-responders receiving low doses of drug and bad-
responders receiving high doses, without advantage. It must indeed be emphasized that the 
PK/PD relationships for a targeted agent such as imatinib may be obscured, or even 
confounded, by the somatic innate or acquired genotypic heterogeneity –with functional 
consequences, in term of susceptibility– of the intracellular pharmacological targets Bcr-Abl and 
c-Kit. In such a context, this issue has been addressed in the present study by also incorporating 
the imatinib target genotypes of CML and GIST patients into the statistical analysis. 
The integration of the target mutation profile has therefore allowed refining our exploration 
of the PK-PD relationships in our population. However, among the CML patients for whom the 
principal BCR-ABL mutations were examined, none of them seemed to present any mutated 
BCR-ABL gene. A number of hypotheses could explain this observation. First, among the 
20 CML patients, most of them (17 patients) were in chronic phase. It has been recently 
suggested –and demonstrated– that detection of mutant clones is not possible during the chronic 
phase of CML, but only during accelerated or blast phases [19]. Secondly, only three patients 
from our CML population were thus in accelerated or blast phase (and characterized by an 
intermediate or absent response). As it has been shown that about only 30% of such patients may 
present mutations [19,20], the very small number of patients included in the present study 
explains the low probability of detecting any mutations in our CML population. Moreover, the 
genotypic analysis of Bcr-Abl is generally done on RNA material, which was not possible in our  
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case (see above, in § 4.2.2.1). In fact, some patients of a recent observational study had reportedly 
to be excluded because of the poor quality of isolated RNA samples [21]. 
Alternately, the inclusion of the genetic profile of KIT into the statistical PK-PD analysis of 
the GIST subpopulation has allowed uncovering interesting relationships between free AUC and 
free CL, and clinical response. For example, Figure 4.5 suggests that patients with tumors 
harboring a protein c-Kit with a sensitive profile (resulting from exon 11 mutations of KIT) are 
exposed to concentrations that are already at the top of the concentration-response curve, 
whereas patients with a resistant profile (exon 9 mutations or wild-type KIT) are probably lying in 
the steep part of the curve, where a concentration-response relationship can be observed, and 
could probably clinically benefit from an adjustment in imatinib exposure. This study thus 
provides additional evidences of the existence of a clinical PK-PD relationship for imatinib and 
confirms the preliminary results of Peng et al, observed in a CML population [1]. Moreover, our 
results clearly show that the total plasma concentration of imatinib is a poor marker of its clinical 
effect. It is thus rather the free exposition (or free levels), either measured or calculated, that 
should ideally be taken into account for an eventual TDM program of imatinib. 
Finally, it is worth noting that circulating imatinib does not account for all active drug, since 
approximately 10% of the dose is indeed metabolized by CYP3A4 into a N-desmethylated 
derivative (CGP74588) characterized by a similar in vitro potency [22]. As the half-life of 
elimination of this metabolite is about twice that of imatinib, it’s accumulation after repeated 
dose intake is greater than the one of the parent compound (accumulation factor of about 2 to 3 
versus 1.5 to 2 for imatinib, for once and twice daily intake, respectively; see also § 1.3.4). 
Practically, it appears that it represents less than 20% of the total imatinib in plasma at steady 
state [23]. Such an amount of active metabolite should not impact much, neither on PK, nor on 
PK-PD analysis. There would be however some interest to measure this compound in future 
studies. 
In conclusion, our study was just exploratory and the results are based only on a very small 
population. The p-value obtained in our analysis should indeed be considered with caution, 
because of the limited number of observation. These results should however stimulate further 
stringent clinical studies in a larger patient population, aimed at confirming the relationships 
observed between imatinib pharmacokinetics –more precisely, imatinib free level–, and its 
efficacy and toxicity. By the way, a French group has just recently published a description of a 
LC-MS/MS method used for clinical monitoring of imatinib, to evaluate adherence to therapy, 
drug-drug interaction and PK-PD relationships [24]. In addition to the important variability 
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demonstrated and quantified in Chapter 3, the potential PK-PD relationship of imatinib 
represents another argument to evaluate further the potential benefit of a TDM program for this 
drug by a well-controlled clinical trial. 
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Chapter 5   Clinical applications 
 
his chapter is devoted to the presentation of two selected case reports of patients taking 
Glivec® and for whom clinicians requested imatinib blood measurement in our laboratory 
for helping them to optimize the treatment. Even though the clinical usefulness of imatinib TDM 
will require formal validation in a carefully controlled prospective randomized trial, these case 
reports provide examples of the potential applications –and clinical usefulness– of the 
monitoring of imatinib plasma levels in day-to-day clinical practice. These two case reports have 
been presented in abstract form at medical congresses [1-3], and one has been published in a 
peer-review international journal [4]. 
5.1 Severe pustular eruption associated with imatinib and 
voriconazole 
5.1.1 Description of the case [1,4] 
A 42-year-old Caucasian man had been followed for CML since 1998 and treated by Glivec® 
400 mg qd since the beginning of 2002, increased to 400 mg bid on July 2002 (because of CML 
evolution into acute myeloid leukemia). In December 2002, an invasive pulmonary apergillosis 
(Aspergillus fumigatus) was diagnosed. A systemic treatment with fluconazole was started, relayed 
with oral voriconazole in January 2003. Twelve weeks after voriconazole initiation, this patient 
developed a confluent, infiltrated, papulopustular cutaneous eruption involving the face, the 
trunk, the arms and the hands, but sparing the folds, associated with high fever (Figure 5.1). The 
patient was followed by the Dermatology service at CHUV. Microbiological examinations were 
negative and the histological examination of a skin biopsy specimen showed a neutrophilic and 
eosinophilic infiltrate within the superficial dermis, without any sign of a Sweet’s syndrome or 
CML specific cutaneous localization. The plasma levels of imatinib were measured using our 
HPLC-UV methods at several occasions between December 2003 and February 2004 (see for 
instance the chromatogram on Figure 5.2). These levels were markedly elevated during the 
simultaneous administration of voriconazole (between 3.5 to 4.1 µg/ml, about 14 h after 
administration), when compared with the predicted levels of about 2 µg/ml extrapolated from a 
previously published pharmacokinetic study (determined at steady state for a 600 mg daily 
dose) [5]. The skin condition improved within three weeks of stopping imatinib and 
T 
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voriconazole, and administration of 30 mg daily oral prednisone. Voriconazole was reintroduced 
one month later without any recurrence of the eruption. 
 
Figure 5.1. Papulopustular nonfollicular eruption tending to colasescence to form plaques with irregular mamillated 
surface, concerning the face (a), the trunk, the arms and the hands (b) (Copyright 2005 S. Karger AG, Basel. All 
rights reserved. Reproduced with permission from Dermatology, 211, Gambillara E et al, Severe pustular eruption 
associated with imatinib and voriconazole in a patient with chronic myeloid leukemia, 363-5) 
 
Figure 5.2. Plasma chromatogram of the CML-patient presented in this case report, obtained 14 h 30 min after 
imatinib intake (400 mg, bid) 
5.1.2 Discussion [1,4] 
Adverse cutaneous reactions induced by imatinib are frequent, and usually observed in 7 to 
21% of patients, with 5% of such reactions being severe or life threatening [6,7]. In a recent 
study, 48 out of 54 (88%) patients with Philadelphia chromosome-positive leukemias treated by 
imatinib experienced at least one cutaneous reaction. Maculopapular rash, edema and pruritus 
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were the most common adverse effects. The rash prevalence rate was significantly higher in 
females, as generally reported with other cutaneous drug reactions [8]. 
In patients treated with imatinib, rashes other than non-specific maculopapular eruption have 
also been observed [9,10]. The case reported here consists of an unusual and severe skin side 
effect following imatinib presenting as a papulopustular eruption. Two similar cases have already 
been described [11], and classified under the denomination of AGEP (acute generalized 
exanthematous pustulosis). However, these two patients, as well as ours, actually suffered 
conditions not exactly corresponding to this dermatosis. Indeed, the patients presented cutaneous 
lesions differing from those of AGEP. This notably because they appeared more than 3 months 
after the beginning of the treatment, and because the papulo-pustular eruptions concerned mainly 
the face and the trunk, and spared the folds. 
The incidence and severity of imatinib adverse cutaneous reactions appear to be dose 
dependent [7,12,13], with mild reaction at low to intermediate doses (200-600 mg daily), and 
severe eruptions at higher doses (600-1000 mg daily) [13]. This pattern suggests that skin 
reactions due to imatinib are related to a pharmacological effect of imatinib rather than to a 
hypersensitivity process. This in turn indirectly supports our observation of severe cutaneous 
toxicity associated with high plasma levels of imatinib in our patient. 
As already mentioned, drugs inhibiting CYP3A4 activity, such as voriconazole and 
fluconazole [14], decrease the metabolism of imatinib, and this should results in increased drug 
plasma levels [15], as seen in our case. The very high levels of plasma imatinib that were 
measured probably reflect pharmacokinetic interactions, mediated by the inhibition of imatinib 
metabolism by voriconazole. The prolonged exposure to high levels of imatinib could thus have 
led to the development of the skin eruption. However, no plasma level values of imatinib before 
the administration of the two antifungal drugs were available for our patient, and this allows us 
only to suggest such a hypothesis. 
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5.2 Dose adjustment of imatinib based on plasma level 
measurement 
5.2.1 Description of the case [2,3] 
A 26-year-old man was diagnosed as having CML in chronic phase at low risk (according to 
Hasford Score). He was taken in charge by the Inselspital in Bern (University hospital) and placed 
on hydroxyurea. After hematological remission, he was treated with interferon-α at 8 MIU/day. 
The interferon-alpha treatment was stopped because of hematological side effects. 
Administration of imatinib was started at 400 mg daily, and after 9 months cytogenetic analysis 
showed Philadelphia (Ph) chromosome positivity in approximately 70% of metaphases, and no 
decrease of BCR-ABL transcripts was noted by quantitative PCR. Because of a body weight of 
110 kg, plasma level measurements of imatinib were performed in our laboratory at PCL, and 
revealed that the plasma level (i.e. 0.4 µg/ml, 25 h 30 min after dose intake) was half of the 
expected values based on the pharmacokinetic data reported at steady state (see previous 
case) [5]. The daily intake of imatinib was therefore increased to 600 mg administered in two 
doses. After 3 and 6 months, repeated cytogenetic analysis showed a major cytogenetic reduction 
(7% of Ph+ metaphases in conventional method and 1% by FISH analysis1), as well as almost a 
3 log reduction of BCR-ABL transcripts. The CML evolution in this patient is illustrated in 
Figure 5.3. 
 
Figure 5.3. Cytogenic course (left; conv = conventional) and quantitative BCR-ABL-transcripts course (right; 
PBGD = reference gene) (courtesy of Heizmann M, with modifications) 
                                                
1 FISH (Fluorescent in situ hybridization) is a cytogenetic technique that can be used to detect and localize specific 
DNA sequences on chromosomes. It uses probes that become fluorescent when binding to parts of the 
chromosome showing a high degree of sequence similarity. 
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5.2.2 Discussion [2,3] 
As stated in Chapter 1, imatinib is metabolized by CYP3A4 known to present a high 
interindividual variability in expression and activity, and is likely to be inhibited or induced by 
numerous dietary and environmental compounds. This suggests that exposure to imatinib is 
highly variable and may be even suboptimal for some individuals. The case described here 
presents a dose adjustment of imatinib based on plasma level measurements in a patient with 
CML, which resulted in an improved cytogenetic response. However, the exact reason for the 
low initial imatinib level is not known. Neither CYP3A4 phenotyping nor CYP3A4 genotyping, 
nor blood AGP levels measurement (also found to influence imatinib clearance; see Chapter 3) 
have been performed in this patient. 
5.3 General discussion 
The two described case reports are typical clinical examples regularly encountered during the 
course of the present study. Very often indeed, practitioners from all Switzerland, facing either an 
absence of therapeutic response or the appearance of serious side effects in their patients on 
imatinib, referred to us for imatinib blood measurements, to verify whether the patients’ 
exposure to the drug was adequate. In fact, since the beginning of the present study (in Summer 
2002) until March 1, 2006, as much as 90 requests for imatinib plasma levels measurements –for 
a total of 38 patients from all over Switzerland– have been addressed to our laboratory, most of 
whom outside the study protocol. 
Despite the fact that no significant influences of CYP3A4 inhibitors on imatinib 
pharmacokinetics could be statistically demonstrated in our patients’ population (see § 3.3), the 
first presented case certainly suggests that the addition of strong CYP3A4 inhibitors such as 
voriconazole to the imatinib treatment has to be considered with caution. Cutaneous reaction to 
imatinib may indeed not be dose-related, but concentration-related instead. As far as the second 
case is concerned, it has allowed demonstrating that the measurement of imatinib plasma level 
can be useful to ascertain plasma exposure and for the adjustment of imatinib dosage, and has 
resulted in an improved cytogenetic response. Figure 5.4 graphically represents the imatinib 
concentrations of the two cases (for a normalized 400 mg daily intake) compared to the whole 
patient population with the prediction intervals defined in Chapter 3 (see Figure 3.6). This Figure 
clearly underscores first, how variable can be imatinib plasma concentration in a patient 
population for a same Glivec® dose, and secondly, that the imatinib plasma levels found in the 
above-mentioned case reports no. 1 and 2, lie in the upper, and lower range of the predicted 
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concentration interval, respectively. However, it is noteworthy to emphasize that no therapeutic 
interval for imatinib has formally been established yet. This could be determined only after the 
initiation of comprehensive PK-PD studies, also taking into account the genetic heterogeneity of 
imatinib pharmacological targets in patients (see Chapter 4 for further details). 
 
Figure 5.4. Imatinib plasma concentrations observed in patients receiving imatinib, along with the average 
population prediction (solid line) and 90% prediction interval (dashed lines). The values are adjusted to 400 mg daily: 
200 mg bid and 400 mg QD on the left and right part, respectively. The patient concentrations of case no. 1 and 2 
are shown on the left and right part, respectively 
5.4 A first step toward TDM of imatinib in clinical practice 
As exemplified by the two above-mentioned cases, information on imatinib plasma exposure 
can be important to help clinicians in the optimal follow-up of their patients. More generally, 
routine monitoring of imatinib plasma levels has been found useful to identify individuals with 
imatinib concentration exposure grossly departing form population average, in the presence of 
toxicity or in the absence of clinical response. 
Since a growing number of physicians throughout Switzerland were asking for information on 
imatinib blood concentrations in their patients (see above), a user friendly graphical plot of the 
drug concentration over time after drug intake has been developed. Based on the NONMEM 
analysis performed in our study population (see Chapter 3), we have being able to establish 
percentile curves for the various imatinib regimens (using a simulation with the Bateman model; 
see § 3.3.1.1 for further details). Figure 5.5 shows one example of such a percentile curve, which 
is now routinely provided to practitioners along with the TDM interpretation report. The full 
report of this example can be found in Appendix 5.1. The imatinib plasma levels measurements 
shown in this Figure are those from one patient whose imatinib plasma exposure was periodically 
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ascertained during his treatment between 2002 and 2005. This was done in accordance to the 
physician’s request and patient’s own scientific interest. Noteworthy, these data illustrate the low 
intraindividual variability in imatinib exposure in this responding patient, mostly comprised in the 
upper percentiles range. 
 
Figure 5.5. Percentile curves of imatinib for the imatinib 600 mg daily regimen, along with concentrations measured 
routinely in one patient during the period 2002-2005 
However, it is important to note that such concentration interpretation does not represent a 
formal TDM approach yet. Our interpretations are only taking into account the pharmacokinetic 
variability of the drug, but are not formally based on any therapeutic interval. Additional 
pharmacokinetic-pharmacodynamic studies on imatinib are thus needed before systematically 
recommending dose adjustments based on plasma levels, in patients lacking adequate clinical 
responses. As already stated, gathering further information to better predict the potential 
effectiveness of a TDM strategy for imatinib is thus necessary. 
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Chapter 6   Intracellular disposition 
 
n connection with the main clinical research project, we were also interested in studying 
imatinib disposition at the cellular level using in vitro cell cultures, and in determining the 
influence of MDR1 gene expression and specific gene silencing (using a siRNA approach), on the 
differential cellular handling of imatinib. Efflux as well as uptake drug transporters are indeed 
increasingly recognized as key determinants of drug disposition and clinical response (see also 
§ 1.4.3) [1]. 
Complementary to the studies on the effect of the efflux transporter P-gp expression and 
silencing, this chapter will also present some preliminary experimental data on the presumed 
influence of the uptake transporter hOCT1 (described in § 1.4.3) on imatinib intracellular 
disposition. 
Even tough these in vitro experiments would first appear only partially related to our main 
research objective aiming at evaluating the potential benefit of a TDM program for imatinib, such 
studies are however essential to gain a more in depth appreciation of the tissular and cellular 
disposition of imatinib (or of any other new anticancer drugs) in the body. Since several drug 
efflux/influx transporters involved in imatinib cellular disposition are the subject of various 
polymorphisms, with consequences in terms of expression and function [1], gaining additional 
knowledge in this field could help us designing randomized TDM trials that also take adequately 
into account the patients’ genetic variability associated to these transporters. 
6.1 Functional consequence of MDR1  expression on imatinib 
intracellular concentrations 
In an article published in 2003, Mahon et al [2] have demonstrated that MDR1 gene 
overexpression can confer resistance to imatinib in leukemia cell lines. Beside MDR1 
overexpression, several other cellular mechanisms of resistance to imatinib have also been 
identified (see § 1.4 for further details) [3-5]. As already mentioned, the generally accepted 
functional consequence of MDR1 gene expression is the reduction of intracellular drug 
accumulation through P-gp-mediated efflux, thus hampering the achievement of effective drug 
levels at the target site. Mahon et al [2], have shown that MDR1 gene overexpression results in 
resistance to imatinib, however without assessing the functional consequence of MDR1 
expression on imatinib intracellular availability. As a complement to their work, we have 
I 
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performed in vitro cellular experiments that provide a first direct evidence of the marked impact 
of P-gp expression on imatinib intracellular concentrations. 
The cell culture and incubation experiments described below were performed in the 
Laboratory of Clinical Chemistry of our hospital with the technical help of Dr Hugues Henry and 
Sara Colombo (PhD student). 
6.1.1 Materials and methods 
6.1.1.1 Imatinib incubation with cell culture 
Homologous MDR1+ and MDR1- LLC-PK1 cells (i.e. transfected porcine kidney epithelial 
cells, a recognized model for assessing drug efflux transporter activity [6]) were obtained from 
Schinkel [7]. Cells were incubated for 18 h at 37°C, in 2 ml growth medium containing 10% fetal 
calf serum in the presence of imatinib at the clinically relevant concentrations of 0.5, 1.5 and 
3.0 µg/ml. All concentrations were tested in duplicates. Following incubation, a 300-µl aliquot 
was removed to determine the extracellular concentration. The excess supernatant was discarded, 
and the resulting adherent cell cultures were washed three times with an ice-cold phosphate 
buffered solution (PBS). Each cell culture was then extracted with 1 ml MeOH/H2O 60 : 40 on a 
planar shaker (Unimax 2010, Heidolph, Kelheim, Germany) by gentle agitation at 100 rpm for 3 
h. The methanolic solutions were collected in Eppendorf vials and centrifuged at 20’000 g 
(14’000 rpm) for 10 min at RT (Benchtop Universal 16R, Hettich, Bäch, Switzerland). The 
supernatant was finally evaporated to dryness with a nitrogen flux and the residues were 
reconstituted in 200 µl MeOH/H2O 60 : 40 prior to analysis using a slight adaptation of the 
HPLC-UV method described in § 2.1. 
6.1.1.2 Imatinib measurement by LC-UV in extra- and intracellular extracts 
Extracellular (i.e. cell culture media) and intracellular (i.e. methanolic) extracts were thus 
measured using the LC-UV method previously developed. However, for this in vitro study, 
calibrations curves were prepared either in the culture medium diluted 2 : 3 with MeOH/H2O 
60 : 40 for extracellular measurement, or directly in a MeOH/H2O 60 : 40 mixture for 
intracellular measurement of imatinib. The 200-µl extracts obtained during the in vitro study were 
diluted 2 : 3 with MeOH/H2O 60 : 40, followed by a 10-min centrifugation (Benchtop Universal 
16R, Hettich, Bäch, Switzerland), prior to injection. The established calibration curves were 
characterized by an excellent regression coefficient (r2 = 0.997). 
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6.1.1.3 Total protein measurement 
The concentrations determined in the 24 extracts (12 intra- and 12 extracellular) were 
normalized on total proteins measurements, used as surrogates of cell counts. This determination 
of protein was carried out by solubilizing the adherent cell cultures with a 400-µl solution 
containing 8 M urea and 1% sodium dodecylsulfate. These solutions were placed in the 
Eppendorf tubes previously used to collect the methanolic extracts, so that the totality of 
proteins (i.e. including those possibly carried during the methanolic extraction) could be 
retrieved. The solutions were then assayed for total protein using the bicinchonic acid (BCA) 
assay [8]. 
This assay was performed using the “BCA protein assay” reagent kit (Pierce Chemical, 
Rockford, USA). It is a mere spectrophotometric dosage (with calibration) after the reaction of 
the proteins with the biuret reagent in a 96-well plate. The classical biuret reaction consists in the 
formation of a colored complex formed between the peptide bonds of proteins and the copper 
cations Cu2+ of the reagent [9]. 
6.1.1.4 Transporters inhibition by rotenone 
The same experiment was repeated by adding rotenone1 to the culture media, aiming at 
inhibiting the ATP-dependent activity of P-gp in cells (following Jones et al procedure [10]). This 
experiment aimed at examining whether the intracellular accumulation obtained with MDR1- 
cells would be similar to MDR1+ cells inhibited by rotenone. 
6.1.2 Results 
6.1.2.1 Initial experiment 
The results given in Table 6.1 highlight the striking differences (up to 24-fold) in intracellular 
concentration of imatinib as a function of the cell ability to express P-gp. These results have been 
published in 2003 in Blood [11]. Figure 6.1 shows the comparison of intracellular accumulations of 
imatinib, normalized according to proteins content, used as a surrogate for cell counts. 
 
 
 
                                                
1 Rotenone is a naturally occurring compound isolated from the roots of several tropical plants (e.g. Derris elliptica 
Benth.), used for more than 2’000 years in equatorial countries as fish poisons. It interferes with NADH 
dehydrogenase, preventing NADH to act as a proton and electron donor in the aerobic cell respiratory chain. 
Rotenone thus inhibits any active (i.e. requiring ATP energy) transport in the cell. 
120 Chapter 6 
Intracellular disposition 
 
Table 6.1. Concentration of imatinib in MDR1+ and MDR1- cells at various imatinib incubation levels 
Genotype 
Incubation 
medium  
[ng/ml] 
Intracell.  
[ng/µg prot] 
Extracell.  
[ng/µg prot] 
Intra/extracell. 
ratio 
 500 0.07 ± 0.006 2.86 ± 0.481 0.023 
MDR1+ 1500 0.10 ± 0.002 5.70 ± 0.687 0.017 
 3000 0.26 ± 0.031 12.70 ± 0.322 0.020 
 500 0.24 ± 0.004 3.04 ± 0.143 0.079 
MDR1- 1500 1.15 ± 0.190 5.92 ± 0.326 0.195 
 3000 6.14 ± 0.432 11.17 ± 0.384 0.550 
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Figure 6.1. Intracellular accumulation of imatinib at incubation concentrations of 500, 1500 and 3000 ng/ml 
(= µg/l) 
Our experiment provides a direct evidence of the influence of P-gp on imatinib intracellular 
availability. Imatinib is very efficiently expelled from MDR1+ cells at all tested concentrations. 
Intracellular concentrations and transmembrane ratios are significantly affected by genotype 
(p < 0.0001) and applied concentration (p < 0.0001, two-way ANOVA). 
6.1.2.2 Drug transporters inhibition by rotenone 
The results of the transport inhibition with rotenone (Table 6.2 and Figure 6.2) essentially 
reveal almost no difference in imatinib cellular exposure between MDR1- and MDR1+ cells. In 
fact, paradoxically, the value of the intra/extracellular ratio in the presence of rotenone was in 
both cell genotypes very low, about 0.014 (Table 6.2), being essentially the same as that measured 
in MDR1+ cells in the first experiment (i.e. without P-gp inhibition; Table 6.1). 
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Table 6.2. Concentration of imatinib in MDR1+ and MDR1- cells at various imatinib incubation levels in the 
presence of rotenone 
Genotype 
Incubation 
medium  
[ng/ml] 
Intracell.  
[ng/µg prot] 
Extracell.  
[ng/µg prot] 
Intra/extracell. 
ratio 
 500 0.12 ± 0.001 9.32 ± 0.481 0.013 
MDR1+ 1500 0.37 ± 0.065 24.92 ± 0.687 0.015 
 3000 0.90 ± 0.235 78.47 ± 0.322 0.012 
 500 0.25 ± 0.107 17.36 ± 0.143 0.014 
MDR1- 1500 0.44 ± 0.001 29.77 ± 0.326 0.015 
 3000 1.18 ± 0.082 70.13 ± 0.384 0.017 
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Figure 6.2. Intracellular accumulation of imatinib at incubation concentrations of 500, 1500 and 3000 ng/ml 
(= µg/l), in the presence of rotenone 
6.1.3 Discussion and conclusion 
Table 6.1 shows that in MDR1+ cells, the intra/extracellular concentration ratio remains 
constant, indicating that imatinib P-gp-mediated efflux is never saturated at all tested 
concentrations. By contrast, the higher ratio observed at low imatinib level in MDR1- cells 
further increases at higher levels, and this suggests the existence of subsidiary, less efficient and 
saturable transport mechanisms. It is however important to note that, as the volume of Schinkel 
cells was not known in this experiment, it was necessary to normalize on total protein amount. 
Therefore, the absolute value of the intra/extracellular ratio has no physiological relevance 
(contrary to a concentration ratio). Instead, relative, rather than absolute ratio values were of 
interest in this comparative study. 
This experiment formally confirms that imatinib interaction with P-gp [12] has important 
functional consequences, and that imatinib efflux from cancer cells by the drug transporter P-gp 
should be seriously considered among the mechanisms of imatinib resistance. Despite the still 
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debated role of P-gp as a resistance factor to imatinib [13], our results supports the initial 
observations by Mahon et al [2]. 
Moreover, our modulation experiments with rotenone resulted paradoxically in very low 
intracellular concentrations of imatinib in both types of cells. The contrary (i.e. higher cellular 
levels) would have been expected from the sole inhibition of active efflux transport system such as 
P-gp. One explanation for this observation could be the simultaneous inhibition of active uptake 
transporters system implied in imatinib influx inside cells, in addition to the inhibition of efflux 
transporters. This simultaneous inhibition of active efflux and influx transport systems by 
rotenone could thus result in a net intra/extracellular equilibrium due to the sole passive 
diffusion of imatinib through the cell membranes. This is in line with the recent demonstration 
that imatinib undergoes active transport inside leukemia cells by the human cationic transporter 
hOCT1 [14]. 
Overall, our experiments support the hypothesis that the clinical activity of imatinib may thus 
be significantly hampered in P-gp expressing cells, and this seems to be particularly the case of 
CML cells in blast phase [15,16]. Moreover, differences in activity of imatinib uptake transporters 
seem also to have some clinical consequences, as reported in a recent study whereby hOCT1 
expression levels were found significantly higher in responders than in non-responders CML 
patients [17]. In line with the previous discussion in § 3.4, these findings should stimulate further 
research to evaluate the effect of addition of P-gp inhibitors and/or hOCT1 modulators to 
imatinib for the treatment of CML blastic crisis. 
6.2 Resistance reversal by siRNA MDR1  in CML cells is 
caused by an increase of imatinib intracellular disposition 
The cell culture and incubation experiments described in the following paragraphs were 
performed in the Laboratory of Tumor Biology and Angiogenesis of the Medical University of 
Innsbruck (Austria) by Holger Rumpold et al. The intracellular imatinib measurement by LC-
MS/MS was carried out in our laboratory in Lausanne. 
6.2.1 Theoretical principles 
Small interfering RNA (siRNA), are a class of 20-25-nucleotide long RNA molecules whose 
importance in cellular biology is being increasingly recognized since their recent discovery. They 
are mainly implicated in the RNA interference pathway (RNAi), whereby the siRNA interferes 
Chapter 6 
Intracellular disposition 
123 
 
with the expression of the specific gene that shares a homologous sequence with the 
RNA [18,19]. It is a naturally occurring mechanism of defense and a regulating process, and many 
hopes and research efforts are put in this approach to transform this gene expression modulation 
approach in a viable therapeutic concept. 
In the context of MDR1 gene modulation, Rumpold et al have shown that RNAi-mediated 
knockdown of P-gp using a transposon2-based vector system durably restores imatinib sensitivity 
in imatinib-resistant CML cell lines K562/Dox [20]. Decreasing, if not abolishing, P-gp 
expression through the silencing of MDR1 gene thus represents an attractive strategy to revert 
drug resistance, and the use of the SB-based RNAi system seems to be a powerful tool for that 
purpose. This system consists in a SB-based3 vector [21], into which a cDNA oligonucleotide 
coding for a siRNA was inserted. In this case, the siRNA was targeted against the MDR1 
gene [20]. 
The specific aim of our experiment was therefore to ascertain whether the resistance reversal 
observed in the above mentioned resistant cell lines subjected to MDR1 siRNA-mediated 
silencing was associated with –and could therefore be explained by– an increase of imatinib 
intracellular disposition. 
6.2.2 Materials and methods 
6.2.2.1 Imatinib incubation with cell cultures 
P-gp overexpressing K562/Dox cells were obtained by long-term culture in the presence of 
doxorubicin by Marie JP at INSERM (University of Paris, France). K562 cells are an 
erythroleukemia cell line derived from a CML patient in blast crisis. These cells were cultured in 
Austria by Rumpold et al in RPMI 1640 medium containing 2% glutamine, penicillin, 
streptomycin (Invitrogen, Lofer, Austria), 10% fetal calf serum (FCS), and 1 nM doxorubicin. 
Half of them were then nucleofected with the siRNA transposon-based vector in order to obtain 
one K562/Dox-siMDR1 cell line and one control cell line K562/Dox-si∅. The cells were 
propagated and stained for P-gp by FACS4 to check for MDR1 expression, and were then seeded 
into 6-well plates (900’000 cells/well). The two cell lines were incubated with 0 (simplicate), 
                                                
2 Transposons (or "jumping genes") are sequences of DNA that can move around to different positions within the 
genome of a single cell, a process called transposition. In the process, they can cause mutations and change the 
amount of DNA in the genome. 
3 SB stands for “Sleeping Beauty” (a classic fairy tail named “La Belle au Bois Dormant”) in French, which in fact 
gave its name to a synthetic transposon derived from the genome of some fish species. This element shows efficient 
transposition in cells of a wide range of vertebrates, including humans. 
4 FACS (Fluorescent-activated cell sorting) is a tool to study and purify cells, based upon specific light scattering and 
fluorescent characteristics of each cell. 
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1 (duplicates), 3 (duplicates), 6 (simplicate) µM imatinib for 2 h. These concentrations correspond 
to 0.5, 1.5, 3.0 µg/ml (i.e. 500, 1500 and 3000 ng/ml) of imatinib, which are typical 
concentrations occurring in patients plasma samples (see Chapter 3). After incubation, cells were 
centrifuged and supernatant collected and frozen at -20°C. The resulting cell pellets were washed 
3 times in cold HBSS buffer and the pellets frozen at -20°C. All samples (12 pellets and 12 
supernatants) were shipped on dry ice to our laboratory in Lausanne for the determination of 
imatinib levels in cells and incubation media. 
6.2.2.2 Imatinib measurement by LC-MS/MS in extra- and intracellular extracts 
The supernatants and cellular pellets extracts were analyzed by LC-MS/MS according to the 
method described on § 2.2.2.2, but using a new system: a TSQ Quantum Discovery Ion Max 
tandem triple-stage quadripole (Thermo Finnigan, San Jose, USA) coupled to a Rheos 2200 
Advanced Chromatography Platform (Flux Instruments, Basel, Switzerland)5. The supernatants 
were diluted with the RPMI medium 1/5 prior to analysis, along with calibration standards 
prepared in the same RPMI medium at concentrations of 0.001, 0.01, 0.05, 0.1, 0.5 and 1 µg/ml 
of imatinib. A 1-ml volume of imatinib-d8 0.2 µg/ml (internal standard) in ACN was then added 
to the diluted supernatant and the resulting solution was finally diluted 1/2 with “Buffer A” 
(= 10 mM NH4Ac and 1% acetic acid, which corresponds to the aqueous mobile phase used for 
the chromatographic elution). 
Cell pellets were extracted with 1-ml MeOH/H2O 50 : 50 by vortex-mixing and 
ultrasonication for 15 min. A 1 ml-volume of imatinib-d8 0.2 µg/ml in ACN was then added to 
the cellular extract suspension, which was vortexed again and sonicated for 5 additional min. The 
mix was finally centrifuged and the resulting supernatant diluted 1/2 with the above-mentioned 
“Buffer A”, which gave the analytical sample for the LC-MS/MS assay. The calibration samples 
were prepared in MeOH/H2O 50 : 50 (levels: 0.001, 0.01, 0.05, 0.1, 0.5 and 1 µg/ml). The 
intracellular concentrations of imatinib were calculated assuming an intracellular volume of 0.4 pl, 
and a cell number of 900’000 in each well. 
6.2.3 Results 
The results given in Table 6.3 highlight the striking differences (between 4- and 9-fold) in 
intracellular concentration of imatinib as a result of MDR1 gene expression knockdown. 
Figure 6.3 shows a comparison of intracellular accumulations of imatinib between K562/Dox  
 
                                                
5 Analysis carried out with the help of Alexandre Béguin (one of our laboratory technician). 
Chapter 6 
Intracellular disposition 
125 
 
cells expressing P-gp and K562/Dox cells with inhibition of P-gp expression via siRNA MDR1 
silencing. 
Table 6.3. Concentration of imatinib in P-gp+ and P-gp- (RNAi knocked down) cells at various imatinib incubation 
levels 
Phenotype 
Incubation 
medium  
[µg/ml] 
Intracell.  
[µg/ml] 
Extracell.  
[µg/ml] 
Intra/extracell. 
ratio 
0.5 18.1 ± 3.93 0.7 ± 0.01 27.2 
1.5 69.4 2.0 ± 0.28 34.7 
P-gp+ 
(si∅) 
3.0 206.7 3.9 52.5 
0.5 206.9 0.7 ± 0.16 301.0 
1.5 433.6 ± 23.96 1.7 ± 0.14 250.7 
P-gp- 
(siRNA) 
3.0 778.6 3.4 230.5 
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Figure 6.3. Intracellular accumulation of imatinib at incubation concentrations of 1, 3 and 6 µM (i.e. 0.5, 1.5 and 
3 µg/ml), according to the cell phenotype after MDR1 gene expression silencing 
Using the si-RNA approach, this experiment provides a first direct evidence of the influence 
of the specific P-gp inhibition on imatinib intracellular availability. Imatinib accumulates at a much 
higher extent in CML cells that have been knocked down for P-gp expression. Intra/extracellular 
ratio is significantly affected by phenotype (p < 0.05; two-way ANOVA), but not by applied 
concentration in the incubation (extracellular) medium. 
6.2.4 Discussion and conclusion 
In complement to the initial experiment of Rumpold et al [20], our analysis formally 
demonstrates that the restoration of imatinib sensitivity observed in the imatinib-resistant CML 
cell lines K562/Dox subjected to MDR1 gene silencing is indeed the result of an increase in 
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imatinib intracellular disposition. In the P-gp knockdown cells, only the uptake process seems to 
occur, resulting in a marked imatinib cellular accumulation, as shown in the right-hand 
histograms of Figure 6.3. 
However, the values of intra/extracellular ratios determined in the P-gp+ cells in these in vitro 
cellular experiments (IC/EC = about 40) are not of the same order of magnitude as the value 
previously determined in vivo in our clinical pharmacokinetics study with patients (8-fold factor, 
see § 3.3.4), or reported in a previous in vitro study (5-fold factor in leukemia cell cultures 
incubated with imatinib and human plasma [22]). The accumulation of imatinib was shown to be 
much higher in our experiment. The difference in the measured IC/EC ratio could probably be 
explained to some extend because these studies have been realized with different cell types (i.e 
K562, PBMCs, etc), and under different experimental conditions (in vivo, in vitro, in the 
presence/absence of proteins in the incubation medium). In the previously reported in vitro and in 
vivo experiments, the total imatinib concentrations were of the same magnitude. However, these 
experiments were carried out in the presence of human plasma proteins –notably AGP– in the 
extracellular environment, onto which imatinib is heavily bound (i.e up to 95% [23]; see also 
§ 3.4). This indicates that the remaining free imatinib concentration available for interacting and 
stacking onto cellular lipid bilayers (and thus likely to be transported by P-gp/hOCT1) is much 
lower. As demonstrated in Chapter 3, the free imatinib concentration is indeed almost 50- to 100-
fold lower than the total concentration. Conversely, in our in vitro study, only a small amount of 
non-human proteins (10% fetal calf serum) was added into the incubation medium. The 
extracellular concentrations of imatinib, which cells were actually exposed to, were accordingly 
substantially higher than in the previous in vitro experiment [22]. It is therefore probable that the 
free imatinib concentration gradient was much higher in our extracellular environment than in 
the previous studies. The cell-associated amount of imatinib measured in our experiment, and 
considered as an intracellular concentration, can thus not be formally compared to the previous 
results. However, as previously stated, the relative (rather than absolute) values of IC/EC ratios 
determined in P-gp- and P-gp+ cells were of interest in our experimental design. Consequently, 
the principal information that emerges from our measurements is that the reversal of imatinib 
resistance upon MDR1 gene silencing observed by Rumpold et al [20] is indeed associated with a 
significant increase of imatinib accumulation into cells. 
Such findings confirm thus the possible usefulness of using RNAi techniques to overcome 
imatinib resistance in vitro. It is certainly an argument to further evaluate such approach in animal 
models. More generally, because of its ultimate gene specificity, the overall RNAi strategy is very 
Chapter 6 
Intracellular disposition 
127 
 
attractive and the future years will probably be determinant for the evolution of this novel 
concept. As previously stated, many hopes and research efforts are put into this RNAi strategy 
approach to transform it into a viable therapeutic concept. 
6.3 Development of cellular models for further in  v i tro  studies 
of drug transport modulation 
6.3.1 Introduction 
As efflux and uptake drug transporters have been found to be essential determinants of drug 
disposition and clinical response [1,14], it is particularly relevant to explore in basic in vitro 
experiments the various ways to modulate these transport systems in order to possibly improve 
drug efficacy and/or to overcome resistance to treatment. In that perspective, the previously 
reported method with siRNA targeted to MDR1 gene is able to suppress P-gp expression and 
function, in an exquisitely selective way. Alternately, pharmacological modulation approaches 
using typical efflux- and influx-transporters inhibitors (e.g. verapamil and valspodar, or prazosin 
and procainamide, for P-gp and hOCT1, respectively) are also being investigated, despite the fact 
that these pharmacological inhibitors are known not to be selective for a single transport system. 
Anyhow, the importance of these drug transporter inhibitors on the cellular disposition of the 
next-generation anticancer drugs such as nilotinib (AMN107), dasatinib (BMS354825) or 
bortezomide has not been studied in details yet and deserves further evaluation. Concerning 
nilotinib, a work has just been published, which has assessed the cellular uptake of this new 
compound in GIST cell lines [24]. 
In our laboratory, we are therefore planning to perform several basic interrelated in vitro 
studies in this field: a) to assess the functional consequence of P-gp and hOCT1 on intracellular 
concentrations of imatinib and newer anticancer drugs; b) to compare their relative importance; 
c) to examine the possibilities of modulating their cellular concentrations by pharmacological 
agents; and finally d) to determine in vitro the importance, in these cellular models, of a possible 
intracellular metabolism on drug cellular disposition. 
In that perspective, the following paragraphs will briefly describe the standard operating 
procedures planned for these future experiments, as an example of possible developments and 
prospects for research in the field of drug intracellular disposition. 
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6.3.2 Summary of the protocol 
The experiments will be carried out by our research group using the cell culture facility 
provided by the collaborating Laboratory of Clinical Chemistry of our University hospital, using 
previously published methods, notably by our group [11,14,25-27]. Cells (e.g. either 
MDR1+/MDR1- Schinkel cells, MDR1+/MDR1- K562 cells, hOCT1+/hOCT1- HeLa cells6 or 
hOCT1+ CEM7 cells) will be incubated in 6-well plates for 18 h at 37°C, in 2 ml growth medium 
containing 10% FCS in the presence of the drug at a clinically relevant range of concentrations. 
All concentrations will be tested in duplicates, for all drugs tested. 
Following incubation, a 300-µl aliquot will be removed to determine the extracellular drug 
concentration. The excess supernatant medium will be discarded and cell cultures will be washed 
3 times with ice-cold PBS before extraction with 1 ml methanol/water 60 : 40 on a planar shaker 
by gentle agitation for 3 h. The methanolic extracts will be collected in Eppendorf vials and 
centrifuged at RT. The supernatant will finally be evaporated to dryness under nitrogen and the 
residue reconstituted in 200 µl methanol/water 60 : 40 prior to analysis using a LC-MS/MS 
method, derived form the ones developed for imatinib (§ 2.2) or anti-HIV drugs [28]. The three 
relevant drugs that we would like to study first in our comparative experiments are imatinib, 
nilotinib and dasatinib. It is planned that other STIs (bortezomid, lonafarnib, sunitinib, etc) will 
be also subsequently studied. 
In the first step, the drugs will be incubated alone at the clinically relevant concentrations in 
the various cell cultures. In a second step, we will perform the same experiments in the presence 
of P-gp inhibitors (e.g. verapamil and valspodar) added to the growth medium of 
MDR1+/MDR1- cells. Drugs known to inhibit hOCT1 transport (e.g. prazosin and 
procainamide) will be tested in the relevant cell systems. 
Intracellular CYP450-mediated metabolism of nilotinib in our cell cultures will also be 
examined using the dependant-scan features of the LC-MS/MS instrument. 
The concentrations determined in the various extracts collected (intra- and extracellular) will 
be normalized on total proteins (or DNA) measurements, used as surrogates of cell counts. The 
determination of protein will be carried out according to the bicinchonic acid assay already 
described in § 6.1.1.3. The quantity of drugs per mg of protein will then be compared between 
the various conditions of the experiments (i.e. regarding the transporter expression, the 
                                                
6 HeLa cell line is the first continuously cultured human malignant cell line, derived from the cervical carcinoma of 
Mrs. Henrietta Lacks (one of several pseudonyms). 
7 CEM cells are a lymphoblastic cell line originally derived from a child with acute lymphoblastic leukemia (ALL). 
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concentration tested, the drug tested and the transporter inhibitor used). A multi-way ANOVA 
analysis will be used in order to assess the significance of these comparisons. 
6.3.3 Expected outcomes 
The proposed in vitro studies will thus bring additional knowledge on the intracellular 
disposition of first and second generation of the new anticancer drugs, notably allowing a head-
to-head comparison of their respective cellular efflux/uptake in stringent in vitro experiments. 
More specifically, these studies will allow to answer the following questions: a) to what extent 
these transporters influence their intracellular accumulation; b) can drug intracellular 
accumulation be influenced by transporters modulators; and c) are the anticancer drugs under 
study subjected to a significant intracellular metabolism in these cell systems? 
More generally, the implementation of the above-mentioned cellular models in our laboratory 
will bring additional knowledge on the cellular –and possibly tissular– disposition of these new 
drugs. It may have important implications in the perspective of clinical trials assessing the 
potential benefit of a TDM program for the emerging class of targeted-anticancer drugs. 
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new era of targeted therapy of cancer is emerging. The drugs used up to now against 
cancer have a narrow therapeutic index and the responses produced are often only 
palliative as well as unpredictable. Targeted therapy, introduced in recent years, is directed against 
cancer-specific molecules and signaling pathways and seems thus to be characterized by more 
limited non-specific toxicities. Tyrosine kinases are an especially important target as they play an 
important role in the modulation of growth factor signaling [1]. Imatinib is a promising example 
of this approach for treating BCR-ABL-positive leukemias and gastrointestinal stromal tumors. It 
is also currently investigated for the treatment of various types of cancer for which several 
tyrosine kinase proteins have been found to be involved in the appearance or progression of the 
malignancy [2]. 
Considering the large interindividual differences in the expression and function of the systems 
involved in imatinib disposition (e.g. CYP3A4, P-gp, hOCT1 and AGP), exposure to this drug 
can be expected to vary widely among patients. Anyway, it becomes increasingly clear that a 
patient’s response to drugs is influenced not only by the genetic heterogeneity of the drug target, 
but also by the patients genetic background and environmental factors that influence drug 
systemic and cellular disposition in the body. 
7.1 Discussion and conclusions 
Imatinib and the new-targeted anticancer drugs (e.g. erlotinib, bortezomib, sunitinib, dasatinib, 
etc), unlike most anticancer chemotherapy regimens, must apparently be taken indefinitely. 
Despite the “magic bullet” term initially associated to these drugs, this aspect represents in fact 
new challenges regarding their long-term tolerability, resistance emergence, as well as their 
pharmacoeconomic impact. 
The threat of resistance in patients has prompted numerous investigators to study all 
mechanisms whereby malignant cells develop resistance to imatinib. Some commonly known 
mechanisms of clinical resistance, such as the emergence of point mutation or genetic 
amplification of the target, have already been largely studied in the past years. Our own study has 
brought additional informations on various other potential resistance mechanisms, which may 
involve overexpression of various cellular drug transporters, metabolizing enzymes and plasma 
carrier proteins. As these systems show a high degree of polymorphisms and are subject to 
A 
134 Chapter 7 
Conclusions and perspectives 
 
numerous environment influences, they may be responsible for the demonstrated large 
interindividual variability in imatinib plasma and cellular pharmacokinetics. Such a variability in 
turn affects the maintenance of adequate drug levels, with direct implication on the treatment 
effectiveness and patient outcome. After the set-up and application of various analytical methods, 
the present study has been able to demonstrate some impacts of the above-mentioned systems (in 
vitro as well as in vivo, based on the clinical trial carried out). It has notably provided an original 
population pharmacokinetic model of imatinib integrating the impact of the carrier protein AGP. 
Concerning the pharmacoeconomic impact of these new drugs, it is important to note that 
imatinib is indeed a rather expensive drug when compared to former anticancer drugs [3]. 
Hopefully for the CML patients, over 5 years, a patient in accelerated phase will, on average, 
accrue an additional 2.09 QALY (quality-adjusted life-years) with imatinib compared with 
conventional therapies, while patients in blast crisis will accrue an additional 0.58 QALY [4]. 
However, it has been shown that the cost estimates initially generated may be underestimated. 
The HTA program1 in the United Kingdom has published a model showing more realistic values, 
with an incremental cost-effectiveness ratios for the chronic phase of $79’453–$525’330 per 
QALY gained [5]. For GIST patients, a recent study of the same program has, for instance, 
shown that the estimated median cost per QALY gained was $89’775-$172’333 after 2 years [6]. 
This represents consequent amounts and the pharmacoeconomic challenges of paying for all of 
the new anticancer agents will thus certainly become an area of increased attention [7]. Some 
authors are starting to recommend to authorities to be more willing to reimburse new cancer 
drugs for patients to benefit and to the pharmaceutical companies to be more prudent in their 
price setting [8]. If not, the availability of these drugs for patients will become more and more 
dependent on economic considerations and the gap between the ‘haves’ and ‘have-nots’ of the 
medical world will widen. 
Despite of the various results obtained during this thesis work, and those largely presented in 
the literature to date, a number of issues such as imatinib disposition in various tissular or cellular 
compartments of the body, as well as its optimal clinical use, remain to be investigated. Gaining 
this knowledge could be useful not only for imatinib itself, but may certainly fruitfully apply to all 
the generation of new anticancer drugs. 
In particular, the potential benefit of a therapeutic drug monitoring (TDM) program for 
imatinib and new related agents remains to be investigated. The important pharmacokinetic 
                                                
1 The Health technology assessment (HTA) program has for role to ensure that high-quality research information on 
the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those 
who use, manage and provide care in the National Health System of the UK. 
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variability demonstrated and quantified in Chapter 3, associated with the potential PK-PD 
relationship of imatinib (evaluated in Chapter 4) represent two arguments to evaluate further the 
potential benefit of a TDM program for this drug by well-controlled clinical trials. 
7.2 Perspectives 
7.2.1 Short-term perspectives 
A number of additional pharmacogenetic polymorphisms with potential clinical consequences 
might be studied among the patient population of our study. It could be worth investigating of 
the polymorphism of the transport proteins hOCT1 and BCRP, for which imatinib has recently 
been demonstrated to be a substrate, and to determine to which extent these polymorphisms can 
explain some of the wide interindividual pharmacokinetic variability of imatinib (in part 
unexplained at present). Furthermore, performing the in vitro experiments on drug transporters 
described at the end of Chapter 6, is anticipated to bring additional knowledge on the cellular –
and possibly tissular– disposition of these new drugs. It may have important implications in the 
perspective of clinical trials design, for assessing the potential benefit of a TDM program for the 
emerging class of targeted anticancer drugs. 
Moreover, increasing exposure to the drug by inhibiting its efflux or its metabolism might 
potentially enhance its efficacy. This could particularly be the case for patients showing 
progressive resistance towards the drug at usual dosages. Such inhibitors would be drugs like 
ketoconazole (for CYP3A4) or verapamil (for P-gp). Their coadministration with imatinib (under 
the careful monitoring of plasma and intracellular concentrations) could potentially diminish both 
the interindividual variability and the intraindividual fluctuations in imatinib pharmacokinetics. 
Such an interaction would not only have a dose-sparing effect –with potential economic 
consequences–, but also increase the probability that the patient is exposed to adequate plasma 
concentrations, and that this translates into sufficiently high intracellular concentrations at the 
target site. Studies evaluating these issues are presently considered in our Division. 
7.2.2 Mid-term perspectives 
A direct clinical consequence of our project would be the development and validation of the 
therapeutic drug monitoring for imatinib, which could also be made available to all clinicians 
throughout Switzerland. However, whether individualization of imatinib dosage regimen based 
on routine drug level monitoring should be recommended for patients’ management still deserves 
further confirmation in well-controlled trials. Such a validation of a TDM for imatinib (or other 
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new anticancer drug) is presently considered in our hospital under the name “Translational 
program for the evaluation of the role of Therapeutic drug monitoring of new anticancer drugs”. 
Combining indeed a TDM approach with an adequate pharmacogenetic approach (i.e. 
genotyping or phenotyping of the drug target in patients) would possibly provide a 
comprehensive set of parameters for the clinical management of gene-targeted therapy. This 
could be of direct help for clinicians at patients’ bed site, in order to use such drug in a fully 
optimized and rational manner. It may help to individualize the dosing regimen before overt 
disease progression or observation of treatment toxicity, thus improving both the long-term 
therapeutic effectiveness and the tolerability of this drug (obtained moreover at lower global drug 
expenditures). Additionally, attention devoted to TDM could contribute to optimize patients’ 
compliance (an important issue for a chronic inhibition of the target proteins) and somehow help 
to control the important costs associated with these new treatments. The large amount of data on 
the markers generated by all these techniques (especially pharmacogenetics) will need to be very 
well integrated and carefully interpreted. To that endeavor, bioinformatics will certainly be of 
great help if wisely used by trained specialists. It is noteworthy that some authors already state 
that we are entering the post-genome era, where use of bioinformatics will be crucial for 
managing all the data regarding oncology research and oncologic patient’s treatments [9]. 
To conclude, we can say that the TDM of anticancer drugs is still in an early development 
phase, but the future years will probably be determinant for the evolution of this new concept 
and for its possible clinical applications. As “every patient is different”, an approach that 
integrates clinical pharmacokinetics (i.e. TDM) and patient/tumor pharmacogenetics should 
allow to administer the right drug at the correct dose to the right patient. 
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Derivation of Cu (imatinib free concentration; equation (11)), assuming the saturable binding of 
imatinib onto AGP (considered as the main binding protein (Gambacorti-Passerini et al, 2000; 
reference [82] in Chapter 1): 
   
! 
imatinib
unbound
+ AGP
unbound
        
! 
imatinib
bound
" AGP
bound
 (16) 
Applying the law of mass action gives (u = unbound; b = bound): 
 
  
! 
K
d
=
C
u
"L " AGP
u
C
b
 (17) 
while: 
   
! 
L " AGP
tot
= C
b
+ L " AGP
u
 (18) 
Combining (17) and (18) thus provides an expression for Cu: 
 
  
! 
C
u
=
K
d
"C
b
L " AGP
tot
#C
b
 (19) 
Therefore, considering that Ctot is equal to the sum of Cu and Cb (i.e. Cb = Ctot – Cu), we can write: 
   
! 
Cu
2
"Cu # (Ctot "Kd "L # AGPtot )"Kd #Ctot = 0 (20) 
Finally, solving this equation according to Cu provides the expression of Cu given in equation 
(11). 
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To express Vd as a function of AGPtot and Ctot, it is useful to figure out the distribution of 
imatinib according to the following Figure (assuming that AGP is the main binding protein 
(Gambacorti-Passerini et al, 2000; reference [82] in Chapter 1): 
 
Representation of imatinib distribution, regarding concentrations and volumes (Vtot = Vd = total imatinib volume of 
distribution, VAGP = total AGP plasma volume, Vu = free imatinib volume, Ctot = total imatinib concentration,  
Cu = free imatinib concentration, Cb = concentration of imatinib bound to AGP, AGPtot = total AGP concentration, 
AGPu = free AGP concentration, AGPb = concentration of AGP bound to imatinib, L = scaling factor) 
Assuming this, it follows that the total unbound and AGP-bound volumes are given by: 
 
  
! 
V
tot
=
A
tot
C
tot
 (21) 
 
  
! 
V
u
=
A
u
C
u
 (22) 
 
  
! 
V
AGP
=
A
b
C
b
 (23) 
Assuming that the total quantity of imatinib (Atot) is equal to the sum of the unbound (Au) and 
bound (Abound) quantities, we can write: 
   
! 
C
tot
" V
tot
= C
u
" V
u
+ C
b
" V
AGP
 (24) 
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Therefore, considering that Ctot is given by the sum of Cu and Cb (i.e. Cu = Ctot - Cb) it follows: 
 
  
! 
Cb =
Ctot " (Vtot # Vu )
VAGP # Vu
 (25) 
Furthermore, assuming the law of mass action and rewriting equation (19) according to Cb gives: 
 
  
! 
C
b
=
C
u
"L " AGP
tot
C
u
+ K
d
 (26) 
Hence, considering again that Cu is given by Ctot - Cb equation (26) can be expressed as: 
   
! 
Cb
2
"Cb # (Ctot + Kd + L # AGPtot )+ Ctot #L # AGPtot = 0 (27) 
Substituting (25) into (27) and resolving according to Vtot gives equation (11), which expresses Vd 
(the ration between Atot and CLtot) as a function of AGPtot and Ctot, with parameters VAGP, Vu, Kd 
and L. The calculations were checked using Mathematica® (version 5.2, Wolfram Research Inc., 
Champaign, USA). Interestingly, equation (12) depicts an oblique hyperbole with one horizontal 
asymptote. 
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Appendix 3.6 
 
The following table summarizes the development of the demographic model of imatinib 
population pharmacokinetics (FO method): 
Hypothesis Model θa θb θc θ1 θ2 θ3 θ4 ΔOF 
Demographic covariates model (n=59)          
Basic model 
Does BW influence CL? 
 Vd? 
Does gender influence CL? 
 Vd? 
Does age influence CL? 
 Vd? 
Does pathology diagn. influence CL? 
 Vd? 
Does CYP3A4 inh. influence CL? 
Does CYP3A4 ind. influence CL? 
Do BW+gender influence CL? 
Do BW+gender+age influence CL? 
 
Do BW+gender+age+pathology diagn. 
influence CL? 
Do BW+gender+age+pathology diagn. 
influence CL, and gender Vd? 
 
θa+θ1·BW 
θb+θ1·BW 
θa+θ2·q-θ2·(1-q) 
θb+θ2·q-θ2·(1-q) 
θa+θ3·AGE 
θb+θ3·AGE 
θa+θ4·p-θ4·(1-p) 
θb+θ4·p-θ4·(1-p) 
θa+θ6·INH 
θb+θ7·IND 
θa+θ1·BW+θ2·q-θ2·(1-q) 
θa+θ1·BW+θ2·q-θ2·(1-q) 
+θ3·AGE 
θa+θ1·BW+θ2·q-θ2·(1-q) 
+θ3·AGE+θ4·p-θ4·(1-p) 
θa+θ1·BW+θ2·q-θ2·(1-q) 
+θ3·AGE+θ4·p-θ4·(1-p) 
θb+θ5·q-θ5·(1-q) 
12.1 
12.1 
12.1 
12.2 
12.1 
12.3 
12.1 
12.8 
12.1 
12.0 
12.1 
12.1 
12.4 
 
12.8 
 
12.8 
299 
255 
299 
267 
281 
307 
299 
295 
255 
295 
299 
259 
268 
 
271 
 
258 
0.467 
0.433 
0.466 
0.433 
0.389 
0.470 
0.466 
0.442 
0.372 
0.454 
0.467 
0.451 
0.466 
 
0.471 
 
0.437 
 
13.5 
0.00 
 
 
 
 
 
 
 
 
11.2 
11.7 
 
11.4 
 
12.7 
 
 
 
2.3 
-77.9 
 
 
 
 
 
 
0.8 
0.7 
 
0.7 
 
0.8 
 
 
 
 
 
 
-1.6 
0.0 
 
 
 
 
 
-2.2 
 
-1.7 
 
-2.1 
 
 
 
 
 
 
 
-1.6 
53.1 
 
 
 
 
 
-0.9 
 
-1.0 
- 
-63.4 
+0.0 
-36.1 
-8.6 
-1.6 
+0.0 
-9.9 
-2.5 
+0.9 
+0.0 
-66.9 
-71.4 
 
-76.0 
 
-81.1 
 
 
θa,b,c = tested PK parameters (clearance, CL, volume of distribution, Vd and absorption constant, ka, respectively); θ1,2,3,4,5,6,7 = 
covariate coefficient estimates. 
BW (body weight) and age are expressed as the relative deviation of the individual BW and age from the population mean (70 kg 
and 50 years, respectively). 
INH or IND = 1 if concomitant inhibitor/inducer drug is present; q = 0 if female and 1 if male; p = 0 if CML, 1 if GIST 
n = number of patient in the data set. 
ΔOF = difference in the NONMEM objective function (OF) compared to baseline model. 
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The following table summarizes the models used to examine the influence of biological 
covariates on imatinib CL and Vd (FO method): 
Hypothesis Model θa θb θc θ1 θ2 θ3 ΔOF 
AGP model (n= 51)         
1-compartment, 1st order 
Does AGP influence CL (eq. 6)? 
Does AGP influence CL (eq. 7)? 
Does AGP influence CL (eq. 8)? 
Does AGP influence CL (eq. 9) 
Does AGP influence CL (eq. 10-11)? 
Does AGP influence Vd (eq. 6)? 
Does AGP influence Vd (eq. 7)? 
Does AGP influence Vd (eq. 8)? 
Does AGP influence Vd (eq. 12)? 
Does BW influence CLu? 
Do BW+gender influence CLu? 
 
Do BW influence CLu and gender 
influence Vd? 
Do BW+gender+age influence CLu? 
 
Do BW+pathology diagn. 
influence CLu? 
 Vd? 
 
 
CL = f(eq. 6) 
CL = f(eq. 7) 
CL = f(eq. 8) 
CL = f(eq. 9) 
CLu = f(eq. 10-11) 
CLu = f(eq. 10-11), Vd =f(eq. 6) 
CLu = f(eq. 10-11), Vd =f(eq. 7) 
CLu = f(eq. 10-11), Vd =f(eq. 8) 
CLu = f(eq. 10-11), Vd =f(eq. 12) 
CLu = f(eq. 10-11), θa+θ1·BW,Vd = f(eq. 6) 
CLu = f(eq. 10-11), θa+θ1·BW 
+θ2·q-θ2·(1-q), Vd = f(eq. 6) 
CLu = f(eq. 10-11), θa+θ1·BW, 
Vd = f(eq. 6), θb+θ2·q-θ2·(1-q) 
CLu = f(eq. 10-11), θa+θ1·BW 
+θ2·q-θ2·(1-q)+θ3·AGE, Vd = f(eq. 6) 
CLu = f(eq. 10-11), θa+θ1·BW 
+θ2·p-θ2·(1-p), Vd = f(eq. 6) 
CLu = f(eq. 10-11), θa+θ1·BW, 
Vd = f(eq. 6), θb+θ2·p-θ2·(1-p) 
11.8 
12.5 
12.2 
12.2 
12.1 
1200 
1110 
1230 
1040 
1290 
1100 
1100 
 
1040 
 
1110 
 
1180 
 
905 
322 
308 
320 
356 
365 
355 
327 
354 
338 
355 
320 
306 
 
317 
 
305 
 
324 
 
313 
0.660 
0.820 
0.672 
0.797 
0.767 
0.741 
0.707 
0.742 
0.732 
0.740 
0.672 
0.656 
 
0.661 
 
0.640 
 
0.698 
 
0.654 
 
 
 
 
 
 
 
 
 
 
1000 
844 
 
964 
 
858 
 
-120 
 
-8 
 
 
 
 
 
 
 
 
 
 
 
61 
 
28 
 
51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-151 
- 
-170.5 
-5.6 
-267.2 
-271.4 
-284.1 
-295.8 
-267.2 
-298.0 
-267.2 
-325.0 
-327.2 
 
-325.6 
 
-328.6 
 
-332.0 
 
-325.7 
 
MDR1 genotype (n=36)         
AGP model 
Does MDR1 influence CLu? 
 Vd? 
 
θa+θ1·MDRT 
θb+θ1·MDRT 
1170 
1240 
11240 
289 
297 
344 
0.699 
0.709 
0.705 
 
-66 
-51 
  - 
-1.3 
-1.0 
CYP3A4 activity (n= 39)         
AGP model 
Does CYP3A4 influence CLu? 
 Vd? 
 
θa+θ2·3A4A 
θb+θ3·3A4A 
1180 
1220 
1090 
257 
256 
278 
0.460 
0.455 
0.489 
  
13 
11 
 - 
-0.2 
-1.0 
CRT clearance (n=47)         
AGP model 
Does CLCRT influence CLu? 
 Vd? 
 
θa+θ3·CLCRT 
θb+θ4·CLCRT 
1120 
1160 
1300 
311 
306 
316 
0.695 
0.692 
0.702 
   
336 
168 
- 
-5.7 
-7.0 
 
θa,b,c = tested PK parameters (clearance, CL, free clearance, CLu, volume of distribution, Vd and absorption constant, ka, 
respectively); θ1,2,3 = covariate estimates (BW, gender, age, or pathology diagnosis, or respectively MDRT, 3A4A and CLCRT). 
BW (body weight), age, AGP (AGP plasma levels), 3A4A (CYP3A4 cortisol ratio), CLCRT (creatinine clearance): expressed as the 
relative deviation of the individual BW, AGE, AGPtot, 3A4A and CRT from the population mean (70 kg, 50 years, 0.95 g/L, 5.4 
and 75 mL/min respectively). 
q = 0 if female, 1 if male; MDRT = -1 if 3435CC, 0 if 3435CT, 1 if 3435TT; p = 0 if CML, 1 if GIST 
n = number of patient in the data set. 
ΔOF = difference in the NONMEM objective function (OF) compared to baseline model. 
In equation (12) the Ctot variable was defined as equal to the DV variable and was thus simply duplicated from this one. 
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